日本臨牀　79/増刊3　皮膚悪性腫瘍（第2版）下

出版社： 日本臨牀社
発行日： 2021-07-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 皮膚悪性腫瘍（第2版）下
電子書籍版： 2021-07-31 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 特集　皮膚悪性腫瘍（第2版）下
    　　　―基礎と臨床の最新研究動向―

    序文

    II．有棘細胞癌(日光角化症・Bowen病)
    　１．有棘細胞癌の診断と治療の変遷
    　　（１）診断・治療の変遷と今後の展望：概論
    　２．有棘細胞癌の危険因子
    　　（１）生活習慣と環境因子
    　　（２）宿主因子
    　３．有棘細胞癌の分子生物学と発がん機序
    　　（１）有棘細胞癌の遺伝子異常：概論
    　　（２）浸潤・転移に関連する分子
    　４．有棘細胞癌の予後因子
    　　（１）有棘細胞癌の予後因子に関するエビデンス
    　　（２）TNM分類
    　５．有棘細胞癌診療ガイドライン
    　　（１）国内・海外診療ガイドラインの要点
    　６．有棘細胞癌の検査・診断
    　　（１）有棘細胞癌の検査・診断：概論
    　　（２）診　断
    　　　１）臨床症状からの診断
    　　　２）病理組織学的検査
    　７．有棘細胞癌の治療
    　　（１）有棘細胞癌の治療戦略：概論（診療アルゴリズム）
    　　（２）外科的治療
    　　　１）手術適応、切除マージン
    　　　２）センチネルリンパ節生検
    　　（３）薬物療法
    　　　１）化学療法
    　　　２）動注化学療法
    　　　３）EGFR阻害薬
    　　　４）免疫チェックポイント阻害薬：cemiplimab他
    　　　５）有棘細胞癌に対して実施中のトライアル
    　　（４）放射線治療
    　　　１）原発巣に対する根治的放射線治療と緩和的放射線治療
    　　　２）術後放射線治療
    　８．表皮内病変
    　　（１）日光角化症
    　　　１）日光角化症―その原因・検査・診断：概論
    　　　２）臨床診断と病理組織検査
    　　　３）治　療
    　　　　①液体窒素療法、外科的治療
    　　　　②非破壊的治療(外用療法、PDT)
    　　（２）Bowen病
    　　　１）Bowen病の原因・検査・診断：概論
    　　　２）臨床診断と病理組織検査
    　　　３）治　療
    　　　　①外科的治療
    　　　　②非外科的治療
    　９．特　論
    　　（１）局所進行病巣の局所管理(モーズ、悪臭対策など)
    　　（２）ケラトアカントーマ
    　　（３）疣状癌
    　　（４）外陰部ボーエン様丘疹症
    　　（５）汗孔癌、脂腺癌との鑑別

    III．基底細胞癌
    　１．診断・治療の変遷と今後の展望：概論
    　２．基底細胞癌の疫学
    　３．危険因子：生活習慣と環境因子・宿主因子
    　４．基底細胞癌の分子生物学と発がん機序
    　　（１）PTCH1と基底細胞癌
    　　（２）TP53と基底細胞癌
    　５．基底細胞癌に関連する遺伝性疾患
    　６．基底細胞癌の検査・診断
    　　（１）基底細胞癌の検査・診断：概論
    　　（２）診　断
    　　　１）病理組織学的病型と鑑別診断
    　　　２）ダーモスコピー
    　　　３）基底細胞癌の診療における超音波検査の利用
    　７．基底細胞癌の治療
    　　（１）基底細胞癌の治療戦略：概論
    　　（２）外科的治療
    　　（３）非手術局所療法
    　　（４）放射線治療
    　　（５）全身薬物療法

    IV．乳房外パジェット病
    　１．診断と治療の変遷
    　２．分子生物学と発がん機序
    　３．病期分類と予後因子
    　４．検査・診断
    　５．治　療
    　　（１）治療戦略：概論(治療アルゴリズム)
    　　（２）手術治療
    　　　１）切除マージンと再建
    　　　２）乳房外パジェット病　センチネルリンパ節生検
    　　（３）化学療法
    　　（４）放射線療法

    V．メルケル細胞癌
    　１．診断と治療の変遷
    　２．疫学と危険因子
    　３．メルケル細胞ポリオーマウイルスと発がん
    　４．臨床的特徴
    　５．病期分類
    　６．診断(病理、画像)と予後因子
    　７．治療
    　　（１）外科的治療
    　　（２）放射線療法（術後照射を含む）
    　　（３）薬物療法
    　　　１）化学療法
    　　　２）免疫チェックポイント阻害薬
    　　（４）注目すべき臨床試験

    VI．血管肉腫
    　１．診断と治療の変遷
    　２．疫学と危険因子
    　３．頭部血管肉腫の臨床的特徴
    　４．診断(病理、遺伝子解析、画像)と予後因子
    　５．治療
    　　（１）外科的治療
    　　（２）薬物療法
    　　（３）放射線治療と化学放射線同時併用療法
    　　（４）注目すべき臨床試験

    VII．皮膚リンパ腫
    　１．皮膚リンパ腫の診断と治療の変遷
    　２．皮膚リンパ腫最新の分類
    　３．臨床検査
    　　（１）免疫組織化学(immunohistochemistry：IHC)検査
    　　（２）フローサイトメトリー
    　　（３）染色体検査と遺伝子検査
    　４．国内外の診療ガイドライン
    　５．病期分類と予後
    　６．皮膚リンパ腫の診断と治療
    　　（１）菌状息肉症
    　　　１）分子生物学的解析
    　　　２）臨床症状と予後
    　　　３）早期病変の診断と類似疾患との鑑別診断
    　　　４）レチノイド製剤
    　　　５）インターフェロンγ
    　　　６）エピジェネティクスHDAC阻害薬
    　　　７）化学療法・造血幹細胞移植
    　　　８）新規治療薬
    　　　９）紫外線療法
    　　　10）放射線療法
    　　　11）進行期菌状息肉症の治療戦略
    　　　12）菌状息肉症の亜型
    　　（２）セザリー（Sézary）症候群
    　　　１）セザリー（Sézary）症候群の病態と診断
    　　　２）セザリー（Sézary）症候群の治療
    　　（３）原発性皮膚CD30陽性T細胞リンパ増殖異常症
    　　　１）原発性皮膚未分化大細胞型リンパ腫
    　　　２）リンパ腫様丘疹症
    　　（４）その他のT細胞リンパ
    　　（５）EBウイルス関連T/NK細胞リンパ増殖性疾患
    　　　１）EBウイルスとT/NK細胞リンパ増殖異常症の病型と診断
    　　　２）節外性NK/T細胞リンパ腫，鼻型の診断と治療
    　　（６）原発性皮膚B細胞リンパ腫
    　　　１）分類、病態と診断、治療
    　７．成人T細胞白血病リンパ腫
    　　（１）HTLV-1の概説－発がん機構を中心に―
    　　（２）疫学と症状
    　　（３）病型分類と予後
    　　（４）皮膚病変を有する成人T細胞性白血病・リンパ腫の治療
    　　　　1）Indolent type ATLの治療方針
    　　　　2）Aggressive type ATLの治療方針

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

II 有棘細胞癌 ( 日光角化症・Bowen 病 )

P.17 掲載の参考文献
1) 安齋眞一, ほか : 日本皮膚科学会ガイドライン 皮膚悪性腫瘍ガイドライン 第3版 有棘細胞癌診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 2501-2533, 2020.
 
2) 斎田俊明, ほか : 日本皮膚科学会ガイドライン 皮膚悪性腫瘍診療ガイドライン. 日本皮膚科学会雑誌 117 : 1855-1925, 2007.
 
3) 土田哲也, ほか : 日本皮膚科学会ガイドライン 皮膚悪性腫瘍診療ガイドライン 第2版. 日本皮膚科学会雑誌 125 : 5-75, 2015.
 
4) Russo T, et al : Dermoscopy of Malignant Skin Tumours : What's New? Dermatology 233 : 64-73, 2017.
 
5) Uhara H, et al : The new clinical practice guideline for squamous cell carcinoma of the skin. Skin Cancer 22 : 226-232, 2008.
 
6) Zhu AQ, et al : High-frequency ultrasound in the diagnosis of the spectrum of cutaneous squamous cell carcinoma : Noninvasively distinguishing actinic keratosis, Bowen's Disease, and invasive squamous cell carcinoma. Skin Res Technol, 2021. [DOI : 10.1111/srt.13028]
 
7) Pampena R, et al : The role of ultrasound examination for early identification of lymph-node metastasis of cutaneous squamous cell carcinoma : results from a single institutional center. G Ital Dermatol Venereol, 2019. [DOI : 10.23736/S0392-0488.19.06487-3]
 
8) 山元修 : 病理組織学的検査. 日本臨牀 71 (増刊 4 : 皮膚悪性腫瘍) : 483-486, 2013.
 
9) Eroglu A, et al : Risk factors related to locoregional recurrence in squamous cell carcinoma of the skin. J Surg Oncol 61 : 124-130, 1996.
PubMed
10) Miller SJ : The National Comprehensive Cancer Network (NCCN) guidelines of care for nonmelanoma skin cancers. Dermatol Surg 26 : 289-292, 2000.
PubMed
11) NCCN Clinical Practice Guidelines in Oncology. [https://www.nccn.org/professionals/physician_gls/default.aspx#squamous] (2021年6月閲覧)
 
12) Harold H, et al : Squamous cell carcinoma of the scalp, face, and neck. In : Cancer of the SKIN-Biology-Diagnosis-Management, Vol two (ed by Rafael A, et al), p899-915, WB Saunders, Philadelphia, 1976.
 
13) Winkelmann RK, et al : Squamous cell carcinoma produced by ultraviolet light in hairless mice. J Invest Dermatol 40 : 217-224, 1963.
PubMed
14) Fears TR, et al : Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. Am J Epidemiol 105 : 420-427, 1977.
PubMed
15) Durinck S, et al : Temporal dissection of tumorigenesis in primary cancers. Cancer Discov 1 : 137-143, 2011.
PubMed
16) Brash DE : Roles of the transcription factor p53 in keratinocyte carcinomas. Br J Dermatol 154 (Suppl 1) : 8-10, 2006.
 
17) Pickering CR, et al : Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 20 : 6582-6592, 2014.
PubMed
18) 小嶋理一. ほか (編) : 有棘細胞癌. 基礎皮膚科学 III, 医歯薬出版, 1976.
 
19) 皮膚悪性腫瘍取扱い規約 第1版 (日本皮膚悪性腫瘍学会編) , p38-48, 金原出版, 2002.
 
20) Brodland DG, Zitelli JA : Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 27 : 241-248, 1992.
PubMed
21) Umebayashi Y, et al : Most cases of cutaneous squamous cell carcinoma in Japan are classified as " high risk" according to the Japanese guideline. J Dermatol 39 : 812-814, 2012.
 
22) 放射線医学年表. [https://www.jira-net.or.jp/vm/various2.html] (2021年6月閲覧)
 
23) 皮膚癌 ; 血液・リンパ・皮膚・骨・軟部. 放射線治療計画ガイドライン 2020年版 (日本放射線腫瘍学会編), p335-341, 金原出版, 2020.
 
24) Rowe DE, et al : Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 26 : 976-990, 1992.
PubMed
25) 澤田匡秀 : 皮膚がんは増えているのか? 美容皮膚医学 BEAUTY 3 : 6-11, 2020.
 
26) Cognetta AB, et al : Superficial x-ray in the treatment of basal and squamous cell carcinomas : a viable option in select patients. J Am Acad Dermatol 67 : 1235-1241, 2012.
PubMed
27) Pampena R, et al : Orthovoltage radiotherapy for nonmelanoma skin cancer (NMSC) : Comparison between 2 different schedules. J Am Acad Dermatol 74 : 341-347, 2016.
PubMed
28) 三木吉治 : 抗腫瘍剤の適応と評価. 皮膚 17 : 320-323, 1975.
 
29) Garcia-Pedrero JM, et al : Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol 77 : 527-533, 2017.
PubMed
30) Migden MR, et al : PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 379 : 341-351, 2018.
PubMed
31) Corchado-Cobos R, et al : Cutaneous Squamous Cell Carcinoma : From Biology to Therapy. Int J Mol Sci 21 : 2956, 2020.
 
32) Canueto J, et al : Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma. Br J Dermatol 176 : 1279-1287, 2017.
PubMed
33) Maubec E, et al : Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29 : 3419-3426, 2011.
PubMed
P.22 掲載の参考文献
1) Murphy GH, et al : Squamous cell carcinoma. In : WHO Classification of Skin Tumors, 4th ed (ed by Elder DE, et al), p35-36, WHO press, IARC, Lyon, 2018.
 
2) 斎田俊明 : 有棘細胞癌の診断と治療方針. Skin Cancer (special) 9 : 69-72, 1994.
 
3) 国定充 : 紫外線発がんのメカニズム. 日皮会誌 130 : 2035-2041, 2020.
 
4) Kamb A : Cancer. Sun protection factor p53. Nature 372 : 730-731, 1994.
PubMed
5) 橋爪鈴男, ほか : 5人の医師の手の放射線皮膚悪性腫瘍. 癌の臨床 36 : 224-228, 1990.
Medical*Online
6) Lazar P, Cullen SI : Basal Cell Epithelioma and Chronic Radiodermatitis. Arch Dermatol 88 : 172-175, 1963.
PubMed
7) 青木繁, ほか. 下口唇熱傷瘢痕癌の1例. Skin Cancer 25 : 200-204, 2010.
 
8) Maclean GM, Coleman DJ : Three fatal cases of squamous cell carcinoma arising in chronic perineal hidradenitis suppurativa. Ann R Coll Surg Engl 89 : 709-712, 2007.
PubMed
9) 内田千恵ほか : 円板状エリテマトーデスに発症した疣状癌・有棘細胞癌の1例. Skin Cancer 35 : 12-15, 2020.
 
10) Arps DP, Patel RM : Cutaneous hypertrophic lupus erythematosus : a challenging histopathologic diagnosis in the absence of clinical information. Arch Pathol Lab Med 137 : 1205-1210, 2013.
PubMed
11) Suurmond D : LICHEN SCLEROSUS ET ATROPHICUS OF THE VULVA. Arch Dermatol 90 : 143-152, 1964.
PubMed
12) Scheurlen W, et al : Molecular cloning of two new HPV types (HPV 37 and HPV 38) from a keratoacanthoma and a malignant melanoma. Int J Cancer 37 : 505-510, 1986.
 
13) Nakajima T, et al : A unique verrucous anogenital tumor associated with type 6b-related human papillomavirus. Acta Pathol Jpn 39 : 528-532, 1989.
PubMed
P.27 掲載の参考文献
1) Egashira S, et al : Chronic sun exposure-related fusion oncogenes EGFR-PPARGC1A in cutaneous squamous cell carcinoma. Sci Rep 7 : 12654, 2017.
PubMed
2) Box NF, et al : Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J Invest Dermatol 116 : 224-229, 2001.
PubMed
3) Vincek V, et al : Tumor Necrosis Factor α Polymorphism Correlates with Deleterious Effects of Ultraviolet B Light on Cutaneous Immunity. Cancer Res 53 : 728-732, 1993.
 
4) Yoshikawa T, et al : Susceptibility to effects of UVB radiation on induction of contact hypersensitivity as a risk factor for skin cancer in humans. J Invest Dermatol 95 : 530-536, 1990.
PubMed
5) Niizeki H, et al : Polymorphisms in the tumor necrosis factor (TNF) genes are associated with susceptibility to effects of ultraviolet-B radiation on induction of contact hypersensitivity. Tissue Antigens 58 : 369-378, 2001.
PubMed
6) Surdu S, et al : Polymorphisms in DNA repair genes XRCC1 and XRCC3, occupational exposure to arsenic and sunlight, and the risk of non-melanoma skin cancer in a European case-control study. Environ Res 134 : 382-389, 2014.
 
7) Yokota A, et al : Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplant 47 : 95-100, 2012.
PubMed
8) Euvrard S, et al : Skin Cancers after Organ Transplantation, N Engl J Med 348 : 1681-1691, 2003.
PubMed
9) Kolb HJ, et al : Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 131 : 738-744, 1999.
 
10) Fryer AA, et al : Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients. Carcinogenesis 26 : 185-191, 2005.
PubMed
11) Alamartine E, et al : Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol 120 : 99-103, 2003.
PubMed
12) Quint KD, et al : Human Beta-papillomavirus infection and keratinocyte carcinomas. J Pathol 235 : 342-354, 2015.
PubMed
13) Rowe DE, et al : Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 26 : 976-990, 1992.
PubMed
14) Maubec E, et al : Common skin cancers in porokeratosis. Br J Dermatol 152 : 1389-1391, 2005.
PubMed
15) Fine JD, et al : Epidermolysis bullosa and the risk of life-threatening cancers : the National EB Registry experience, 1986-2006. J Am Acad Dermatol 60 : 203-211, 2009.
PubMed
P.31 掲載の参考文献
1) Di Nardo L, et al : Molecular genetics of cutaneous squamous cell carcinoma : perspective for treatment strategies. J Eur Acad Dermatol Venereol 34 : 932-941, 2020.
PubMed
2) Bito T, et al : Inhibition of epidermal growth factor receptor and PI3K/Akt signaling suppresses cell proliferation and survival through regulation of stat3 activation in human cutaneous squamous cell carcinoma. J Skin Cancer 2011 : 874571, 2011.
PubMed
3) Yamane K, et al : Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. J Mol Med (Berl) 91 : 69-81, 2013.
 
4) Chamcheu JC, et al : Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer : a review of current status and future trends on natural and synthetic agents therapy. Cells 8 : 803, 2019.
 
5) 宇原久 : メラノーマの新しい治療とがん免疫療法の新展開. 信州医誌 64 : 63-73, 2016.
Medical*Online
6) Wu JH, et al : BRAF inhibitor-associated cutaneous squamous cell carcinoma : new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. Br J Dermatol 177 : 914-923, 2017.
PubMed
7) Su F, et al : RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366 : 207-215, 2012.
PubMed
8) South AP, et al : NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol 134 : 2630-2638, 2014.
PubMed
9) 温川恭, 清野透 : ヒトパピローマウイルスによる発がんの分子機構. ウィルス 58 : 141-154, 2008.
 
10) Mulvaney PM, Schumults CD : Molecular prediction of metastasis in cutaneous squamous cell carcinoma. Curr Opin Oncol 32 : 129-136, 2020.
 
11) Chahal HS, et al : Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. Nat Commun 7 : 12510, 2016.
PubMed
12) Persson M, et al : Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 106 : 18740-18744, 2009.
PubMed
13) Zhang W, et al : Construction of a CXCL12-KDEL fusion gene to inhibit head and neck squamous cell carcinoma metastasis by intracellular sequestration of CXCR4. Biomed Res Int 2015 : 195828, 2015.
PubMed
14) Egashira S, et al : Chronic sun exposure-related fusion oncogenes EGFR-PPARGC1A in cutaneous squamous cell carcinoma. Sci Rep 7 : 12654, 2017.
PubMed
15) Egashira S, et al : Recurrent Fusion Gene ADCK4-NUMBL in Cutaneous Squamous Cell Carcinoma Mediates Cell Proliferation. J Invest Dermatol 139 : 954-957, 2019.
PubMed
16) Hervas-Marin D, et al : Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma. PLoS One 14 : e0223341, 2019.
PubMed
17) Matsushita M, et al : Decreased H3K27me3 Expression Is Associated With Merkel Cell Polyomavirus-negative Merkel Cell Carcinoma, Especially Combined With Cutaneous Squamous Cell Carcinoma. Anticancer Res 39 : 5573-5579, 2019.
PubMed
18) Xu N, et al : MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J Biol Chem 287 : 29899-29908, 2012.
PubMed
P.36 掲載の参考文献
1) Lee KJ, Soyer HP : Cutaneous keratinocyte cancers of the head and neck : Epidemiology, risk factors and clinical, dermoscopic and reflectance confocal microscopic features. Oral Oncol 98 : 109-117, 2019.
 
2) Lambert AW, et al : Emerging Biological Principles of Metastasis. Cell 168 : 670-691, 2017.
PubMed
3) Moustakas A, Heldin CH : Mechanisms of TGFβ-Induced Epithelial-Mesenchymal Transition. J Clin Med 5 : 63, 2016. [DOI : 10.3390-jcm5070063]
 
4) Miyazono K, et al : Intracellular and extracellular TGF-β signaling in cancer : some recent topics. Front Med 12 : 387-411, 2018.
 
5) Derynck R, et al : TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol 18 : 9-34, 2021.
 
6) Jia S, Meng A : TGFβ family signaling and development. Development 148 : dev188490, 2021.
 
7) Saxena K, et al : Hypoxia, partial EMT and collective migration : Emerging culprits in metastasis. Transl Oncol 13 : 100845, 2020.
PubMed
8) Liu S, et al : Targeting TGFβ signal transduction for cancer therapy. Signal Transduct Target Ther 6 : 8, 2021.
 
9) Zhu H, et al : A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers. Clin Cancer Res 24 : 2780-2793, 2018.
 
10) del Re E, et al : In the absence of type III receptor, the transforming growth factor (TGF) -beta type II-Breceptor requires the type I receptor to bind TGF-beta2. J Biol Chem 279 : 22765-22772, 2004.
 
11) Takahashi K, et al : Targeting all transforming growth factor-β isoforms with an Fc chimeric receptor impairs tumor growth and angiogenesis of oral squamous cell cancer. J Biol Chem 295 : 12559-12572, 2020.
 
12) Sakakitani S, et al : Activation of β2-adrenergic receptor signals suppresses mesenchymal phenotypes of oral squamous cell carcinoma cells. Cancer Sci 112 : 155-167, 2021.
 
P.41 掲載の参考文献
1) Motaparthi K, et al : Cutaneous Squamous Cell Carcinoma : Review of the Eighth Edition of the American Joint Committee on Cancer Staging Guidelines, Prognostic Factors, and Histopathologic Variants. Adv Anat Pathol 24 : 171-194, 2017.
PubMed
2) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Squamous Cell Skin Cancer, Version 2. 2018, NCCN. org, 2017. [https://oncolife.com.ua/doc/nccn/Squamous_Cell_Skin_Cancer.pdf] (2021年4月閲覧)
 
3) Brierley JD, et al (ed) : TNM Classification of Malignant Tumours, 8th ed, Wiley, Chichester, 2017.
 
4) Brantsch KD, et al : Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma : a prospective study. Lancet Oncol 9 : 713-720, 2008.
PubMed
5) Brougham ND, et al : The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol 106 : 811-815, 2012.
PubMed
6) Schmults CD, et al : Factors predictive of recurrence and death from cutaneous squamous cell carcinoma : a 10-year, single-institution cohort study. JAMA Dermatol 149 : 541-547, 2013.
PubMed
7) Brantsch KD, et al : Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma : a prospective study. Lancet Oncol 9 : 713-720, 2008.
PubMed
8) Szewczyk M, et al : Analysis of selected risk factors for nodal metastases in head and neck cutaneous squamous cell carcinoma. Eur Arch Otorhinolaryngol 272 : 3007-3012, 2015.
PubMed
9) Kanitakis J, et al : Histopathologic features predictive of aggressiveness of post-transplant cutaneous squamous-cell carcinomas. Anticancer Res 35 : 2305-2308, 2015.
PubMed
10) Cassarino DS, et al : Cutaneous squamous cell carcinoma : a comprehensive clinicopathologic classification. Part one. J Cutan Pathol 33 : 191-206, 2006.
 
11) Cassarino DS, et al : Cutaneous squamous cell carcinoma : a comprehensive clinicopathologic classification. Part two. J Cutan Pathol 33 : 261-279, 2006.
 
12) Sulica VI, Kao GF : Squamous-cell carcinoma of the scalp arising in lesions of discoid lupus erythematosus. Am J Dermatopathol 10 : 137-141, 1988.
PubMed
13) Lichter MD, et al : Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol 136 : 1007-1011, 2000.
 
14) Carter JB, et al : Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion : an 11-year cohort study. JAMA Dermatol 149 : 35-41, 2013.
PubMed
15) Karia PS, et al : Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 32 : 327-334, 2014.
 
16) Cheng J, Yan S : Prognostic variables in high-risk cutaneous squamous cell carcinoma : a review. J Cutan Pathol 43 : 994-1004, 2016.
PubMed
17) Haisma MS, et al : Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol 75 : 722-730, 2016.
PubMed
18) Brinkman JN, et al : The Effect of Differentiation Grade of Cutaneous Squamous Cell Carcinoma on Excision Margins, Local Recurrence, Metastasis, and Patient Survival : A Retrospective Follow-Up Study. Ann Plast Surg 75 : 323-326, 2015.
PubMed
19) Patel NK, et al : Primary metaplastic carcinoma (carcinosarcoma) of the skin. A clinicopathologic study of four cases and review of the literature. Am J Dermatopathol 19 : 363-372, 1997.
 
20) Jambusaria-Pahlajani A, et al : Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol 149 : 402-410, 2013.
 
21) Saito Y, et al : Risk factors for lymph node metastasis in cutaneous squamous cell carcinoma : a long-term retrospective study of Japanese patients. Int J Clin Oncol 26 : 606-612, 2021.
PubMed
P.48 掲載の参考文献
1) Kallini JR, et al : Squamous cell carcinoma of the skin : epidemiology, classification, management, and novel trends. Int J Dermatol 54 : 130-140, 2015.
PubMed
2) Breuninger H, et al : Microstaging of squamous cell carcinomas. Am J Clin Pathol 94 : 624-627, 1990.
PubMed
3) Union for International Cancer Control : TNM classification of Malignant Tumors, 8th ed (ed by Brierley JD, et al), John Wiley & Sons Ltd, Chichester, 2017.
 
4) American Joint Committee on Cancer : AJCC Cancer Staging Manual, 8th ed (ed by Amin MB, et al), Springer, New York, 2017.
 
5) Bowe CM, et al : Comparison of the eighth edition of the TNM and Brigham Women's Hospital staging systems for cutaneous squamous cell carcinoma of the head and neck : asix-year review. Br J Oral Maxillofac Surg 58 : 1158-1163, 2020.
 
6) National Comprehensive Cancer Network [https://www.nccn.org] (2021年4月閲覧)
 
7) 日本皮膚科学会, ほか : 皮膚悪性腫瘍ガイドライン 第3版 有棘細胞癌診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 2501-2533, 2020.
 
P.54 掲載の参考文献
1) 安齋眞一, ほか : 皮膚悪性腫瘍診療ガイドライン改訂委員会 : 皮膚悪性腫瘍ガイドライン 第3版 有棘細胞癌ガイドライン 2020. 日本皮膚科学会雑誌 130 : 2501-2533, 2020.
 
2) NCCN Guidelines Version 1. 2021-Squamous Cell Skin Cancer. [https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf] (2021年5月閲覧)
 
3) Gupta AK, Paquet M : Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis : a follow-up on a Cochrane review. Br J Dermatol 169 : 250-259, 2013.
PubMed
4) Keohane SG, et al : British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020. Br J Dermatol 184 : 401-414, 2021.
PubMed
5) Siegel JA, et al : Current perspective on actinic keratosis : a review. Br J Dermatol 177 : 350-358, 2017.
PubMed
6) Brodland DG, zitelli JA : Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 27 : 241-248, 1992.
PubMed
7) Cognetta AB, et al : Superficial x-ray in the treatment of basal and squamous cell carcinomas : a viable option in select patients. J Am Acad Dermatol 67 : 1235-1241, 2012.
PubMed
8) Samstein RM, et al : Locally advanced and unresectable cutaneous squamous cell carcinoma : outcomes of concurrent cetuximab and radiotherapy. J Skin Cancer 2014 : 284582, 2014.
PubMed
9) Hourbeigt K et al : Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol 34 : 2789-2794, 2020.
PubMed
10) Lin C, et al : A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma. Radiat Oncol 16 : 69, 2021.
PubMed
11) Montaudie H, et al : Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma : a retrospective, multicentre study. Oncotarget 11 : 378-385, 2020.
PubMed
12) In GK, et al : PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma : a retrospective analysis from the University of Southern California. J Cancer Res Clin Oncol 147 : 1803-1811, 2021.
PubMed
13) Bonneville R, et al : Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol 2017 : PO.17.00073, 2017,
 
14) Gray SE, et al : Enhanced detection of microsatellite instability and mismatch repair gene expression in cutaneous squamous cell carcinomas. Mol Diagn Ther 10 : 327-334, 2006.
PubMed
15) Dudley JC, et al : Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res 22 : 813-820, 2016.
PubMed
P.59 掲載の参考文献
1) 斎田俊明 : 有棘細胞癌の診断と治療方針. Skin Cancer 9 (Special Issue) : 69-72, 1994.
 
2) Zalaudek I, et al : Dermoscopy of facial nonpigmented actinic keratosis. Br J Dermatol 155 : 951-956, 2006.
PubMed
3) Bugatti L, et al : Dermoscopic observation of Bowen's disease. J Eur Acad Dermatol Venereol 18 : 572-574, 2004.
 
4) Cassarino DS, et al : Cutaneous squamous cell carcinoma : a comprehensive clinicopathologic classification. Part one. J Cutan Pathol 33 : 191-206, 2006.
 
5) 安齋眞一, ほか : 皮膚原発有棘細胞癌 (Primary Cutaneous Squamous cell caricnoma) の臨床病理学的検討. 日皮会誌 118 : 29-36, 2008.
 
6) 安齋眞一, ほか : 皮膚悪性腫瘍ガイドライン 第3版 有棘細胞癌診療ガイドライン 2020. 日皮会誌 130 : 2501-2533, 2020.
 
7) 福本大輔, ほか : 皮膚原発浸潤性有棘細胞癌 (Primary Cutaneous Invasive Squamous cell caricnoma) の臨床病理学的検討 : 臨床病理学的新分類と予後の関係. 日皮会誌 121 : 2247-2256, 2011.
 
P.62 掲載の参考文献
1) 石原和之 : 統計調査よりみた紫外線と皮膚がん. Biotherapy 19 : 411-416, 2005.
Medical*Online
2) 石原和之 : 皮膚の老化と腫瘍病変-悪性腫瘍. Biotherapy 24 : 237-242, 2010.
Medical*Online
3) 石井良征, ほか : 有棘細胞癌およびボーエン病の全国調査. Skin Cancer 28 : 195-204, 2013.
 
4) 藤澤康弘 : [マルホ皮膚セミナー] 第111回日本皮膚科学会総会 (5) 教育講演20-1 皮膚腫瘍の最新疫学データ. [http://medical.radionikkei.jp/maruho_hifuka_pdf/maruho_hifuka-121206.pdf] (2021年4月閲覧)
 
5) 石原和之 : 発生頻度増加の要因. 癌と化学療法 33 : 1380-1385, 2006.
Medical*Online
6) 石原和之 : 本邦における皮膚悪性腫瘍の疫学. Skin Cancer 12 : 18-25, 1997.
 
7) 安齋眞一, ほか : 皮膚悪性腫瘍ガイドライン 第3版 有棘細胞癌診療ガイドライン 2020. 日皮会誌 130 : 2501-2533, 2020.
 
P.66 掲載の参考文献
1) 福本大輔, ほか : 皮膚原発浸潤性有棘細胞癌 (Primary Cutaneous Invasive Squamous cell carcinoma) の臨床病理学的検討 : 臨床病理学的新分類と予後の関係. 日皮会誌 121 : 2247-2255, 2011.
 
2) Ogita A, et al : Histopathological diagnosis of epithelial crateriform tumors : Keratoacanthoma and other epithelial crateriform tumors. J Dermatol 43 : 1321-1331, 2016.
PubMed
3) Murphy GF, et al : Squamous cell carcinoma. In : WHO Classification of Skin Tumours, 4th ed (ed by Elder DE, et al), p35-45, International Agency for Research on Cancer, Lyon, 2018.
 
P.72 掲載の参考文献
1) 有棘細胞癌 (SCC). 科学的根拠に基づく皮膚悪性腫瘍診療ガイドライン [第1版] (日本皮膚悪性腫瘍学会編), p41-57, 金原出版, 2007.
 
2) 有棘細胞癌 (SCC). 科学的根拠に基づく皮膚悪性腫瘍診療ガイドライン [第2版] (日本皮膚科学会/日本皮膚悪性腫瘍学会編), p43-62, 金原出版, 2015.
 
3) 安齋眞一, ほか : 皮膚悪性腫瘍ガイドライン 第3版 有棘細胞癌診療ガイドライン 2020. 日皮会誌 130 : 2501-2533, 2020.
 
4) Minds診療ガイドライン作成マニュアル 2020 ver. 3.0 (Minds診療ガイドライン作成マニュアル編集委員会編), p1-424, 公益財団法人日本医療機能評価機構, 2021.
 
5) Minds診療ガイドライン作成マニュアル 2017 (小島原典子, ほか編), p1-279, 公益財団法人日本医療機能評価機構, 2017.
 
6) Li6geois N, Olbricht S : Squamous cell carcinoma. In : Evidence-Based Dermatology (ed by Williams H, et al), p316-323, BMJ, London, 2003.
 
7) 有棘細胞癌. 皮膚悪性腫瘍取扱い規約 [第1版] (日本皮膚悪性腫瘍学会編), p38-48, 金原出版, 2002.
 
8) Brodland DG, Zitelli JA : Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 27 : 241-248, 1992.
PubMed
9) Motley R, et al : Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol 146 : 18-25, 2002.
PubMed
10) Cancer Council Australia/Australian Cancer Network : Clinical practice guide, basal cell carcinoma, squamous cell carcinoma (and related lesions) -a guide to clinical management in Australia, p1-160, 2008.
 
11) Newlands C, et al : Non-melanoma skin cancer : United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 130 : S125-S132, 2016.
PubMed
12) Weinstein MC, et al : The art and science of surgical margins for the dermatopathologist. Am J Dermatopathol 34 : 737-745, 2012.
PubMed
13) Kauvar AN, et al : Consensus for Nonmelanoma Skin Cancer Treatment, Part II : Squamous Cell Carcinoma, Including a Cost Analysis of Treatment Methods. Dermatol Surg 41 : 1214-1240, 2015.
PubMed
14) Fahradyan A, et al : Updates on the Management of Non-Melanoma Skin Cancer (NMSC). Healthcare (Basel) 5 : 82, 2017.
 
15) Work Group ; Invited Reviewers ; Kim JYS, et al : Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol 78 : 560-578, 2018.
PubMed
16) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) : Squamous Cell Skin Cancer. Verssion 1. 2019-Augest 31, 2018.
 
17) Stratigos A, et al : Diagnosis and treatment of invasive squamous cell carcinoma of the skin : European consensus-based interdisciplinary guideline. Eur J Cancer 51 : 1989-2007, 2015.
PubMed
18) Skulsky SL, et al : Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology. Head Neck 39 : 578-594, 2017.
PubMed
19) Khan AA, et al : Guidelines for the excision of cutaneous squamous cell cancers in the United Kingdom : the best cut is the deepest. J Plast Reconstr Aesthet Surg 66 : 467-471, 2013.
PubMed
20) Schell AE, et al : Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. JAMA Facial Plast Surg 15 : 337-343, 2013.
PubMed
21) Ribero S, et al : Squamocellular Carcinoma of the Skin : Clinicopathological Features Predicting the Involvement of the Surgical Margins and Review of the Literature. Dermatology 232 : 279-284, 2016.
PubMed
22) Lansbury L, et al : Interventions for non-metastatic squamous cell carcinoma of the skin : systematic review and pooled analysis of observational studies. BMJ 347 : f6153, 2013.
PubMed
23) Batchelor RJ, Stables GI : An audit of the management of cutaneous squamous cell carcinoma according to the multiprofessional guidelines. Br J Dermatol 154 : 1202-1203, 2006.
 
24) Umebayashi Y, et al : Most cases of cutaneous squamous cell carcinoma in Japan are classified as "high risk" according to the Japanese guideline. J Dermatol 39 : 812-814, 2012.
 
25) 石川雅士 : 局所進行病巣の局所管理 (モーズ, 悪臭対策など). 日本臨牀 71 (増刊 : 皮膚悪性腫瘍) : 565-567, 2013.
 
26) 梅林芳弘 : 有棘細胞癌の放射線療法, 薬物療法, 外用療法. 皮膚科臨床アセット 17 皮膚の悪性腫瘍 実践に役立つ最新の診断・治療 (山崎直也, ほか編), p236-240, 中山書店, 2014.
 
27) 梅林芳弘 : 有棘細胞癌. エキスパートから学ぶ皮膚病診療パワーアップ (秀道広, ほか編), p259-262, 中山書店, 2018 ; 梅林芳弘, ほか : 有棘細胞癌の診療ガイドラインについて. Derma 166 : 43-50, 2010.
 
P.77 掲載の参考文献
1) Rowe DE et al : Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 26 : 976-990, 1992.
PubMed
2) Krediet JT, et al : Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. Br J Dermatol 172 : 1029-1036, 2015.
PubMed
3) Levine DE, et al : Outcomes of Patients With Multiple Cutaneous Squamous Cell Carcinomas : A 10-Year Single-lnstitution Cohort Study. JAMA Dermatol 151 : 1220-1225, 2015.
 
4) Karia PS, et al : Clinical and Incidental Perineural Invasion of Cutaneous Squamous Cell Carcinoma : A Systematic Review and Pooled Analysis of Outcomes Data JAMA Dermatol 153 : 781-788, 2017.
PubMed
5) Breuninger H, et al : Desmoplastic squamous cell carcinoma of skin and vermilion surface : a highly malignant subtype of skin cancer. Cancer 79 : 915-919, 1997.
PubMed
6) https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf (2021年4月閲覧).
 
7) 安齋眞一, ほか : 皮膚悪性腫瘍ガイドライン 第3版 有棘細胞癌診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 2501-2533, 2020.
 
8) 有棘細胞癌. 皮膚悪性腫瘍取扱い規約, 第1版 (日本皮膚悪性腫瘍学会編), p38-48, 金原出版, 2002.
 
9) 整形外科・病理 悪性軟部腫瘍取扱い規約 [第3版] (日本整形外科学会 骨・軟部腫瘍委員会編), 金原出版, 2002.
 
10) 廣瀬寮二, ほか : 日光角化症の側方断端陽性例についての検討. Skin cancer 25 : 85-89, 2010.
 
11) Hansen JP, et al : Bowen's Disease : a four-year retrospective review of epidemiology and treatment at a university center. Dermatol Surg 34 : 878-883, 2008.
 
12) Mansouri B, et al : Mohs Micrographic Surgery for the Management of Cutaneous Malignancies. Facial Plast Surg Clin North Am 25 : 291-301, 2017.
PubMed
P.83 掲載の参考文献
1) Tejera-Vaquerizo A, et al : Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma. J Dermatol 45 : 781-790, 2018.
PubMed
2) Samsanavicius D, et al : Importance of sentinel lymphatic node biopsy in detection of early micrometastases in patients with cutaneous squamous cell carcinoma. J Plast Reconstr Aesthet Surg 71 : 597-603, 2018.
PubMed
3) Renzi C, et al : Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma : case series and review of the literature. Eur J Surg Oncol 33 : 364-369, 2007.
PubMed
4) Schmitt AR, et al : Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results : meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol 150 : 19-24, 2014.
 
5) Fukushima S, et al : Evaluation of sentinel node biopsy for cutaneous squamous cell carcinoma. J Dermatol 41 : 539-541, 2014.
PubMed
6) Stratigos AJ, et al : European interdisciplinary guideline on invasive squamous cell carcinoma of the skin : Part 1. epidemiology, diagnostics and prevention. Eur J Cancer 128 : 60-82, 2020.
PubMed
7) Morton DL, et al : Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370 : 599-609, 2014.
PubMed
8) Maruyama H, et al : Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma. J Dermatol 44 : 431-437, 2017.
PubMed
9) Takahashi A, et al : Sentinel node biopsy for high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol 40 : 1256-1262, 2014.
PubMed
10) Gore SM, et al : Prospective study of sentinel node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 38 (Suppl 1) : E884-889, 2016.
 
11) 皮膚悪性腫瘍ガイドライン 第3版 有棘細胞癌診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 2501-2533, 2020.
 
12) Faries MB, et al : Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 376 : 2211-2222, 2017.
 
P.89 掲載の参考文献
1) Ogata D, et al : Systemic treatment of patients with advanced cutaneous squamous cell carcinoma : response rates and outcomes of the regimes used. Eur J Cancer 127 : 108-117, 2020.
PubMed
2) Ikegawa S, et al : Cisplatin combination chemotherapy in squamous cell carcinoma and adenoid cystic carcinoma of the skin. J Dermatol 16 : 227-230, 1989.
PubMed
3) Sadek H, et al : Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66 : 1692-1696, 1990.
PubMed
4) Guthrie TH, et al : Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin : results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 8 : 342-346, 1990.
PubMed
5) Jarkowski A, et al : Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC) : The Roswell Park Experience and a Review of the Literature. Am J Clin Oncol 39 : 545-548, 2016.
 
6) Nakamura Y, et al : Carboplatin and epirubicin combination therapy for advanced malignant epithelial skin tumors : Retrospective study of six patients. J Dermatol 45 : 874-875, 2018.
PubMed
7) Teramoto Y, et al : Oral S-1 in advanced cutaneous squamous cell carcinoma. J Dermatol 41 : 494-497, 2014.
 
8) Ikeda S, et al : Peplomycin therapy for skin cancer in Japan. Drugs Exp Clin Res 12 : 247-255, 1986.
PubMed
9) 池田重雄, ほか : 有棘細胞癌および悪性黒色腫に対する塩酸イリノテカン (CPT-11) の後期第II相臨床試験. Skin Cancer 8 : 503-513, 1993.
 
10) 今高博美, ほか : CPT-11の有害事象のリスク. 日本臨牀 74 : 1847-1851, 2016.
Medical*Online
11) Porceddu SV, et al : Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck : The Randomized Phase III TROG 05.01 Trial. J Clin Oncol 36 : 1275-1283, 2018.
 
12) Tanvetyanon T, et al : Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 37 : 840-845, 2015.
PubMed
13) Hiura A, et al : Chemoradiotherapy could improve overall survival of patients with stage IV cutaneous squamous cell carcinoma : analysis of 34 cases. Br J Dermatol 180 : 1557-1558, 2019.
PubMed
P.93 掲載の参考文献
1) 坂下智博 : 動注化学療法の症例. 頭頸部癌FRONTIER 4 : 114-116, 2016.
Medical*Online
2) 高橋和宏, 赤坂俊英 : 有棘細胞癌の動注化学療法. 日本臨牀 71 (増刊 : 皮膚悪性腫瘍) : 512-516, 2013.
 
3) 中谷宏章, ほか : 皮下埋込式リザーバーを用いた新動注療法. 耳鼻咽喉科臨床 97 : 47-54, 2004.
 
4) 權藤寿喜, ほか : 動注化学と放射線療法が奏効した大腿部外傷瘢痕に生じた巨大有棘細胞癌の1例. Skin Cancer 23 : 379-383, 2008.
 
P.97 掲載の参考文献
1) Reuter CW, et al : Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 96 : 408-416, 2007.
PubMed
2) Cariueto J, et al : Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma. Br J Dermatol 176 : 1279-1287, 2017.
PubMed
3) 三窪将史, 佐藤之俊 : 分子標的治療とは. Medical Technology 45 : 328-332, 2017.
Medical*Online
4) Al-Rohil RN, et al : Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer 122 : 249-257, 2016.
PubMed
5) Picard A, et al : Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab. JAMA Dermatol 153 : 291-298, 2017.
PubMed
6) de Lima PO, et al : Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies. Curr Treat Options Oncol 21 : 9, 2020.
 
7) Bauman JE, et al : Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 143 : 889-892, 2007.
PubMed
8) Maubec E, et al : Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29 : 3419-3426, 2011,
PubMed
9) Foote MC, et al : Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 25 : 2047-2052, 2014.
PubMed
10) Huang SM, Harari PM : Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas : inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 : 2166-2174, 2000.
PubMed
11) Preneau S, et al : Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat 25 : 424-427, 2014.
PubMed
12) Joseph K, et al : Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma. J Med Imaging Radiat Oncol 63 : 257-263, 2019.
PubMed
13) Mecca C, et al : Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol 22 : 758-761, 2012.
PubMed
14) 朝長絵理子, ほか : セツキシマブ・パクリタキセル併用療法が有効であった難治性転移性有棘細胞癌の1例. Skin Cancer 31 : 276-279, 2017.
 
15) Magrini SM, et al : Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer : A Randomized Phase II Trial. J Clin Oncol 34 : 427-435, 2016.
PubMed
16) 澤田匡秀, ほか : Cetuximabによる治療が奏功した頭頸部有棘細胞癌の2例. 西日本皮膚 79 : 55-58, 2017.
 
17) Chen A et al : Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab. J Clin Med 7 : 10, 2018.
 
18) William WN, et al : Gefitinib for patients with incurable cutaneous squamous cell carcinoma : A single-arm phase II clinical trial. J Am Acad Dermatol 77 : 1110-1113. e2, 2017.
 
19) Gold KA, et al : Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma : A single-arm phase 2 clinical trial. Cancer 124 : 2169-2173, 2018.
PubMed
20) Montaudie H, et al : Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma : a retrospective, multicentre study. Oncotarget 11 : 378-385, 2020.
PubMed
21) 高橋克昌, ほか : 頭頸部癌におけるセツキシマブによる間質性肺炎. 日本耳鼻咽喉科学会会報 120 : 1467-1472, 2017.
Medical*Online
22) 畑智恵子, ほか : 大腸がんまたは頭頸部がん患者における抗EGFR抗体薬による低マグネシウム血症の発現実態調査. 日本病院薬剤師会雑誌 56 : 905-912, 2020.
Medical*Online
23) 千貫祐子 : 生物製剤. アレルギー・免疫 25 : 634-641, 2018.
 
24) Keohane SG et al : British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020. Br J Dermatol 184 : 401-414, 2021.
PubMed
25) Migden MR, et al : PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 379 : 341-351, 2018.
PubMed
26) 小澤雄一 : 免疫チェックポイント阻害薬と抗体医薬の併用. がん分子標的治療 14 : 217-221, 2016.
Medical*Online
27) Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer. [https://clinicaltrials.gov/ct2/show/NCT03944941] (2021年6月閲覧)
 
P.103 掲載の参考文献
1) 科学的根拠に基づく皮膚悪性腫瘍診療ガイドライン [第2版] (日本皮膚科学会, 日本皮膚悪性腫瘍学会編), 金原出版, 2015.
 
2) Euvrard S, et al : Skin cancers after organ transplantation. N Engl J Med 348 : 1681-1691, 2003.
PubMed
3) Chalmers ZR, et al : Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9 : 34, 2017.
PubMed
4) National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Squamous Cell Skin Cancer Version 2. 2020.
 
5) Kiyota N, et al : A randomized, open-1abel, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck : A subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol 73 : 138-146, 2017.
 
6) Burtness B, et al : Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study. Lancet 394 : 1915-1928, 2019.
 
7) National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Head and Neck Cancers Version 1. 2021
 
8) Migden MR, et al : PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 379 : 341-351, 2018.
PubMed
9) Guminski AD, et al : Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC ; group 1) : 12-month follow-up. J Clin Oncol 37 (suppl) : 9526, 2019. (DOI : 10.1200/JCO.2019.37.15_suppl.9526)
 
10) Migden MR, et al : Cemiplimab in locally advanced cutaneous squamous cell carcinoma : results from an open-label, phase 2, single-arm trial. Lancet Oncol 21 : 294-305, 2020.
PubMed
11) Grob JJ, et al : Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma : A Single-Arm Phase II Trial (KEYNOTE-629). J Clin Oncol 38 : 2916-2925, 2020.
PubMed
12) Maubec E, et al : Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC) : Phase 2 results from CARSKIN. J Clin Oncol 37 (Suppl) : 9547, 2019. (DOI : 10.1200/JCO.2019.37.15_suppl.9547)
 
13) Tsung I, et al : A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma. Oncologist 26 : 133-138, 2021.
PubMed
14) Leiter U, et al : Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy : a retrospective multicenter DeCOG study of 84 patients. J Immunother Cancer 8 : e000897, 2020. (DOI : 10.1136/jitc-2020-000897)
 
P.108 掲載の参考文献
1) Al-Rohil RN, et al : Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer 122 : 249-257, 2016.
PubMed
2) Pickering CR, et al : Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 20 : 6582-6592, 2014.
PubMed
3) Arora S, et al : Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors, Adv Ther 36 : 2638-2678, 2019.
PubMed
4) Yarchoon M, et al : Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med 377 : 2500-2501, 2017.
 
5) Falchook GS, et al : Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer 4 : 70, 2016.
PubMed
6) Migden MR, et al : PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 379 : 341-351, 2018.
PubMed
7) Migden MR, et al : Cemiplimab in locally advanced cutaneous squamous cell carcinoma : results from an open-label, phase 2, single-arm trial. Lancet Oncol 21 : 294-305, 2020.
PubMed
8) Aung N, et al : Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8 : e000347, 2020.
 
9) Grob JJ, et al : Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma : A Single-Arm Phase II Trial (KEYNOTE-629). J Clin Oncol 38 : 2916-2925, 2020.
PubMed
10) Ferris RL, et al : Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 375 : 1856-1867, 2016.
PubMed
11) Ishii M, et al : Anti-PD-1 antibody therapy for epithelial skin malignancies : An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study). Medicine (Baltimore) 99 : e22913, 2020.
PubMed
12) Jalili A, et al : Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 6 : 1066-1069, 2008.
 
13) de Lima PO, et al : Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies. Curr Treat Options Oncol 21 : 9, 2020.
 
14) Kim JH, et al : Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy. Clin Transl Immunology 9 : e1168, 2020.
PubMed
15) Porceddu SV, et al : Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck : The Randomized Phase III TROG 05.01 Trial. J Clin Oncol 36 : 1275-1283, 2018.
 
P.112 掲載の参考文献
1) Alam M, Ratner D : Cutaneous squamous-cell carcinoma. N Engl J Med 344 : 975-983, 2001.
PubMed
2) Kwan W, et al : Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 60 : 406-411, 2004.
PubMed
3) NCCN Clinical Practice Guidelines in Oncology Squamous Cell Skin Cancer Version 1. 2021. [https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf]
 
4) Strom TJ, et al : Management of BCC and SCC of the Head and Neck. Cancer Control 23 : 220-227, 2016.
PubMed
5) Fowler JF : The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 : 679-694, 1989.
PubMed
6) Zaorsky NG, et al : Hypofractionated radiation therapy for basal and squamous cell skin cancer : A meta-analysis. Radiother Oncol 125 : 13-20, 2017.
PubMed
7) Nottage MK, et al : Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck 39 : 679-683, 2017.
PubMed
8) Barnes EA, et al : Palliative radiotherapy for non-melanoma skin cancer. Clin Oncol (R Coll Radiol) 22 : 844-849, 2010.
PubMed
9) Vuong W, et al : Palliative radiotherapy for skin malignancies. Ann Palliat Med 6 : 165-172, 2017.
PubMed
P.115 掲載の参考文献
1) Strom TJ, et al : Management of BCC and SCC of the Head and Neck. Cancer Control 23 : 220-227, 2016.
PubMed
2) Warren TA, et al : Outcomes after surgery and postoperative radiotherapy for perineural spread of head and neck cutaneous squamous cell carcinoma. Head Neck 38 : 824-831, 2016.
PubMed
3) Gluck I, et al : Skin cancer of the head and neck with perineural invasion : defining the clinical target volumes based on the pattern of failure. Int J Radiat Oncol Biol Phys 74 : 38-46, 2009.
PubMed
4) Tanvetyanon T, et al : Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 37 : 840-845, 2015.
PubMed
5) Porceddu SV, et al : Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck : The Randomized Phase III TROG 05.01 Trial. J Clin Oncol 36 : 1275-1283, 2018.
 
P.119 掲載の参考文献
1) Leffell DJ : The scientific basis of skin cancer. J Am Acad Dermatol 42 : 18-22, 2000.
PubMed
2) Naylor MF, et al : High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 131 : 170-175, 1995.
PubMed
3) Boyd AS, et al : The effects of chronic sunscreen use on the histologic changes of dermatoheliosis. J Am Acad Dermatol 33 : 941-946, 1995.
PubMed
4) Iannacone MR, et al : Effects of sunscreen on skin cancer and photoaging. Photodermatol Photoimmunol Photomed 30 : 55-61, 2014.
PubMed
5) Nagano T, et al : Skin cancer screening in Okinawa, Japan. J Dermatol Sci 19 : 161-165, 1999.
 
6) Thomson J, et al : The Genomic Landscape of Actinic Keratosis : J Invest Dermatol. 2021. (DOI : 10.1016/j.jid.2020.12.024)
 
7) Boyle J, et al : Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet 1 : 702-705, 1984.
 
8) McBride P, et al : Sun-related factors, betapapillomavirus, and actinic keratoses : a prospective study. Arch Dermatol 143 : 862-868, 2007.
PubMed
9) 市橋正光 : 光老化. 皮膚臨床 43 : 1305-1312, 2001.
 
10) Siegel JA, et al : Current perspective on actinic keratosis : a review. Br J Dermatol 177 : 350-358, 2017.
PubMed
P.127 掲載の参考文献
1) 日本皮膚科学会ガイドライン 皮膚悪性腫瘍ガイドライン 第3版 有棘細胞癌診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 2501-2533, 2020.
 
2) 廣瀬寮二, ほか : 日光角化症の臨床診断の不確かさと危険性. Skin Cancer 29 : 33-37, 2014.
 
3) Huerta-Brogeras M, et al : Validation of dermoscopy as a real-time noninvasive diagnostic imaging technique for actinic keratosis. Arch Dermatol 148 : 1159-1164, 2012.
PubMed
4) Szeimies RM, et al : Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis : Aprospective, randomized study. J Am Acad Dermatol 47 : 258-262, 2002.
 
5) Fayter D, et al : A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess 14 : 1-288, 2010.
 
6) Goldberg LH, et al : Liquid nitrogen : temperature control in the treatment of actinic keratosis. Dermatol Surg 36 : 1956-1961, 2010.
PubMed
7) Thai KE, et al : A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 43 : 687-692, 2004.
PubMed
8) American Academy of Dermatology Association : ACTINIC KERATOSIS : DIAGNOSIS AND TREATMENT. [https://www.aad.org/public/diseases/skin-cancer/actinic-keratosis-treatment] (2021年5月閲覧)
 
9) Werner RN, et al : Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis-International League of Dermatological Societies in cooperation with the European Dermatology Forum-Short version. J Eur Acad Dermatol Venereol 29 : 2069-2079, 2015.
PubMed
10) 廣瀬寮二, ほか : 日光角化症の側方断端陽性例についての検討. Skin Cancer 25 : 85-89, 2010.
 
P.132 掲載の参考文献
1) 土田哲也, ほか : CQ12 日光角化症の治療は何が勧められるか ; 皮膚悪性腫瘍診療ガイドライン 第2版. 日本皮膚科学会雑誌 125 : 43, 2015.
 
2) 斎田俊明 (監) : 日光角化症. 日光角化症・皮膚癌カラーアトラス, p12-39, メディカルレビュー社, 2012.
 
3) ベセルナクリーム 5% : 添付文書, 持田製薬, 2017.
 
4) Schon MP, Schon M : Imiquimod : mode of action. Br J Dermatol 157 (Suppl 2) : 8-13, 2007.
 
5) 5-FU軟膏5%協和 : 添付文書, 協和キリン, 2019.
 
6) Askew DA, et al : Effectiveness of 5-fluorouracil treatment for actinic keratosis-a systematic review of randomized controlled trials. Int J Dermatol 48 : 453-463, 2009.
PubMed
7) 小澤俊幸 : 光線過敏を使用した皮膚科治療 : PDT. 日本皮膚科学会雑誌 127 : 2791-2797, 2017.
 
P.136 掲載の参考文献
1) Bowen JT : Precancerous dermatoses : A study of two cases of chronic atypical epithelial proliferation. J Cutan Dis Syph 30 : 241-255, 1912.
PubMed
2) Chuang TY, et al : Nonmelanoma skin cancer in Japanese ethnic Hawaiians in Kauai, Hawaii : an incidence report. J Am Acad Dermatol 33 : 422-426, 1995.
PubMed
3) Liang SB, et al : Sun-exposure-and aging-dependent p53 protein accumulation results in growth advantage for tumour cells in carcinogenesis of nonmelanocytic skin cancer. Virchows Arch 434 : 193-199, 1999.
PubMed
4) 小林桂子, ほか : 外用PUVA療法と発癌. 日皮会誌 112 : 1247-1251, 2002.
 
5) Matsui M, et al : The role of oxidative DNA damage in human arsenic carcinogenesis : detection of 8-hydroxy-2'-deoxyguanosine in arsenic-related Bowen's disease. J Invest Dermatol 113 : 26-31, 1999.
PubMed
6) Meyer T, et al : Importance of human papillomaviruses for the development of skin cancer. Cancer Detect Prev 25 : 533-547, 2001.
PubMed
7) McGrae JD, et al : Multiple Bowen's disease of the fingers associated with human papilloma virus type 16. Int J Dermatol 32 : 104-107, 1993.
 
8) Asai J, Ohyama M : Human papillomavirus and cutaneous squamous cell carcinoma : does ethnicity matter? Br J Dermatol 171 : 689, 2014.
PubMed
9) Perruchoud DL, et al : Bowen disease of the nail unit : a retrospective study of 12 cases and their association with human papillomaviruses. J Eur Acad Dermatol Venereol 30 : 1503-1506, 2016.
PubMed
10) Shimizu A, et al : Detection of human papillomavirus type 56 in Bowen's disease involving the nail matrix. Br J Dermatol 158 : 1273-1279, 2008.
 
11) Kao GF : Carcinoma arising in Bowen's disease. Arch Dermatol 122 : 1124-1126, 1986.
PubMed
P.144 掲載の参考文献
1) 科学的論拠に基づく皮膚悪性腫瘍診療ガイドライン [第2版] (日本皮膚科学会, 日本皮膚悪性腫瘍学会編), p57, 金原出版, 2015.
 
2) 廣瀬寮二, ほか : 日光角化症の側方断端陽性例についての検討. Skin Cancer 25 : 85-89, 2010.
 
3) Basal cell and squamous cell skin cancers. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology 2010.
 
4) Morton CA, et al : British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014. Br J Dermatol 170 : 245-260, 2014.
 
5) Bell HK, Rhodes LE : Bowen's disease-a retrospective review of clinical management. Clin Exp Dermatol 24 : 338-339, 1999.
 
6) Wollina U : Bowen's disease of the nail apparatus : a series of 8 patients and a literature review. Wien Med Wochenschr 165 : 401-405, 2015.
 
7) Honeycutt WM, Jansen GT : Treatment of squamous cell carcinoma of the skin. Arch Dermatol 108 : 670-672, 1973.
PubMed
8) Stevens DM, et al : Treatment of Bowen's disease with grenz rays. Int J Dermatol 16 : 329-339, 1977.
 
P.149 掲載の参考文献
1) 科学的根拠に基づく皮膚悪性腫瘍診療ガイドライン [第2版] (日本皮膚科学会, 日本皮膚悪性腫瘍学会編), p55-58, 金原出版, 2015.
 
2) Cox NH, et al : Guidelines for management of Bowen's disease : 2006 update. Br J Dermatol 156 : 11-21, 2007.
PubMed
3) Morton CA, et al : British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014. Br J Dermatol 170 : 245-260, 2014.
 
4) 八田尚人 : イミキモド (ベセルナクリーム). 皮膚科の臨床 58 : 988-993, 2016.
 
5) 長野徹 : ベセルナクリームの使い方-日光角化症に使用した例. Visual Dermatology 19 : 1052-1053, 2020.
 
6) 山田瑞穂, ほか : 皮膚悪性腫瘍に対する5FU軟膏の使用経験. 皮膚科紀要 68 : 75-88, 1973.
 
7) 延山嘉眞 : 皮膚に表在する悪性腫瘍に対する外用療法. Monthly Book Derma 300 : 165-172, 2020.
 
8) Love WE, et al : Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma : a systematic review. Arch Dermatol 145 : 1431-1438, 2009.
PubMed
9) 長野徹, 錦織千佳子 : PDTの臨床例 (1) 腫瘍性病変 日光角化症. Visual Dermatology 7 : 860-861, 2008.
 
10) 長野徹 : 光線力学療法-その現況と展望-. 皮膚病診療 38 : 860-864, 2016.
 
11) 松本義也 : PDTの適応疾患と海外の評価. Visual dermatology 7 : 846-847, 2008.
 
12) Morton C, et al : Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ : Results of a multicenter randomized trial. Arch Dermatol 142 : 729-735, 2006.
 
13) 村田洋三 : Bowen病補遺. 皮膚の科学 16 : 298-305, 2017.
 
14) 安井敬子, ほか : 使い捨てカイロを用いて温熱療法を行ったBowen病の1例. 皮膚科の臨床 46 : 2047-2049, 2004.
 
P.153 掲載の参考文献
1) Saito Y, et al : Risk factors for lymph node metastasis in cutaneous squamous cell carcinoma : a long-term retrospective study of Japanese patients. Int J Clin Oncol 26 : 606-612, 2021.
PubMed
2) 藤原豊博 : がん患者の皮膚潰瘍部位の悪臭. 月刊薬事 58 : 2597-2602, 2016.
Medical*Online
3) Malodorous tumours. In : Symptom Relief in Terminal Illness, p95, WHO, 1998.
 
4) 竹之内辰也 : 癌性悪臭に対するメトロニダゾール外用薬. 臨床皮膚科 70 : 119-123, 2016.
 
5) 吉野公二 : 癌性潰瘍に対するマネジメント. 皮膚病診療 42 : 934-938, 2020.
 
6) 松井悠, 竹之内辰也 : 亜鉛華デンプンの使い方～腫瘍に使用した例. Visual Dermatology 19 : 1002-1003, 2020.
 
7) Mohs FE, et al : Chemosurgery : a microscopically controlled method of cancer excision. Arch Surg 42 : 279-295, 1941.
 
8) 吉福孝介, ほか : 出血を繰り返す中咽頭癌後発リンパ節転移症例に対するMohs軟膏の有用性. 耳鼻と臨床 60 : 67-71, 2014.
 
9) 亀井滝士, ほか : Mohsペーストと薬物療法によりQOLが著明に改善した進行乳癌の1例. 癌と化学療法 45 : 2099-2101, 2018.
Medical*Online
10) 藤原豊博 : がん性創傷. 月刊薬事 58 : 2777-2781, 2016.
Medical*Online
P.158 掲載の参考文献
1) Lever WF, Schaumburg-Lever G : Keratoacanthoma. In : Histopathology of the Skin, 7th ed, p560-563, Lippincott, Philadelphia, 1990.
 
2) Rook A, Whimster I : Keratoacanthoma-a thirty year retrospect. Br J Dermatol loo : 41-47, 1979.
 
3) Schwartz RA : Keratoacanthoma. J Am Acad Dermatol 30 : 1-19 ; quiz 20-22, 1994.
 
4) Schwartz RA : Keratoacanthoma : a clinico-pathologic enigma. Dermatol Surg 30 : 326-333 ; discussion 333, 2004.
 
5) Ko CJ : Keratoacanthoma : Facts and controversies. Clin Dermatol 28 : 254-261, 2010.
PubMed
6) Kwiek B, Schwartz RA : Keratoacanthoma (KA) : An update and review. J Am Acad Dermatol 74 : 1220-1233, 2016.
 
7) Gleich T, et al : Keratoacanthoma : a distinct entity? Exp Dermatol 25 : 85-91, 2016.
PubMed
8) Hutchinson J : Morbid growths and tumors : 1. The "crateriform ulcer of the face", a form of acute epithelial cancer. Trans Pathol Soc London 40 : 275-281, 1889.
 
9) Yamagiwa K, Ichikawa K : Experimental study of the pathogenesis of carcinoma. J Cancer Res 3 : 1-29, 1918.
 
10) Ghadially FN : The role of the hair follicle in the origin and evolution of some cutaneous neopalsms of man and experimental animals. Cancer 14 : 801-816, 1961.
 
11) Kossard S, et al : Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol 30 : 127-134, 2008.
PubMed
12) Misago N, et al : The changes in the expression levels of follicular markers in keratoacanthoma depend on the stage : keratoacanthoma is a follicular neoplasm exhibiting infundibular/isthmic differentiation without expression of CK15. J Cutan Pathol 41 : 437-446, 2014.
PubMed
13) Misago N, et al : Keratoacanthoma and other types of squamous cell carcinoma with crateriform architecture : classification and identification. J Dermatol 40 : 443-452, 2013.
PubMed
14) Misago N, et al : Infundibular (follicular) and infundibulocystic squamous cell carcinoma : a clinicopathological and immunohistochemical study. Am J Dermatopathol 33 : 687-694, 2011.
PubMed
15) Misago N, et al : Crater/ulcerated form of infundibular squamous cell carcinoma : A possible distinct entity as a malignant (or high-grade) counterpart to keratoacanthoma. J Dermatol 42 : 667-673, 2015.
PubMed
16) Takai T, et al : Natural course of keratoacanthoma and related lesions after partial biopsy : clinical analysis of 661esions. J Dermatol 42 : 353-362, 2015.
PubMed
P.161 掲載の参考文献
1) Murphy GF, et al : Squamous cell carcinoma. In : WHO Classification of Skin Tumours, 4th ed (ed by Elder DE, et al), p3545, IARC, Lyon, 2018.
 
2) Minielly JA, et al : Verrucous squamous cell carcinoma of the esophagus. Cancer 20 : 2078-2087, 1967.
PubMed
3) Sun D, et al : Non-HPV-related verrucous carcinoma of the endometrium : report of one case and review of literature. Int J Clin Exp Pathol 13 : 1444-1450, 2020.
PubMed
4) Ackerman LV : Verrucous carcinoma of the oral cavity. Surgery 23 : 670-678, 1948.
PubMed
5) Burkhardt A : Verrucous carcinoma and carcinoma cuniculatum-forms of squamous cell carcinoma?. Hautarzt 37 : 373-383, 1986.
PubMed
6) Aird I, et al : Epithelioma cuniculatum : a variety of squamous carcinoma peculiar to the foot. Br J Surg 42 : 245-250, 1954.
 
7) Buschke A, Loewenstein L : Uber Carcinomahnliche Condylomata Acuminata des Penis. Klin Wochenschr 4 : 1726-1728, 1925.
 
8) Knoblich R, Failing JF Jr : Giant condyloma acuminatum (Buschke-Lowenstein tumor) of the rectum. Am J Clin Pathol 48 : 389-395, 1967.
PubMed
9) Bean SM, Bentley RC : Squamous Cell Carcinoma of the Vulva. In : Vulvar Pathology (ed by Hoang MP, Selim MA), p297-324, Springer, New York,2014.
 
10) Haenen CCP, et al : Squamous cell carcinoma arising in hypertrophic lichen planus. BMJ Case Rep 2018 : bcr2017224044, 2018.
PubMed
11) Velazquez EF, Cubilla AL : Lichen sclerosus in 68 patients with squamous cell carcinoma of the penis : frequent atypias and correlation with special carcinoma variants suggests a precancerous role. Am J Surg Pathol 27 : 1448-1453, 2003.
PubMed
12) Priesand SJ, Holmes CM : Malignant Transformation of a Site of Prior Diabetic Foot Ulceration to Verrucous Carcinoma : A Case Report. Wounds 29 : E125-E131, 2017.
PubMed
13) Brandsma JL, et al : Presence of human papillomavirus type 16 related sequences in verrucous carcinoma of the larynx. Cancer Res 46 : 2185-2188, 1986.
PubMed
14) Imko-Walczuk B, et al : Human papillomavirus-related verrucous carcinoma in a renal transplant patient after long-term immunosuppression : a case report. Transplant Proc 46 : 2916-2919, 2014.
 
15) del Pino M, et al : Comprehensive analysis of human papillomavirus prevalence and the potential role of low-risk types in verrucous carcinoma. Mod Pathol 25 : 1354-1363, 2012.
PubMed
16) Handisurya A, et al : Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy. Br J Dermatol 157 : 788-794, 2007.
 
17) Habif TP : Premalignant and Malignant Nonmelanoma Skin Tumors. In : Clinical Dermatology, 6th ed (ed by Habif TP), p836-837, Elsevier, Edinburgh, 2015.
 
18) 塩見達志 : 表皮系腫瘍 悪性病変. 癌診療指針のための病理診断プラクティス 皮膚腫瘍 (青笹克之, 清水道生, 新井栄一編) , p90-101, 中山書店, 2017.
 
19) Wang G, et al : Genital verruciform xanthoma : lessons from a contemporary multi-institutional series. Histopathology 77 : 841-846, 2020.
PubMed
20) Di Palma V, et al : Mistaken Diabetic Ulcers : A Case of Bilateral Foot Verrucous Carcinoma. Case Rep Dermatol Med 2018 : 4192657, 2018.
 
21) Rozas-Mufioz E, et al : Verrucous Plaque With Unusually Large Candida Blastoconidia : A Unique Clinicopathological Presentation of Systemic Mucocutaneous Candidiasis. Am J Dermatopathol 40 : 846-848, 2018.
 
22) Salman A, et al : Cutaneous leishmaniasis mimicking verrucous carcinoma : Acase with an unusual clinical course. Indian J Dermatol Venereol Leprol 81 : 392-394, 2015.
 
23) Ruiz-Villaverde R, et al : Verrucous tumor mimicking squamous cell carcinoma in immunocompetent patient. Dermatol Online J 22 : 13030/qt93z9c7pm, 2016.
PubMed
24) Ezzedine K, et al : Cutaneous verrucous carcinoma arising in lupus vulgaris. J Dermatol 39 : 505-507, 2012.
PubMed
25) Gertler R, Weber KD : Management of verrucous carcinoma of the hand : a case report. Int J Dermatol 48 : 1233-1235, 2009.
 
P.166 掲載の参考文献
1) Pulitzer MP, et al : Squamous cell carcinoma in situ (Bowen disease). In : WHO Classification of Skin Tumours, 4th ed (ed by Elder DE, et al), p46-47, IARC, Lyon, 2018.
 
2) Lloyd KM : Multicentric pigmented Bowen's disease of the groin. Arch Dermatol 101 : 48-51, 1970.
 
3) Kopf AW, Bart RS : Tumor conference No. 11 : multiple bowenoid papules of the penis : anew entity? J Dermatol Surg Oncol 3 : 265-269, 1977.
 
4) Ikenberg H, et al : Human papillomavirus type-16-related DNA in genital Bowen's disease and in Bowenoid papulosis. Int J Cancer 32 : 563-565, 1983.
 
5) Habif TP : Premalignant and Malignant Nonmelanoma Skin Tumors. In : Clinical Dermatology, 6th ed (ed by Habif TP), p426, Elsevier, Edinburgh, 2015.
 
6) Heppt MV, et al : Epithelial Precancerous Lesions. In : Fitzpatrick's Dermatology, 9th ed (ed by Kang S, et al), pl857-1883, McGraw Hill, New York, 2019.
 
7) Dubina M, Goldenberg G : Viral-associated nonmelanoma skin cancers : a review. Am J Dermatopathol 31 : 561-573, 2009.
PubMed
8) Murao K, et al : Human papillomavirus infection in Bowen disease : negative p53 expression, not p16 (INK4a) overexpression, is correlated with human papillomavirus-associated Bowen disease. J Dermatol 41 : 878-884, 2014.
 
9) Kutlubay Z, et al : Anogenital malignancies and premalignancies : facts and controversies. Clin Dermatol 31 : 362-373, 2013.
PubMed
10) 石地尚興 : ウイルス性疣贅update ; 尖圭コンジローマとボーエン様丘疹症の病態と鑑別. 日皮会誌 127 : 427-434, 2017.
 
11) Shimizu A, et al : Bowenoid papulosis successfully treated with imiquimod 5% cream. J Dermatol 41 : 545-546, 2014.
 
12) 江川清文 : ボーエン様丘疹症. 疣贅 (いぼ) のみかた, 治療のしかた (江川清文編著), p128-133, 秀潤社, 2017.
 
13) Kawakami A, et al : Spontaneous regression of bowenoid papulosis in a patient with acquired immunodeficiency syndrome after an increase in peripheral CD4+ T lymphocytes. Int J Dermatol 48 : 210-212, 2009.
 
P.170 掲載の参考文献
1) Abenoza P, Ackerman AB : Porocarcinomas. In : Neoplasms with Eccrine Differentiation, p413-431, Lea & Febiger, Philadelphia, 1990.
 
2) Robson A, et al : Eccrine porocarcinoma (malignant eccrine poroma) : aclinicopathologic study of 69 cases. Am J Surg Pathol 25 : 710-720, 2001.
 
3) Cardoso JC, Calonje E : Malignant sweat gland tumours : an update. Histopathology 67 : 589-606, 2015.
PubMed
4) 山元修, 安齋眞一 : 汗孔癌の病理組織学的診断の落とし穴. 皮膚科臨床アセッ ト 9エキスパートに学ぶ皮膚病理診断学 (古江増隆, 山元修編), p416-419, 中山書店, 2012.
 
5) Goto K, et al : CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma. J Cutan Pathol 43 : 219-226, 2016.
PubMed
6) Mahalingam M, et al : An immunohistochemical comparison of cytokeratin 7, cytokeratin 15, cytokeratin l9, CAM 5.2, carcinoembryonic antigen, and nestin in differentiating porocarcinoma from squamous cell carcinoma. Hum Pathol 43 : 1265-1272, 2012.
 
7) Miura K, et al : Engrailed Homeobox 1 and Cytokeratin 19 Are Independent Diagnostic Markers of Eccrine Porocarcinoma and Distinguish It From Squamous Cell Carcinoma. Am J Clin Pathol 154 : 499-509, 2020.
PubMed
8) Sekine S, et al : Recurrent YAP1-MAML2 and YAPI-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest 129 : 3827-3832, 2019.
 
9) Patterson JW : Sebaceous tumors. In : Weedon's Skin Pathology, 4th ed, p923-932, Churchill Livingstone, Edinburgh, 2016.
 
10) Steffen C : Neoplasms with sebaceous differentiation. In : Pathology of the Skin, 2nd ed (ed by Farmer ER, Hood AF), plO35-1058, McGraw-Hill, New York, 1999.
 
11) Wu A, et al : Cutaneous sebaceous carcinoma. Australas J Dermatol 61 : e285-e292, 2020.
 
12) 山元修 : 脂腺系腫瘍. 癌診療指針のための病理診断プラクティス : 皮膚腫瘍 (青笹克之, ほか編), p121-129, 中山書店, 2017.
 
13) Ho J, Bhawan J : Folliculosebaceous neoplasms : Areview of clinical and histological features. J Dermatol 44 : 259-278, 2017.
 
14) Ansai SI : Topics in histopathology of sweat gland and sebaceous neoplasms. J Dermatol 44 : 315-326, 2017.
PubMed
15) Kuo T : Clear cell carcinoma of the skin. A variant of the squamous cell carcinoma that simulates sebaceous carcinoma. Am J Surg Pathol 4 : 573-583, 1980.
PubMed

III 基底細胞癌

P.177 掲載の参考文献
1) 小野友道 : 基底細胞癌の診断と治療方針. Skin Cancer 9 : 78-80, 1994.
 
2) NCCN clinical practice guidelines in oncology (NCCN guidelines), Basal cell skin cancer, version 12020, Oct 24, 2019.
 
3) 帆足俊彦, ほか : 日本皮膚科学会ガイドライン 皮膚悪性腫瘍診療ガイドライン 第3版 基底細胞癌診療ガイドライン 2021. 日本皮膚科学会雑誌 131 : 1467-1496, 2021
 
4) 小野友道 : 基底細胞癌. 最新皮膚科学大系 第12巻 上皮性腫瘍 (玉置邦彦編), p82-98, 中山書店, 2002.
 
5) MacKie RM : An aid to the preoperative assessment of pigmented lesions of the skin. Br J Dermatol 85 : 232-238, 1971.
 
6) Reiter O, et al : The diagnostic accuracy of dermoscopy for basal cell carcinoma : Asystematic review and meta-analysis. J Am Acad Dermatol 80 : 1380-1388, 2019.
 
7) Ichiyama S, et al : Pigmented poroma on the temporal region dermoscopically mimicking basal cell carcinoma : A report of two cases. J Dermatol 45 : e94-e95, 2018.
 
8) Tanaka T, et al : Usefulness of real-time tissue elastography for detecting the border of basal cell carcinomas. J Dermatol 44 : 438-443, 2017.
PubMed
9) Kawaguchi M, et al : Magnetic Resonance Imaging Findings Differentiating Cutaneous Basal Cell Carcinoma from Squamous Cell Carcinoma in the Head and Neck Region. Korean J Radiol 21 : 325-331, 2020.
PubMed
10) Xiong YD, et al : A meta-analysis of reflectance confocal microscopy for the diagnosis of malignant skin tumours. J Eur Acad Dermatol Venereol 30 : 1295-1302, 2016.
 
11) Cheng HM, et al : Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma : a prospective, consecutive, cohort study of l68 cases. Br J Dermatol 175 : 1290-1300, 2016.
 
12) Sellheyer K, Krahl D : PHLDA1 (TDAG51) is a follicular stem cell marker and differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma. Br J Dermatol 164 : 141-147, 2011.
PubMed
13) Haws AL, et al : Accuracy of biopsy sampling for subtyping basal cell carcinoma. J Am Acad Dermatol 66 : 106-111, 2012.
PubMed
14) Armstrong A, et al : Discrepancies between biopsy and formal excision histology of non-melanoma skin cancer. J Plast Reconstr Aesthet Surg 69 : 1714-1716, 2016.
PubMed
15) Ito T, et al : Narrow-margin excision is a safe, reliable treatment for well-defined, primary pigmented basal cell carcinoma : an analysis of 288 lesions in Japan. J Eur Acad Dermatol Venereol 29 : 1828-1831, 2015.
PubMed
16) Nakamura Y, et al : Evaluation of the appropriate surgical margin for pigmented basal cell carcinoma according to the risk factors for recurrence : a single-institute retrospective study in Japan. J Eur Acad Dermatol Venereol 32 : e453-e455, 2018.
 
17) 齋藤晋太郎, ほか : 皮膚科医による基底細胞癌の側方マージン設定の正確性に関する検討. 日本皮膚科学会雑誌 129 : 2157-2164, 2019.
 
18) Wandrey N, et al : Dramatic Resolution of an Unresectable Giant Basal Cell Carcinoma Treated with Intensity-Modulated Radiation Therapy (IMRT) -A Case Report. Cureus 7 : e416, 2015.
PubMed
19) Siller G, et al : PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma : results of a randomized phase IIa trial. Australas J Dermatol 51 : 99-105, 2010.
PubMed
20) Kim DJ, et al : Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 32 : 745-751, 2014.
PubMed
21) Liu Y, et al : A deep learning system for differential diagnosis of skin diseases. Nat Med 26 : 900-908, 2020.
 
22) Han SS, et al : Keratinocytic Skin Cancer Detection on the Face Using Region-Based Convolutional Neural Network. JAMA Dermatol 156 : 29-37, 2020.
PubMed
23) Campanella G, et al : Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat Med 25 : 1301-1309, 2019.
PubMed
P.182 掲載の参考文献
1) 小野友道 : 基底細胞癌. 最新皮膚科学大系 第12巻 上皮性腫瘍 (玉置邦彦編), p82-98, 中山書店, 2002.
 
2) Baxter JM, et al : Facial basal cell carcinoma. BMJ 345 : e5342, 2012.
PubMed
3) 石井良征ほか : 基底細胞癌の全国調査. Skin Cancer 28 : 205-211, 2013.
 
4) 石原和之 : 本邦における皮膚悪性腫瘍の疫学. Skin Cancer 12 : 18-25, 1997.
 
5) 覚道奈津子 : 過去19年間に経験した基底細胞癌の臨床統計学的検討. 日本形成外科学会会誌 28 : 245-252, 2008.
 
6) 黒川景子, 金子高英 : 弘前大学皮膚科における10年間の基底細胞癌の統計学的検討. 皮膚病診療 39 : 994-1000, 2017.
 
7) 松岡摩耶, ほか : 聖マリアンナ医科大学皮膚科における過去11年間の基底細胞癌の統計的検討. 聖マリアンナ医科大学雑誌 44 : 203-211, 2017.
Medical*Online
8) 土屋未央, ほか : 当院の皮膚悪性腫瘍外来における基底細胞癌患者のシェーマ化による統計的検討. 日本形成外科学会会誌 40 : 326-333, 2020.
 
9) 宮本秀明 : 皮膚科診療所における10年間の皮膚腫瘍の臨床統計. 皮膚科の臨床 59 : 1269-1273, 2017.
 
10) 山田健一 : 基底細胞上皮腫の臨床的, 組織計測学的研究 (第1報) -最近20年間における教室例の臨床的, 統計的検討. 西日本皮膚科 46 (増刊号) : 115-118, 1984.
 
11) 天津朗典, ほか : 当科における最近5年間の基底細胞上皮腫の組織分類 : 既報告集計例との比較. Skin Cancer 14 : 302-307, 1999.
 
12) 落合宏司, ほか : 当科における基底細胞癌の統計的検討. Skin Cancer 17 : 48-50, 2002.
 
13) 石田晋之介, ほか : 獨協医大皮膚科における基底細胞上皮腫の統計. Skin Cancer 9 : 379-383, 1994.
 
14) 土田哲也, ほか : 日本皮膚科学会ガイドライン 皮膚悪性腫瘍診療ガイドライン 第2版. 日本皮膚科学会会誌 125 : 5-75, 2015.
 
15) 石原和之 : 基底細胞癌 全国アンケートの集計と説明. Skin Cancer 9 (special号) : 80-83, 1994.
 
P.186 掲載の参考文献
1) 石原和之 : 基底細胞癌-全国アンケートの集計と説明. Skin Cancer 9 : 80-83, 1994.
 
2) 土田哲也, ほか : 皮膚悪性腫瘍診療ガイドライン 第2版. 日本皮膚科学会雑誌 125 : 5-75, 2015.
 
3) Kricker A, et al : Does intermittent sun exposure cause basal cell carcinoma? a case-control study in Western Australia. Int J Cancer 60 : 489-494, 1995.
PubMed
4) Walther U, et al : Risk and protective factors for sporadic basal cell carcinoma : results of a two-centre case-control study in southern Germany. Clinical actinic elastosis may be a protective factor. Br J Dermatol 151 : 170-178, 2004.
PubMed
5) 尾藤利憲, ほか : 全国8大学皮膚科の共同による皮膚癌の発症因子と予防因子の症例対照研究及び皮膚癌検診10年間の結果. 太陽紫外線防御研究委員会学術報告 14 : 13-19, 2004.
 
6) Savoye I, et al : Patterns of Ultraviolet Radiation Exposure and Skin Cancer Risk : the E3N-SunExp Study. J Epidemiol 28 : 27-33, 2018.
PubMed
7) Stern RS ; PUVA Follow-Up Study : The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy : a 30-year prospective study. J Am Acad Dermatol 66 : 553-562, 2012.
PubMed
8) Hearn RM, et al : Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 159 : 931-935, 2008.
PubMed
9) Zhang M, et al : Use of tanning beds and incidence of skin cancer. J Clin Oncol 30 : 1588-1593, 2012.
PubMed
10) Euvrard S, et al : Skin cancers after organ transplantation. N Engl J Med 348 : 1681-1691, 2003.
PubMed
11) Omland SH, et al : Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant Recipients : A Population-Based Cohort Study. JAMA Dermatol 152 : 177-183, 2016.
PubMed
12) Wu PA, et al : Reduced-lntensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation. J Invest Dermatol 139 : 591-599, 2019.
PubMed
13) Lange E, et al : Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients : a retrospective cohort study. Rheumatology (Oxford) 55 : 1594-1600, 2016.
PubMed
14) Snapper SB, et al : A family of WASPs. N Engl J Med 348 : 350-351, 2003.
PubMed
15) Robinson SN, et al : Photosensitizing agents and the risk of non-melanoma skin cancer : a population-based case-control study. J Invest Dermatol 133 : 1950-1955, 2013.
PubMed
16) Wu S, et al : Citrus consumption and risk of basal cell carcinoma and squamous cell carcinoma of the skin. Carcinogenesis 36 : 1162-1168, 2015.
PubMed
17) Cheng PS, et al : Relationship between arsenic-containing drinking water and skin cancers in the arseniasis endemic areas in Taiwan. J Dermatol 43 : 181-186, 2016.
PubMed
18) Karagas MR, et al : Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst 88 : 1848-1853, 1996.
 
19) Milan T, et al : Lifestyle differences in twin pairs discordant for basal cell carcinoma of the skin. Br J Dermatol 149 : 115-123, 2003.
PubMed
20) Khalesi M, et al : A meta-analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin. Cancer Epidemiol 37 : 534-543, 2013.
PubMed
21) Robinson JK : Risk of developing another basal cell carcinoma. A 5-year prospective study. Cancer 60 : 118-120, 1987.
PubMed
22) Farndon PA, et al : Location of gene for Gorlin syndrome. Lancet 339 : 581-582, 1992.
PubMed
23) MacDonald DS : A systematic review of the literature of nevoid basal cell carcinoma syndrome affecting East Asians and North Europeans. Oral Surg Oral Med Oral Pathol Oral Radiol 120 : 396-407, 2015.
PubMed
24) DiGiovanna JJ, et al : Shining a light on xeroderma pigmentosum. J Invest Dermatol 132 : 785-796, 2012.
PubMed
25) Torrelo A, et al : What syndrome is this? Bazex-Dupre-Christol syndrome. Pediatr Dermatol 23 : 286-290, 2006.
PubMed
26) Kiprono SK, et al : Histological review of skin cancers in African Albinos : a 10-year retrospective review. BMC Cancer 14 : 157, 2014.
PubMed
P.193 掲載の参考文献
1) Verkouteren JAC, et al : Epidemiology of basal cell carcinoma : scholarly review. Br J Dermatol 177 : 359-372, 2017.
PubMed
2) Gorlin RJ, Goltz RW : Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 262 : 908-912, 1960.
PubMed
3) Gailani MR, et al : Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 69 : 111-117, 1992.
PubMed
4) Gailani MR, et al : The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 14 : 78-81, 1996.
PubMed
5) Bonilla X, et al : Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 48 : 398-406, 2016.
PubMed
6) Daya-Grosjean L, Couve-Privat S : Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett 225 : 181-192, 2005.
PubMed
7) Briscoe J, Therond PP : The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 14 : 416-429, 2013.
PubMed
8) Otsuka A, et al : Hedgehog signaling in basal cell carcinoma. J Dermatol Sci 78 : 95-100, 2015.
PubMed
9) Katoh Y, Katoh M : Hedgehog target genes : mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 9 : 873-886, 2009.
PubMed
10) Rimkus TK, et al : Targeting the Sonic Hedgehog Signaling Pathway : Review of Smoothened and GLI Inhibitors. Cancers (Basel) 8 : 22, 2016.
 
11) Heitzer E, et al : UV fingerprints predominate in the PTCH mutation spectra of basal cell carcinomas independent of clinical phenotype. J Invest Dermatol 127 : 2872-2881, 2007.
PubMed
12) Sekulic A, et al : Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366 : 2171-2179, 2012.
PubMed
13) Grob JJ, et al : Vismodegib, a Hedgehog Pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC) : STEVIE study interim analysis in 300 patients. J Clin Oncol 31 (Suppl) : 9036, 2013. (DOI : 10.1200/jco.2013.31.15_suppl.9036)
 
14) Tang JY, et al : Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366 : 2180-2188, 2012.
PubMed
15) Kim DJ, et al : Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 32 : 745-751, 2014.
PubMed
P.199 掲載の参考文献
1) Gailani MR, et al : The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 14 : 78-81, 1996.
PubMed
2) Zhang H, et al : Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am J Pathol 158 : 381-385, 2001.
PubMed
3) Bonilla X, et al : Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma, Nat Genet 48 : 398-406, 2016.
PubMed
4) Baker SJ, et al : Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244 : 217-221, 1989.
PubMed
5) el-Deiry WS, et al : WAF1, a potential mediator of p53 tumor suppression. Cell 75 : 817-825, 1993.
PubMed
6) Harper JW, et al : The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 : 805-816, 1993.
PubMed
7) Canman CE, et al : Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9 : 600-611, 1995.
PubMed
8) Hall PA, et al : p53-integrating the complexity. J Pathol 180 : 1-5, 1996.
PubMed
9) Yogianti F, et al : Skin tumours induced by narrowband UVB have higher frequency of p53 mutations than tumours induced by broadband UVB independent of Ogg1 genotype. Mutagenesis 27 : 637-643, 2012.
PubMed
10) Pellegrini C, et al : Understanding the Molecular Genetics of Basal Cell Carcinoma. Int J Mol Sci 18 : 2485, 2017.
 
11) Song H, et al : p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9 : 573-580, 2007.
PubMed
12) GigliaMari G, Sarasin A : TP53 mutations in human skin cancers. Hum Mutat 21 : 217-228, 2003.
PubMed
13) Rosenstein BS, et al : p53 mutations in basal cell carcinomas arising in routine users of sunscreens. Photochem Photobiol 70 : 798-806, 1999.
PubMed
14) Tornaletti S, Pfeifer GP : Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science 263 : 1436-1438, 1994.
PubMed
15) Zhu G, et al : Mutant p53 in Cancer Progression and Targeted Therapies. Front Oncol 10 : 595187, 2020.
PubMed
P.203 掲載の参考文献
1) Dika E, et al : Basal cell carcinoma : a comprehensive review. Int J Mol Sci 21 : 5572, 2020.
 
2) Gorin RJ, Goltz RW : Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib-A syndrome. N Engl J Med 262 : 908-912, 1960.
 
3) Hahn H, et al : Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85 : 841-851, 1996.
PubMed
4) Johnson RL, et al : Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272 : 1668-1671, 1996.
PubMed
5) Gailani MR, et al : The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 14 : 78-81, 1996.
PubMed
6) Von Hoff DD, et al : Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361 : 1164-1172, 2009.
PubMed
7) Bresler SC, et al : Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Head Neck Pathol 10 : 119-124, 2016.
PubMed
8) Endo M, et al : Nationwide survey of nevoid basal cell carcinoma syndrome in Japan revealing the low frequency of basal cell carcinoma. Am J Med Genet A 158A : 351-357, 2012.
PubMed
9) Fan Z, et al : A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family. J Med Genet 45 : 303-308, 2008,
 
10) Smith MJ, et al : Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 32 : 4155-4161, 2014.
PubMed
11) Kimonis VE, et al : Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 69 : 299-308, 1997.
PubMed
12) 小児慢性特定疾病情報センター. [https://www.shouman.jp] (2021年5月閲覧)
 
13) Migden M, et al : A review of Hedgehog inhibitors sonidegib and vismodegib for treatment of advanced basal cell carcinoma. J Drugs Dermatol 20 : 156-165, 2021.
PubMed
14) Skvara H, et al : Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 131 : 1735-1744, 2011.
PubMed
15) かずさDNA研究所 HP. [https://www.kazusa.or.jp] (2021年5月閲覧)
 
P.207 掲載の参考文献
1) 竹之内辰也 : 基底細胞癌. 1冊でわかる皮膚がん (斎田俊明, ほか編), p122-134, 文光堂, 2011,
 
2) 安齋眞一, 木村鉄宣 : Basal cell carcinoma : 基底細胞癌の臨床病理学的検討. 日本皮膚科学会雑誌 118 : 1697-1707, 2008.
 
3) 石井良征, ほか : 基底細胞癌の全国調査. Skin Cancer 28 : 205-211, 2013.
 
4) 小野友道, ほか : 基底細胞癌. 最新皮膚科学大系 12 上皮性腫瘍 (玉置邦彦, ほか編), p82-98, 中山書店, 2002.
 
5) 土田哲也, ほか : 皮膚悪性腫瘍診療ガイドライン 第2版. 日本皮膚科学会誌 125 : 5-75, 2015.
 
6) 土屋和夫, ほか : ダーモスコピーによる悪性黒色腫と基底細胞癌の臨床診断精度の検討. 日本皮膚科学会雑誌 117 : 985-989, 2007.
 
7) Menzies SW, et al : Surface microscopy of pigmented basal cell carcinoma. Arch Dermatol 136 : 1012-1016, 2000.
PubMed
8) 高木裕子, ほか : ダーモスコピーによる基底細胞癌診断基準の日本人患者における有用性の検討. 日本皮膚科学会誌 116 : 2234-2236, 2006.
 
9) 宇原久, ほか : 基底細胞癌の高周波エコー所見. 臨床皮膚科 62 : 76-79, 2008.
 
P.213 掲載の参考文献
1) Wang YJ, et al : Genital basal cell carcinoma, a different pathogenesis from sun-exposed basal cell carcinoma? A case-control study of 30 cases. J Cutan Pathol, 2018. (DOI : 10.1111/cup.13304)
 
2) WHO Classification of Skin Tumours, 4th ed (ed by Elder DE, et al), IARC Press, Lyon, 2018.
 
3) 安齋眞一, 木村鉄宣 : Basal cell carcinoma : 基底細胞癌の臨床病理学的検討. 日皮会誌 118 : 1697-1707, 2008.
 
4) Scrivener Y, et al : Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 147 : 41-47, 2002.
PubMed
5) 辛島正志, ほか : 外陰部に生じたPinkus型Basal Cell Epithelioma (BCE). 西日本皮膚科 52 : 942-945, 1990.
 
6) 村田洋三, ほか : Infundibulo-cystic basal cell carcinomaの1例. Skin Cancer 14 : 41-43, 1999.
 
7) Lindboe CF, Lovdal L : Epidermal basaloid cell hyperplasia overlying dermatofibromas. Am J Dermatopathol 33 : 52-55, 2011.
PubMed
8) Evangelista MT, North JP : Comparative analysis of cytokeratin 15, TDAG51, cytokeratin 20 and androgen receptor in sclerosing adnexal neoplasms and variants of basal cell carcinoma. J Cutan Pathol 42 : 824-831, 2015.
PubMed
9) Sabeti S, et al : The rate and pattern of bcl-2 and cytokeratin 15 expression in trichoepithelioma and nodular Basal cell carcinoma : a comparative study. Indian J Dermatol 58 : 331-336, 2013.
PubMed
10) Yeh I, et al : Differential expression of PHLDA1 (TDAG51) in basal cell carcinoma and trichoepithelioma. Br J Dermatol 167 : 1106-1110, 2012.
PubMed
11) Yu L, et al : Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. J Cutan Pathol 36 : 1074-1176, 2009.
PubMed
12) Danialan R, et al : Challenges in the diagnosis of cutaneous adnexal tumours. J Clin Pathol 68 : 992-1002, 2015.
 
13) Muthusamy K, et al : Immunohistochemical staining for adipophilin, perilipin and TIP47. J Clin Pathol 59 : 1166-1170, 2006.
PubMed
14) Prieto-Granada C, et al : Sebaceous Carcinoma of the Eyelid. Cancer Control 23 : 126-132, 2016.
PubMed
P.218 掲載の参考文献
1) Menzies SW, et al : Surface microscopy of pigmented basal cell carcinoma Arch Dermatol 136 : 1012-1016, 2000.
PubMed
2) 基底細胞癌. ダーモスコピーのすべて 皮膚科の新しい診断法 (斎田俊明編著), p114-121, 南江堂, 2012.
 
3) Argenziano G, et al : Dermoscopy of pigmented skin lesions : results of a consensus meeting via the Internet. J Am Acad Dermatol 48 : 679-693, 2003.
PubMed
4) Marghoob AA, Braun R : Proposal for a revised 2-step algorithm for the classification of lesions of the skin using dermoscopy. Arch Dermatol 146 : 426-428, 2010.
PubMed
5) Liebman TN, et al : White shiny structures : dermoscopic features revealed under polarized light. J Eur Acad Dermatol Venereol 26 : 1493-1497, 2012.
 
6) Liebman TN, et al : Dermoscopic features of basal cell carcinomas : differences in appearance under non-polarized and polarized light. Dermatol Surg 38 : 392-399, 2012.
PubMed
7) Altamura D, et al : Dermatoscopy of basal cell carcinoma : morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol 62 : 67-75, 2010.
PubMed
8) Felder S, et al : Dermoscopic differentiation of a superficial basal cell carcinoma and squamous cell carcinoma in situ. Dermatol Surg 32 : 423-425, 2006.
PubMed
9) Giacomel J, Zalaudek I : Dermoscopy of superficial basal cell carcinoma. Dermatol Surg 31 : 1710-1713, 2005.
PubMed
10) Scalvenzi M, et al : Dermoscopic patterns of superficial basal cell carcinoma. Int J Dermatol 47 : 1015-1018, 2008.
 
11) Pan Y, et al : Dermatoscopy aids in the diagnosis of the solitary red scaly patch or plaque-features distinguishing superficial basal cell carcinoma, intraepidermal carcinoma, and psoriasis. J Am Acad Dermatol 59 : 268-274, 2008.
PubMed
12) Lallas A, et al : The dermatoscopic universe of basal cell carcinoma. Dermatol Pract Concept 4 : 11-24, 2014.
PubMed
13) Kittler H : Pigmented basal cell carcinoma. In : Dermatoscopy : An Algorithmic Method Based on Pattern Analysis (ed by Kittler H, et al), p80-86, Facultas Verlags-und Buchhandels AG, Vienna, 2011.
 
14) レベル2 : 基底細胞癌の所見. 日常の皮膚診療が変わる やってみよう! ダーモスコピー 良・悪性病変の診かたとアルゴリズム (外川八英著), p26-27, 文光堂, 2020.
 
P.223 掲載の参考文献
1) 若林祐次郎, ほか : 皮膚体表超音波での深達度硫価が術式決定に有用であった耳介後面の基底細胞癌の1例. 臨床皮膚科 70 : 695-699, 2016.
 
2) 正畠千夏, ほか : 基底細胞癌の術前超音波検査の有用性について. 皮膚の科学 14 : 6-11, 2015.
 
3) 中村泰大, ほか : 日本皮膚科学会ガイドライン 皮膚悪性腫瘍ガイドライン 第3版 メラノーマ診療ガイドライン 2019. 日皮会誌 129 : 1759-1843, 2019.
 
4) Nassiri-Kashani M, et al : Pre-operative assessment of basal cell carcinoma dimensions using high frequency ultrasonography and its correlation with histopathology. Skin Res Technol 19 : e132-138, 2013.
 
5) Khlebnikova AN, et al : Ultrasonographic features of superficial and nodular basal cell carcinoma. Med Ultrason 20 : 475-479, 2018.
PubMed
6) Khlebnikova A, et al : Basal cell carcinoma invasion depth determined with 30 and 75 MHz high-frequency ultrasound and histopathology-a comparative study. Med Ultrason 22 : 31-36, 2020.
PubMed
7) Bobadilla F, et al : Pre-surgical high resolution ultrasound of facial basal cell carcinoma : correlation with histology. Cancer Imaging 8 : 163-172, 2008.
PubMed
8) Wortsman X, et al : Ultrasound as predictor of histologic subtypes linked to recurrence in basal cell carcinoma of the skin. J Eur Acad Dermatol Venereol 29 : 702-707, 2015.
PubMed
9) 宇原久, ほか : 基底細胞癌の高周波エコー所見. 臨床皮膚科 62 : 76-79, 2008.
 
10) 米山昌司, ほか : 皮膚腫瘤性病変における25MHzプローブ (メカニカルセクタ型) の有用性. 超音波検査技術 34 : 548-559, 2009.
Medical*Online
11) 中村聡子, ほか : 手掌に生じ, 結節型悪性黒色腫を思わせた基底細胞癌の1例. 皮膚科の臨床 61 : 91-95, 2019.
 
P.226 掲載の参考文献
1) 石原和之 : 基底細胞癌 全国アンケートの集計と説明. Skin Cancer 9 : 80-83, 1994.
 
2) 科学的根拠に基づく皮膚悪性腫瘍ガイドライン [第2版] (日本皮膚科学会, 日本皮膚悪性腫瘍学会編), 金原出版, 2015.
 
3) Scmults C, et al : NCCN Guidelines for Basal Cell Skin Cancer Version 1. 2020. National Comprehensive Cancer Network, 2020. [www.nccn. org]
 
4) Nakamura Y, et al : 2-mm surgical margins are adequate for most basal cell carcinomas in Japanese : a retrospective multicentre study on 1000 basal cell carcinomas. J Eur Acad Dermatol Venereol 34 : 1991-1998, 2020.
PubMed
5) Geisse J, et al : Imiquimod 5% cream for the treatment of superficial basal cell carcinoma : results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50 : 722-733, 2004.
PubMed
6) Basset-Seguin N, et al : Vismodegib in patients with advanced basal cell carcinoma : Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 86 : 334-348, 2017.
PubMed
7) Moeholt K, et al : Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. Acta Oncol 35 : 677-682, 1996.
PubMed
P.230 掲載の参考文献
1) Takenouchi T, Takatsuka S : Long-term prognosis after surgical excision of basal cell carcinoma : a single institutional study in Japan. J Dermatol 40 : 696-699, 2013.
PubMed
2) Nakamura Y, et al : Evaluation of the appropriate surgical margin for pigmented basal cell carcinoma according to the risk factors for recurrence : asingle-institute retrospective study in Japan. J Eur Acad Dermatol Venereol 32 : e453-e455, 2018.
 
3) Basal cell skin cancer Ver 2. 2021, NCCN clinical practice guidelines in Oncology, 2021.
 
4) Bath-Hextall F, et al : Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS) : a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 15 : 96-105, 2014.
PubMed
5) Williams HC, et al : Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma : 5-Year Results of the SINS Randomized Controlled Trial. J Invest Dermatol 137 : 614-619, 2017.
PubMed
6) Stein JM, et al : Mohs micrographic surgery and the otolaryngologist Am J Otolaryngol 25 : 385-393, 2004.
PubMed
7) Ito T, et al : Narrow-margin excision is a safe, reliable treatment for well-defined, primary pigmented basal cell carcinoma : an analysis of 2881esions in Japan. J Eur Acad Dermatol Venereol 29 : 1828-1831, 2015.
PubMed
8) Maloney ME, et al : Pigmented basal cell carcinoma : investigation of 70 cases. J Am Acad Dermatol 27 : 74-78, 1992.
 
9) Kiely JR, Patel AJK : A retrospective study of 694 Basal Cell Carcinoma excisions to quantify deep margin documentation and clearance compared to histological type and surgical margin. J Plast Reconstr Aesthetic Surg 72 : 1805-1812, 2019. [DOI : 10.1016/j.bjps.2019.06.002]
 
10) Matsushita S, et al : Prediction of the invasive level of basal cell carcinomas in the facial area : Analysis of 718 Japanese cases. J Dermatol Sci 99 : 152-157, 2020.
 
11) Luz FB, et al : Surgical treatment of basal cell carcinoma : an algorithm based on the literature. An Bras Dermatol 90 : 377-383, 2015.
PubMed
12) Bourlidou E, et al : Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face : a 15-year retrospective analysis based on a single centre. Eur J Dermatol 29 : 490-499, 2019.
 
13) Miszczyk J, et al : Incomplete excision of basal cell carcinoma (BCC) in the head and neck region : To wait, or not to wait? Postepy Dermatol Alergol 34 : 607-611, 2017.
PubMed
P.234 掲載の参考文献
1) Thomson J, et al : Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 11 : CD003412, 2020.
PubMed
2) Jansen MHE, et al : Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma, J Invest Dermatol 138 : 527-533, 2018.
PubMed
3) Kuflik EG : Cryosurgery for cutaneous malignancy : An update. Dermatol Surg 23 : 1081-1087, 1997.
PubMed
4) Hall VL, et al : Treatment of basal-cell carcinoma : comparison of radiotherapy and cryotherapy. Clin Radiol 37 : 33-34, 1986.
PubMed
5) Wang I, et al : Photodynamic therapy vs. cryosurgery of basal cell carcinomas : results of a phase III clinical trial. Br J Dermatol 144 : 832-840, 2001.
PubMed
6) Collier NJ, et al : Conventional and combination topical photodynamic therapy for basal cell carcinoma : systematic review and meta-analyis. Br J Dermatol 179 : 1277-1296, 2018.
 
7) Szeimies RM, et al : A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 22 : 1302-1311, 2008.
PubMed
8) Rhodes LE, et al : Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 143 : 1131-1136, 2007.
PubMed
9) Geisse J, et al : Imiquimod 5% cream for the treatment of superficial basal cell carcinoma : results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50 : 722-733, 2004.
PubMed
10) McKay KM, et al : Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy : a proposal for a thickness-based definition of sBCC. Br J Dermatol 169 : 549-554, 2013.
PubMed
11) Williams HC, et al : Surgery Versus 5%Imiquimod for Nodular and Superficial Basal Cell Carcinoma : 5-Year Results of the SINS Randomized Controlled Trial. J Invest Dermatol 137 : 614-619, 2017.
PubMed
12) van der Geer S, et al : Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face : a prospective randomized controlled study. Br J Dermatol 167 : 110-115, 2012.
 
13) Butler DF, et al : Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery : a randomized, double blind, vehicle-controlled study. Dermatol Surg 35 : 24-29, 2009.
PubMed
P.239 掲載の参考文献
1) Wilder RB, et al : Basal cell carcinoma treated with radiation therapy. Cancer 68 : 2134-2137, 1991.
PubMed
2) Wilder RB, et al : Recurrent basal cell carcinoma treated with radiation therapy. Arch Dermatol 127 : 1668-1672, 1991.
PubMed
3) Childers BJ, et al : Long-term results of irradiation for basal cell carcinoma of the skin of the nose. Plast Reconstr Surg 93 : 1169-1173, 1994.
PubMed
4) Hernandez-Machin B, et al : Office-based radiation therapy for cutaneous carcinoma : evaluation of 710 treatments. Int J Dermatol 46 : 453-459, 2007.
PubMed
5) 小川智広, ほか : 神経周囲浸潤, 筋層浸潤およびリンパ節への直接浸潤を認めた右耳介後部の浸潤型基底細胞癌に対して術後放射線療法を施行した1例. 皮膚科の臨床 59 : 1391-1394, 2017.
 
6) NCCN clinical practice guidelines in oncology (NCCN guidelines), Basal cell skin cancer, version 2. 2021-February 2, 2021.
 
7) Likhacheva A, et al : Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin : Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol 10 : 8-20, 2020.
PubMed
8) Peris K, et al : Diagnosis and treatment of basal cell carcinoma : European consensus-based interdisciplinary guidelines. Eur J Cancer 118 : 10-34, 2019.
PubMed
9) 皮膚癌 ; 血液・リンパ・皮膚・骨・軟部. 放射線治療計画ガイドライン 2020年版 (日本放射線腫瘍学会編), p335-341, 金原出版, 2020.
 
10) McCusker M, et al : Metastatic basal cell carcinoma : prognosis dependent on anatomic site and spread of disease. Eur J Cancer 50 : 774-783, 2014.
PubMed
11) Stratigos A, et al : Diagnosis and treatment of invasive squamous cell carcinoma of the skin : European consensus-based interdisciplinary guideline. Eur J Cancer 51 : 1989-2007, 2015.
PubMed
12) Duinkerken CW, et al : Orthovoltage X-rays for Postoperative Treatment of Resected Basal Cell Carcinoma in the Head and Neck Area. J Cutan Med Surg 21 : 243-249, 2017.
PubMed
13) Cuperus E, et al : Post radiation skin tumors : basal cell carcinomas, squamous cell carcinomas and angiosarcomas. A review of this late effect of radiotherapy. Eur J Dermatol 23 : 749-757, 2013.
PubMed
14) Petit JY, et al : Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg 105 : 2544-2551, 2000.
PubMed
15) Cho M, et al : Utility of radiotherapy for treatment of basal cell carcinoma : a review. Br J Dermatol 171 : 968-973, 2014.
PubMed
P.246 掲載の参考文献
1) Gailani MR, et al : The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 14 : 78-81, 1996.
PubMed
2) Dreier J, et al : Basal cell carcinomas in a tertiary referral centre : a systematic analysis. Br J Dermatol 171 : 1066-1072, 2014.
 
3) Dummer R, et al : Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma : 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol 182 : 1369-1378, 2020.
PubMed
4) Sekulic A, et al : Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma : final update of the pivotal ERIVANCE BCC study. BMC Cancer 17 : 332, 2017.
PubMed
5) Basset-S6guin N, et al : Vismodegib in patients with advanced basal cell carcinoma : Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 86 : 334-348, 2017.
PubMed
6) Dreno B, et al : Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE) : a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol 18 : 404-412, 2017.
PubMed
7) Chang AL, et al : Safety and efficacy of vismodegib in patients aged ≧ 65 years with advanced basal cell carcinoma. Oncotarget 7 : 76118-76124, 2016.
 
8) Dummer R, et al : Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma : Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months. J Am Acad Dermatol 84 : 1162-ll64, 2021.
PubMed
9) Lear JT, et al : Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma : 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol 32 : 372-381, 2018.
PubMed
10) Dummer R, et al : Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma : a joint expert opinion. J Eur Acad Dermatol Venereol 34 : 1944-1956, 2020.
PubMed
11) Ally MS, et al : Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatol 152 : 452-456, 2016.
PubMed
12) Lockhart NR, et al : Itraconazole therapy in a pancreatic adenocarcinoma patient : A case report. J Oncol Pharm Pract 22 : 528-532, 2016.
 
13) Kim DJ, et al : Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 32 : 745-751, 2014.
PubMed
14) Otsuka A, et al : Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. Clin Cancer Res 21 : 1289-1297, 2015.
PubMed
15) Otsuka A, et al : Hedgehog signaling in basal cell carcinoma. J Dermatol Sci 78 : 95-100, 2015.
PubMed

IV 乳房外パジェット病

P.254 掲載の参考文献
1) Jones RE, et al : Extramammary Paget's disease. A critical reexamination. Am J Dermatopathol 1 : 101-132, 1979.
PubMed
2) 村田洋三 : 下床の腺癌は幻. Visual Dermatology 18 : 238-243, 2019.
 
3) Toker C : Clear cells of the nipple epidermis. Cancer 25 : 601-610, 1970.
PubMed
4) Kazakov DV, et al : Lesions of anogenital mammary-like glands : an update. Adv Anat Pathol 18 : 1-28, 2011.
PubMed
5) van der Putte SC : Mammary-like glands of the vulva and their disorders. Int J Gynecol Pathol 13 : 150-160, 1994.
PubMed
6) Willman JH, et al : Vulvar clear cells of Toker : precursors of extramammary Paget's disease. Am J Dermatopathol 27 : 185-188, 2005.
PubMed
7) van der Putte SC : Clear cells of Toker in the developing anogenital region of male and female fetuses. Am J Dermatopathol 33 : 811-818, 2011.
PubMed
8) 熊野公子, 村田洋三 : 乳房外Paget病-その素顔, 全日本病院出版会, 2015.
 
9) Murata Y, Kumano K : Extramammary Paget's disease of the genitalia with clinically clear margins can be adequately resected with 1 cm margin. Eur J Dermatol 15 : 168-170, 2005.
PubMed
10) Kaku-Ito Y, et al : Evaluation of mapping biopsies for extramammary Paget disease : A retrospective study. J Am Acad Dermatol 78 : 1171-1177. e4, 2018.
 
11) Ohara K, et al : A proposal for a TNM staging system for extramammary Paget disease : Retrospective analysis of 301 patients with invasive primary tumors. J Dermatol Sci 83 : 234-239, 2016.
PubMed
12) Fujisawa Y, et al : The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease : Multi-center, retrospective study of 151 patients. J Dermatol Sci 79 : 38-42, 2015.
 
13) Matsushita S, et al : Successful treatment of metastatic extramammary Paget's disease with S-1 and docetaxel combination chemotherapy. J Dermatol 38 : 996-998, 2011.
 
14) Karam A, et al : HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. Gynecol Oncol 111 : 568-571, 2008.
 
15) 高山恵律子, ほか : 肛門の潜在性腺癌由来の続発性肛囲Paget病の1例. 日本皮膚科学会雑誌 124 : 331-337, 2014.
 
P.258 掲載の参考文献
1) Mazoujian G, et al : Extramammary Paget's disease--evidence for an apocrine origin. An immunoperoxidase study of gross cystic disease fluid protein-15, carcinoembryonic antigen, and keratin proteins. Am J Surg Pathol 8 : 43-50, 1984.
 
2) Willman JH, et al : Vulvar clear cells of Toker : precursors of extramammary Paget's disease. Am J Dermatopathol 27 : 185-188, 2005.
PubMed
3) Ghazawi FM, et al : Demographic and clinical characteristics of extramammary Paget's disease patients in Japan from 2000 to 2019. J Eur Acad Dermatol Venereol 35 : e133-e135, 2021.
 
4) Zhang X, et al : Extramammary Paget's Disease in Two Brothers. Indian J Dermatol 60 : 423, 2015.
 
5) Kambayashi Y, et al : Advanced Invasive Extramammary Paget's Disease Concomitant with Cecal Cancer Possessing Rare Variant of TP53 Single Nucleotide Polymorphism. Case Rep Oncol 12 : 855-860, 2019.
 
6) Kang Z, et al : Genetic Analysis of Mismatch Repair Genes Alterations in Extramammary Paget Disease. Am J Surg Pathol 40 : 1517-1525, 2016.
PubMed
7) Tanaka R, et al : Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. Br J Dematol 168 : 1259-1266, 2013.
 
8) Barth P, et al : Metastatic extramammary Paget's disease of scrotum responds completely to single agent trastuzumab in a hemodialysis patient : Case report, Molecular profiling and brief review of the literature. Case Rep Oncol Med 2015 : 895151, 2015.
 
9) Zhang G, et al : Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget's Diseases. J Invest Dermatol 139 : 789-795, 2019.
 
10) Ishida Y, et al : Unbiased Detection of Driver Mutations in Extramammary Paget Disease. Clin Cancer Res 27 : 1756-1765, 2021.
PubMed
11) Vieira VC, Soares MA : The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int 2013 : 683095, 2013.
PubMed
12) Henderson S, et al : APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7 : 1833-1841, 2014.
PubMed
13) Revathidevi S, et al : APOBEC : A molecular driver in cervical cancer pathogenesis. Cancer Lett 496 : 104-116, 2021.
PubMed
14) Snow SN, et al : Failure to detect human papillomavirus DNA in extramammary Paget's disease. Cancer 69 : 249-251, 1992.
 
P.263 掲載の参考文献
1) Herrel LA, et al : Extramammary Paget's disease in males : survival outcomes in 495 patients. Ann Surg Oncol 22 : 1625-1630, 2015.
 
2) Siesling S, et al : Epidemiology and treatment of extramammary Paget disease in the Netherlands. Eur J Surg Oncol 33 : 951-955, 2007.
PubMed
3) Hatta N, et al : Extramammary Paget's disease : treatment, prognostic factors and outcome in 76 patients. Br J Dermatol 158 : 313-318, 2008.
PubMed
4) Fujisawa Y, et al : The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease : Multi-center, retrospective study of 151 patients. J Dermatol Sci 79 : 38-42, 2015.
 
5) Dai B, et al : Primary invasive carcinorlla associated with penoscrotal extramammary Paget's disease : a clinicopathological analysis of 56 cases. BJU Int 115 : 153-160, 2015.
 
6) 大原國章, ほか : 乳房外Paget病の診断と治療. Skin Cancer 8 : 187-208, 1993.
 
7) 吉野公二, ほか : 乳房外パジェット病のTNM分類について. 日皮会誌 116 : 1313-1318, 2006.
 
8) Ohara K, et al : A proposal for a TNM staging system for extramammary Paget disease : Retrospective analysis of 301 patients with invasive primary tumors. J Dermatol Sci 83 : 234-239, 2016.
PubMed
9) Oji M, et al : Serum carcinoembryonic antigen level in Paget's disease. Br J Dermatol 110 : 211-213, 1984.
 
10) Kato J, et al : Serum cytokeratin 19 fragment 21-1 is a useful tumor marker for the assessment of extramammary Paget's disease. J Derrnatol 44 : 666-670, 2017.
 
11) Nakamura Y, et al : Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease. Br J Dermatol 181 : 535-543, 2019.
PubMed
12) Fukuda K, Funakoshi T : Metastatic Extramammary Paget's Disease : Pathogenesis and Novel Therapeutic Approach. Front Oncol 8 : 38, 2018.
 
13) Takata M, et al : erbB-20verexpression but no activation of beta-Catenin gene in extramammary Paget's disease. J Invest Dermatol 113 : 258-262, 1999.
 
14) Tanaka R, et al : Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. Br J Dermatol 168 : 1259-1266, 2013.
PubMed
15) Hata H, et al : MUC5AC expression correlates with invasiveness and progression of extramammary Paget's disease. J Eur Acad Dermatol Venereol 28 : 727-732, 2014.
 
P.269 掲載の参考文献
1) Mazoujian G, et al : Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J pathol 110 : 105-112, 1983.
PubMed
2) 石川真衣, ほか : Signet-ring cellの細胞形態を呈した浸潤性乳房外Paget病の1例. 日皮会誌 127 : 31-38, 2017.
 
3) Tanaka R, et al : Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. Br J Dermatol 168 : 1259-1266, 2013.
PubMed
4) Ordonez NG, et al : Mammary and extramammary Paget's disease. An immunocytochemical and ultrastructural study. Cancer 59 : 1173-1183, 1987.
 
5) Goldblum JR, Hart WR : Perianal Paget's disease : a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. Am J Surg Pathol 22 : 170-179, 1998.
PubMed
6) Goldblum JR, Hart WR : Vulvar Paget's disease : a clinicopathologic and immunohistochemical study of 19 cases. Am J Surg Pathol 21 : 1178-1187, 1997.
 
7) Ishibuchi H, et al : A perianal erythematous plaque : a quiz. Secondary extramammary Paget's disease from adenocarcinoma of the anorectal region. Acta Derm Venereol 94 : 492-493, 2014.
 
8) Shepherd V, et al : Extramammary Paget's disease. BJOG 112 : 273-279, 2005.
 
9) 浅野一弘, ほか : 巨大腫瘤を形成した乳房外Paget病の1例. 皮膚臨床 39 : 701-704, 1997.
 
P.275 掲載の参考文献
1) 乳房外Paget病. 皮膚悪性腫瘍取扱い規約 [第1版] (日本皮膚悪性腫瘍学会編), p58-71, 金原出版, 2002.
 
2) 乳房外Paget病. 皮膚悪性腫瘍取扱い規約 [第2版] (日本皮膚悪性腫瘍学会編), p57-77, 金原出版, 2010.
 
3) 斎田俊明, ほか : 皮膚悪性腫瘍診療ガイドライン. 日皮会誌 117 : 1855-1925, 2007.
 
4) 土田哲也, ほか : 皮膚悪性腫瘍診療ガイドライン 第2版. 日皮会誌 125 : 5-75, 2015.
 
5) 熊野公子, 村田洋三 : 乳房外Paget病の手術治療の進め方. 乳房外Paget病-その素顔-, p181-216, 全日本病院出版会, 2015.
 
6) Hatta N, et al : Extramammary Paget's disease : treatment, prognostic factors and outcome in 76 patients. Br J Dermatol 158 : 313-318, 2008.
PubMed
7) Murata Y, Kumano K : Extramammary Paget's disease of the genitalia with clinically clear margins can be adequately resected with 1 cm margin. Eur J Dermatol 15 : 168-170, 2005.
PubMed
8) Morris CR, Hurst EA : Extramammary Paget Disease : A Review of the Literature-Part I : History, Epidemiology, Pathogenesis, Presentation, Histopathology, and Diagnostic Work-up. Dermatol Surg 46 : 151-158, 2020.
PubMed
9) Fujisawa Y, et al : The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease : Multi-center, retrospective study of 151 patients. J Dermatol Sci 79 : 38-42, 2015.
 
10) Ogata D, et al : Usefulness of sentinel lymph node biopsy for prognostic prediction in extramammary Paget's disease. Eur J Dermatol 26 : 254-259, 2016.
 
11) Tsutsui K, et al : Outcomes of lymph node dissection in the treatment of extramammary Paget's disease : A single-institution study. J Dermatol 47 : 512-517, 2020.
 
12) 神谷秀喜 : Paget病 : 進行期への対応. 日皮会誌 119 : 2838-2841, 2009.
 
13) Yoshino K, et al : Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease. J Dermatol 43 : 633-637, 2016.
PubMed
14) Sekiguchi N, et al : Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget's disease : Four cases and a review. J Dermatol 47 : 1276-1279, 2020.
 
15) 熊野公子, 村田洋三 : 乳房外Paget病とserendipityの世界. 乳房外Paget病-その素顔-, p1-8, 全日本病院出版会, 2015.
 
P.280 掲載の参考文献
1) Mohs FE, Blanchard L : Microscopically controlled surgery for extramammary Paget's disease. Arch Dermatol 115 : 706-708, 1979.
 
2) Murata Y, Kumano K : Extramammary Paget's disease of the genitalia with clinically clear margins can be adequately resected with 1 cm margin. Eur J Dermatol 15 : 168-170, 2005.
PubMed
3) 皮膚悪性腫瘍取扱い規約 [第2版] (日本皮膚悪性腫瘍学会編), 金原出版, 2010.
 
4) 藤井義久, ほか : 組織学的に病巣の範囲を検討した腋窩および外陰部Paget病の4例. 西日本皮膚科 46 : 1118-1122, 1984.
 
5) 坂井秀彰, ほか : 乳房外Paget病の治療 : 特にマージンの幅と所属リンパ節郭清について. Skin Cancer 5 : 85-88, 1990.
 
6) 織田知明, ほか : Mapping biopsyを施行した乳房外Paget病17例の組織学的検討. Skin Cancer 14 : 172-177, 1999.
 
7) Hatta N, et al : Extramammary Paget's disease : treatment, prognostic factors and outcome in 76 patients. Br J Dermatol 158 : 313-318, 2008.
PubMed
8) 科学的根拠に基づく皮膚悪性腫瘍ガイドライン 第2版 (日本皮膚科学会, 日本皮膚悪性腫瘍学会編), 金原出版, 2015.
 
9) 今川孝太郎, ほか : 当院で経験した乳房外Paget病の臨床的検討. 日本形成外科学会会誌 27 : 219-226, 2007.
 
10) 岡村俊哉, ほか : 大陰唇の隆起を作成するために両側よりGluteal Fold Flapを用いた1例. 日本美容外科学会会報 25 : 35-40, 2003.
 
11) 下総美奈子, ほか : 新たな便失禁管理システム (フレキシシール : Conva Tec社製) の使用経験. 埼玉県医学会雑誌 42 : 178-181, 2007.
 
12) 吉岡学, ほか : 肛門再建における臀溝皮弁の知覚皮弁としての有用性について. 日本皮膚外科学会誌 23 : 138-139, 2019.
 
P.285 掲載の参考文献
1) Morton DL, et al : Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127 : 392-399, 1992.
PubMed
2) Alex JC, et al : Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 2 : 303-308, 1993.
PubMed
3) Kusatake K, et al : Usefulness of sentinel lymph node biopsy for the detection of metastasis in the early stage of extramammary Paget's disease. Eur J Dermatol 25 : 156-161, 2015.
 
4) Fujisawa Y, et al : The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease : Multi-center, retrospective study of 151 patients. J Dermatol Sci 79 : 38-42, 2015.
 
5) 藤澤康弘 : 乳房外Paget病のTNM分類. Visual Dermatology 18 : 244-247, 2019.
 
6) Hatta N, et al : Extramammary Paget's disease : treatment, prognostic factors and outcome in 76 patients. Br J Dermatol 158 : 313-318, 2008.
PubMed
7) Nakamura Y, et al : Usefulness of sentinel lymph node biopsy for extramammary Paget disease. Br J Dermatol 167 : 954-956, 2012.
PubMed
8) Ohara K, et al : A proposal for a TNM staging system for extramammary Paget disease : Retrospective analysis of 301 patients with invasive primary tumors. J Dermatol Sci 83 : 234-239, 2016.
PubMed
9) Tsutsumida A, et al : Indications for lymph node dissection in the treatment of extramammary Paget's disease. Dermatol Surg 29 : 21-24, 2003.
 
10) Ogata D, et al : Usefulness of sentinel lymph node biopsy for prognostic prediction in extramammary Paget's disease. Eur J Dermatol 26 : 254-259, 2016.
 
11) 川村龍吉, ほか : RI・色素法併用によるセンチネルリンパ節生検を施行した皮膚悪性腫瘍135例の検討. 日皮会誌 121 : 2265-2271, 2011.
 
12) 藤澤康弘, ほか : インドシアニングリーンの蛍光を用いたセンチネルリンパ節生検50例のまとめ. 日皮会誌 122 : 2875-2883, 2012.
 
13) Hatta N, et al : Sentinel lymph node biopsy in patients with extramammary Paget's disease. Dermatol Surg 30 : 1329-1334, 2004.
PubMed
P.290 掲載の参考文献
1) 吉野公二, ほか : 皮膚悪性腫瘍ガイドライン 第3版 乳房外パジェット病診療ガイドライン 2021. 日本皮膚科学会雑誌 131 : 225-244, 2021.
 
2) 徳田安孝, ほか : 5-FUとCDDPの低濃度持続投与法 (low dose FP療法) が奏効した進行期乳房外Paget病の3例. 日本皮膚科学会雑誌 107 : 21-27, 1997.
 
3) Tokuda Y, et al : Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget's disease. Int J Clin Oncol 20 : 194-197, 2015.
PubMed
4) Kato H, et al : Efficacy of low-dose 5-fluorouracil/cisplatin therapy for invasive extramammary Paget's disease. J Dermatol 45 : 560-563, 2018.
 
5) 山崎直也, ほか : 化学療法が有効であった汗腺癌の1例. Skin Cancer 6 : 380-383, 1991.
 
6) Oashi K et al : Combination chemotherapy for metastatic extramammary Paget disease. Br J Dermatol 170 : 1354-1357, 2014.
PubMed
7) Nakamori R, et al : Complete remission of advanced extramammary Paget's disease treated with docetaxel : a case report. Clin Exp Dermatol 37 : 194-195, 2012.
 
8) Kato M, et al : Single-agent taxane is useful in palliative chemotherapy for advanced extramammary Paget disease : a case series. Br J Dermatol 181 : 831-832, 2019.
PubMed
9) Yoshino K, et al : Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease. J Dermatol 43 : 633-637, 2016.
PubMed
10) Nakamura Y, et al : Weekly docetaxel monotherapy for metastatic extramammary Paget's disease : Retrospective single-institute analysis. J Dermatol 47 : 418-422, 2020.
 
11) Matsushita S, et al : Successful treatment of metastatic extramammary Paget's disease with S-1 and docetaxel combination chemotherapy. J Dermatol 38 : 996-998, 2011.
 
12) Kato J et al : Successful TS-1 monotherapy as the second-line treatment for advanced extramammary Paget's disease : A report of two cases. J Dermatol 45 : 80-82, 2018.
 
13) 福山國太郎, ほか : Weekly PET (シスプラチン-エピルビシン-パクリタキセル) 療法が奏効した外陰Paget癌多発骨転移例. 日本皮膚科学会雑誌 114 : 1787-1792, 2004.
 
14) 船越建, ほか : Weekly PET (cisplatin-epirubicin-taxol) 療法が奏効した転移性乳房外パジェット病の1例. Skin Cancer 24 : 99-103, 2009.
 
15) Hirai I, et al : Modified weekly regimen of cisplatin, epirubicin and paclitaxel induced a durable response in two cases of metastatic extramammary Paget's disease. J Dermatol 44 : 1148-1151, 2017.
 
16) 福本隆也, ほか : Etoposideが奏効した外陰部Paget癌の1例. Skin Cancer 12 : 13-17, 1997.
 
P.297 掲載の参考文献
1) Niibe Y, et al : Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012 : 261096, 2012.
PubMed
2) Fukuda K, Funakoshi T : Metastatic Extramammary Paget's Disease : Pathogenesis and Novel Therapeutic Approach. Front Oncol 8 : 38, 2018.
 
3) Hata M, et al : Role of Radiotherapy as Curative Treatment of Extramammary Paget's Disease. Int J Radiat Oncol Biol Phys 80 : 47-54, 2011.
 
4) Tolia M, et al : Primary extramammary invasive Paget's vulvar disease : what is the standard, what are the challenges and what is the future for radiotherapy? BMC Cancer 16 : 563, 2016.
 
5) van der Linden M, et al : Paget disease of the vulva. Crit Rev Oncol Hematol 101 : 60-74, 2016.
PubMed
6) Tagliaferri L, et al : The Role of Radiotherapy in Extramammary Paget Disease : A Systematic Review. Int J Gynecol Cancer 28 : 829-839, 2018.
PubMed
7) Marcos S, et al : HDR-plesiotherapy for the treatment of anogenital extramammary Paget's disease. Rep Pract Oncol Radiother 17 : 163-167, 2012.
 
8) Carrozzo AM, et al : Dermo Beta Brachytherapy with 188Re in extramammary Paget's disease. G Ital Dermatol Venereol 149 : 115-121, 2014.
 
9) Hata M, et al : Postoperative radiation therapy for extramammary Paget's disease. Br J Dermatol 172 : 1014-1020, 2015.
 
10) Inayama Y, et al : Invasive Paget's disease of the vulva treated with a combination of surgery and concurrent chemoradiotherapy : Acase report. Mol Clin Oncol 9 : 489, 2018.
 
11) Hata M, et al : Radiation therapy for extramammary Paget's disease : treatment outcomes and prognostic factors. Ann Oncol 25 : 291-297, 2014. (DOI : 10.1093/annonc/mdt478)
 
12) Yamamoto R, et al : Radiotherapy with concurrent chemotherapy for vulvar adenocarcinoma associated with extramammary Paget's disease. Gynecol Oncol 80 : 267-271, 2001.
 
13) Palma DA, et al : Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET) : a randomised, phase 2, open-label trial. Lancet 393 : 2051-2058, 2019.
 
14) Feldmeier JJ : Hyperbaric oxygen therapy and delayed radiation injuries (soft tissue and bony necrosis) : 2012 update. Undersea Hyperb Med 39 : 1121-1139, 2012.
PubMed
P.301 掲載の参考文献
1) 科学的根拠に基づく皮膚悪性腫瘍診療ガイドライン [第2版] (日本皮膚科学会, 日本皮膚悪性腫瘍学会編), 金原出版, 2015.
 
2) Fujisawa Y, et al : Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan. J Dermatol Sci 92 : 230-236, 2018.
PubMed
3) Oguchi S, et al : Docetaxel induced durable response in advanced extramammary Paget's disease : a case report. J Dermatol 29 : 33-37, 2002.
 
4) 吉野公二 : 進行期乳房外Paget病に対するドセタキセルを中心とした新規化学療法の提案. Skin Cancer 23 : 347-354, 2008.
 
5) Yoshino K, et al : Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease. J Dermatol 43 : 633-637, 2016.
PubMed
6) Kato M, et al : Single-agent taxane is useful in palliative chemotherapy for advanced extramammary Paget disease : a case series. Br J Dermatol 181 : 831-832, 2019.
PubMed
7) Nakamura Y, et al : Weekly docetaxel monotherapy for metastatic extramammary Paget's disease : Retrospective single-institute analysis. J Dermatol 47 : 418-422, 2020.
 
8) Oashi K, et al : Combination chemotherapy for metastatic extramammary Paget disease. Br J Dermatol 170 : 1354-1357, 2014.
PubMed
9) Kato H, et al : Efficacy of low-dose 5-fluorouracil/cisplatin therapy for invasive extramammary Paget's disease. J Dermatol 45 : 560-563, 2018.
 
10) Cai H, et al : Docetaxel Combined With Cisplatin for Metastatic Extramammary Paget Disease. Clin Genitourin Cancer 16 : e899-e901, 2018.
PubMed
11) Hirai I, et al : Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease. Oncologist 24 : e394-e396, 2019.
 
12) Fukuda K, et al : S-1 in combination with docetaxel as salvage therapy for patients with metastatic extramammary Paget's disease. Eur J Dermatol 30 : 301-302, 2020.
 
13) Maeda T, et al : Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies. Oncogene 39 : 5867-5875, 2020.
 
14) Hirai I, et al : Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease. Med Oncol 35 : 92, 2018.
 
15) Matsushita S, et al : Efficacy of S-1 plus docetaxel in the treatment of metastatic extramammary Paget's disease : a multicentre retrospective study. Br J Dermatol, 2021. [DOI : 10.1111/bjd.20135]
 

V メルケル細胞癌

P.308 掲載の参考文献
1) Toker C : Trabecular carcinoma of the skin. Arch Dermatol 105 : 107-110, 1972.
PubMed
2) Tang CK, Toker C : Trabecular carcinoma of the skin : an ultrastructural study. Cancer 42 : 2311-2321, 1978.
PubMed
3) Paulson KG, et al : Merkel cell carcinoma : Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol 78 : 457-463. e2, 2018.
 
4) Feng H, et al : Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319 : 1096-1100, 2008.
PubMed
5) Tolstov YL, et al : Asymptomatic primary Merkel cell polyomavirus infection among adults. Emerg Infect Dis 17 : 1371-1380, 2011.
PubMed
6) Paulson KG, et al ; Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res 70 : 8388-8397, 2010.
PubMed
7) Moshiri AS, et al : Polyomavirus-Negative Merkel Cell Carcinoma : A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. J Invest Dermatol 137 : 819-827, 2017.
PubMed
8) Heath M, et al : Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients : the AEIOU features. J Am Acad Dermatol 58 : 375-381, 2008.
 
9) Nagase K, et al : Usefulness of ulceration and hyperkeratosis as clinical predictors of Merkel cell polyomavirus-negative and combined Merkel cell carcinoma : A retrospective study. J Dermatol 46 : 103-109, 2019.
PubMed
10) Shinogi T, et al : Merkel cell carcinoma : A systematic review of the demographic and clinical characteristics of 847 cases in Japan. J Dermatol, 2021. (DOI : 10.111/1346-8138.15875)
 
11) Bichakjian CK, et al : NCCN clinical practice guidelines in oncology (NCCN guidelines), Merkel cell carcinoma version 1. 2021, National Comprehensive Cancer Network, 2021. [https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf]
 
12) Iyer JG, et al : Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med 5 : 2294-2301, 2016.
PubMed
13) Nghiem PT, et al : PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 374 : 2542-2552, 2016.
PubMed
14) Kaufman HL, et al : Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma : a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17 : 1374-1385, 2016.
PubMed
15) D'Angelo SP, et al : Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma : A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol 4 : e180077, 2018.
 
P.312 掲載の参考文献
1) Youlden DR, et al : Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993-2010. JAMA Dermatol 150 : 864-872, 2014.
PubMed
2) Amaral T, et al : Merkel cell carcinoma : Epidemiology, pathogenesis, diagnosis and therapy. Rev Endocr Metab Disord 18 : 517-532, 2017.
PubMed
3) Lemos B, Nghiem P : Merkel cell carcinoma : more deaths but still no pathway to blame. J Invest Dermatol 127 : 2100-2103, 2007.
PubMed
4) Deneve JL, et al : Merkel cell carcinoma of unknown primary origin. Ann Surg Oncol 19 : 2360-2366, 2012.
 
5) Paulson KG, et al : Merkel cell carcinoma : Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol 78 : 457-463. e2, 2018.
 
6) Becker JC, et al : Merkel cell carcinoma. Nat Rev Dis Primers 3 : 17077, 2017.
PubMed
7) Stang A, et al : The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma : An international assessment. Eur J Cancer 94 : 47-60, 2018.
PubMed
8) Albores-Saavedra J, et al : Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases : a population based study. J Cutan Pathol 37 : 20-27, 2010.
 
9) Harms KL, et al : Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 23 : 3564-3571, 2016.
PubMed
10) Chen KT, et al : A better prognosis for Merkel cell carcinoma of unknown primary origin. Am J Surg 206 : 752-757, 2013.
PubMed
11) Agelli M, Clegg LX : Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 49 : 832-841, 2003.
PubMed
12) Lunder EJ, Stern RS : Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med 339 : 1247-1248, 1998.
PubMed
13) Miyazawa H, et al : Voriconazole-photoinduced polyomavirus-negative Merkel cell carcinoma. J Dermatol 46 : e287-e288, 2019.
PubMed
14) Clarke CA, et al : Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst 107 : dju382, 2015.
PubMed
15) Lanoy E, et al : Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS 23 : 385-393, 2009.
PubMed
16) Howard RA, et al : Merkel cell carcinoma and multiple primary cancers. Cancer Epidemiol Biomarkers Prev 15 : 1545-1549, 2006.
PubMed
17) Chen T, et al : Serological evidence of Merkel cell polyomavirus primary infections in childhood. J Clin Virol 50 : 125-129, 2011.
PubMed
P.317 掲載の参考文献
1) Feng H, et al : Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319 : 1096-1100, 2008.
PubMed
2) Haley CT, et al : Human oncoviruses : Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention : Papillomaviruses and Merkel cell polyomavirus. J Am Acad Dermatol 81 : 1-21, 2019.
PubMed
3) Hattori T, et al : The prevalence of Merkel cell polyomavirus in Japanese patients with Merkel cell carcinoma. J Dermatol Sci 70 : 99-107, 2013.
PubMed
4) Spurgeon ME, Lambert PF : Merkel cell polyomavirus : a newly discovered human virus with oncogenic potential. Virology 435 : 118-130, 2013.
PubMed
5) Faust H, et al : Antibodies to Merkel cell polyomavirus correlate to presence of viral DNA in the skin. J Infect Dis 203 : 1096-1100, 2011.
PubMed
6) Martel-Jantin C, et al : Merkel cell polyomavirus infection occurs during early childhood and is transmitted between siblings. J Clin Virol 58 : 288-291, 2013.
PubMed
7) Shuda M, et al : Tantigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A 105 : 16272-16277, 2008.
 
8) Verhaegen ME, et al : Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice. J Invest Dermatol 135 : 1415-1424, 2015.
PubMed
9) Shuda M, et al : Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4EBP1 translation regulator. J Clin Invest 121 : 3623-3634, 2011.
 
10) Zhao J, et al : Merkel Cell Polyomavirus Small T Antigen Activates Noncanonical NF-KB Signaling to Promote Tumorigenesis. Mol Cancer Res 18 : 1623-1637, 2020.
PubMed
11) Starrett GJ, et al : Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma. Genome Med 12 : 30, 2020.
PubMed
12) Garneski KM, et al : Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol 129 : 246-248, 2009.
PubMed
13) Suarez AL, et al : Clinical and dermoscopic features of combined cutaneous squamous cell carcinoma (SCC)/neuroendocrine [Merkel cell] carcinoma (MCC). J Am Acad Dermatol 73 : 968-975, 2015.
 
14) Moshiri AS, et al : Polyomavirus-Negative Merkel Cell Carcinoma : AMore Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. J Invest Dermatol 137 : 819-827, 2017.
 
15) Carter MD, et al : Genetic profiles of different subsets of Merkel cell carcinoma show links between combined and pure MCPyV-negative tumors. Hum Pathol 71 : 117-125, 2018.
PubMed
P.320 掲載の参考文献
1) Coggshall K, et al : Merkel cell carcinoma : An update and review : Pathogenesis, diagnosis, and staging. J Am Acad Dermatol 78 : 433-442, 2018.
PubMed
2) Heath M, et al : Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients : the AEIOU features. J Am Acad Dermatol 58 : 375-381, 2008.
 
3) Paulson KG, et al : Merkel cell carcinoma : Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol 78 : 457-463. e2, 2018.
 
4) Koike Y, et al : A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor. JAAD Case Rep 3 : 498-500, 2017.
PubMed
5) Youlden DR, et al : Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993-2010. JAMA Dermatol 150 : 864-872, 2014.
PubMed
6) Nagase K, et al : Case of probable spontaneous regression of Merkel cell carcinoma combined with squamous cell carcinoma without surgical intervention. J Dermatol 45 : 858-861, 2018.
PubMed
7) Walsh NM : Complete spontaneous regression of Merkel cell carcinoma (1986-2016) : a 30 year perspective. J Cutan Pathol 43 : 1150-1154, 2016.
PubMed
8) Walsh NM, et al : A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma. Hum Pathol 52 : 190-196, 2016.
PubMed
9) Feng H, et al : Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319 : 1096-1100, 2008.
PubMed
10) Tolstov YL, et al : Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer 125 : 1250-1256, 2009.
PubMed
11) 鍬塚大 : 有棘細胞癌病巣内にメルケル細胞癌を合併した1例. 西日本皮膚科 74 : 608-613, 2012.
 
12) Kuwamoto S : Recent advances in the biology of Merkel cell carcinoma. Hum Pathol 42 : 1063-1077, 2011.
PubMed
13) Nagase K, et al : Usefulness of ulceration and hyperkeratosis as clinical predictors of Merkel cell polyomavirus-negative and combined Merkel cell carcinoma : A retrospective study. J Dermatol 46 : 103-109, 2019.
PubMed
14) Calder KB, Smoller BR : New insights into Merkel cell carcinoma. Adv Anat Pathol 17 : 155-161, 2010.
PubMed
15) Tello TL, et al : Merkel cell carcinoma : An update and review : Current and future therapy. J Am Acad Dermatol 78 : 445-454, 2018.
PubMed
P.324 掲載の参考文献
1) Bichakjian CK, et al : Merkel Cell Carcinoma, Version 1. 2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16 : 742-774, 2018.
PubMed
2) Harms KL, et al : Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 23 : 3564-3571, 2016.
PubMed
3) Amin MB, et al (ed) : AJCC Cancer Staging Manual, 8th ed, Springer International Publising, New York, 2017.
 
4) Tetzlaff MT, Nagarajan P : Update on Merkel Cell Carcinoma. Head Neck Pathol 12 : 31-43, 2018.
PubMed
5) Assouline A, et al : Merkel cell carcinoma of skin-current controversies and recommendations. Rare Tumors 3 : e23, 2011.
PubMed
6) Ding S, et al : Change in Eyelid Carcinoma T Category With Use of the 8th Versus 7th Edition of the American Joint Committee on Cancer : Cancer Staging Manual. Ophthalmic Plast Reconstr Surg 35 : 38-41, 2019.
PubMed
P.328 掲載の参考文献
1) Heath M, et al : Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients : the AEIOU features. J Am Acad Dermatol 58 : 375-381, 2008.
 
2) Nagase K, et al : Usefulness of ulceration and hyperkeratosis as clinical predictors of Merkel cell polyomavirus-negative and combined Merkel cell carcinoma : A retrospective study. J Dermatol 46 : 103-109, 2019.
PubMed
3) Shinogi T, et al : Merkel cell carcinoma : A systematic review of the demographic and clinical characteristics of 847 cases in Japan. J Dermatol, 2021. (DOI : 10.1111/1346-8138.15875)
 
4) Gould VE, et al : Neuroendocrine (Merkel) cells of the skin : hyperplasias, dysplasias, and neoplasms. Lab Invest 52 : 334-353, 1985.
PubMed
5) Martin B, et al : Merkel cell carcinoma with divergent differentiation : histopathological and immunohistochemical study of 15 cases with PCR analysis for Merkel cell polyomavirus. Histopathology 62 : 711-722, 2013.
PubMed
6) Gupta SG, et al : Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma : The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 142 : 685-690, 2006.
 
7) Harms KL, et al : Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 23 : 3564-3571, 2016.
PubMed
8) Iyer JG, et al : Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol 70 : 637-643, 2014.
PubMed
9) Schwartz JL, et al : Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol 29 : 1036-1041, 2011.
PubMed
10) Smith FO, et al : Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma. Cancer 121 : 3252-3260, 2015.
PubMed
11) Ma JE, Brewer JD : Merkel cell carcinoma in immunosuppressed patients. Cancers (Basel) 6 : 1328-1350, 2014.
PubMed
12) Paulson KG, et al : Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol 133 : 642-646, 2013.
 
13) Paulson KG, et al : Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 29 : 1539-1546, 2011.
PubMed
14) Miller NJ, et al : Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. Cancer Immunol Res 5 : 137-147, 2017.
PubMed
15) Lipson EJ, et al : PD-L1 expression in the Merkel cell carcinoma microenvironment : association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 1 : 54-63, 2013.
 
P.333 掲載の参考文献
1) Schadendorf D, et al : Merkel cell carcinoma : Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 71 : 53-69, 2017.
PubMed
2) Sais G, et al : Spontaneous regression in primary cutaneous neuroendocrine (Merkel cell) carcinoma : a rare immune phenomenon? J Eur Acad Dermatol Venereol 16 : 82-83, 2002.
PubMed
3) Kobayashi Y, et al : Distant recurrence of Merkel cell carcinoma after spontaneous regression. J Dermatol 46 : e133-e134, 2019.
PubMed
4) Yoshimitsu M, et al : Surgical invasion resulted in increased programmed death ligand 1 expression in a case of multicentric Merkel cell carcinoma with six primary lesions. J Dermatol 47 : e305-e307, 2020.
 
5) Sihto H, et al : Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst 101 : 938-945, 2009.
PubMed
6) Lipson EJ, et al : PD-L1 expression in the Merkel cell carcinoma microenvironment : association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 1 : 54-63, 2013.
 
7) Nakamura M, et al : Giucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma. J Immunother Cancer 8 : 2020.
PubMed
8) Paulson KG, et al : Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol 133 : 642-646, 2013.
 
9) Schmults C, et al : Merkel cell carcinoma, version 1. 2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2019.
 
10) Lebbe C, et al : Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer 51 : 2396-2403, 2015.
PubMed
11) Boyer JD, et al : Local control of primary Merkel cell carcinoma : review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiation. J Am Acad Dermatol 47 : 885-892, 2002.
PubMed
12) Finnigan R, et al : The impact of preradiation residual disease volume on time to locoregional failure in cutaneous Merkel cell carcinoma--a TROG substudy. Int J Radiat Oncol Biol Phys 86 : 91-95, 2013.
PubMed
13) Harrington C, et al : Radiotherapy and Conservative Surgery in the Locoregional Management of Merkel Cell Carcinoma : The British Columbia Cancer Agency Experience. Ann Surg Oncol 23 : 573-578, 2016.
PubMed
14) Gunaratne DA, et al : Sentinel lymph node biopsy in Merkel cell carcinoma : a 15-year institutional experience and statistical analysis of 721 reported cases. Br J Dermatol 174 : 273-281, 2016.
 
15) Jouary T, et al : Sentinel node status and immunosuppression : recurrence factors in localized Merkel cell carcinoma. Acta Derm Venereol 95 : 835-840, 2015.
PubMed
16) Wright GP, et al : Surgical resection improves median overall survival with marginal improvement in long-term survival when compared with definitive radiotherapy in Merkel cell carcinoma : A propensity score matched analysis of the National Cancer Database. Am J Surg 215 : 384-387, 2018.
PubMed
17) Bhatia S, et al : Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma : survival analyses of 6908 cases from the National Cancer Data Base. J Natl Cancer Inst 108 : djw042, 2016.
 
18) Nakamura M, et al : Heterogeneity of programmed death-ligand expression in a case of Merkel cell carcinoma exhibiting complete regression after multiple metastases. Br J Dermatol 180 : 1228-1229, 2019.
 
19) Nakamura M, et al : Increased programmed death ligand-1 expression in metastatic Merkel cell carcinoma associates with better prognosis. J Dermatol Sci 97 : 165-167, 2020.
PubMed
P.338 掲載の参考文献
1) Schmults CD, et al : NCCN clinical practice guidelines in oncology (NCCN guidelines). Merkel cell carcinoma version 1. 2021, National Comprehensive Cancer Network, 2021. [https://www.nccn.org/professionals/physician_gls/pdf/mcc_blocks.pdf]
 
2) Ghadjar P, et al : The essential role of radiotherapy in the treatment of Merkel cell carcinoma : a study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys 81 : e583-591, 2011.
PubMed
3) Lewis KG, et al : Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol 142 : 693-700, 2006.
PubMed
4) Veness M, Howle J : Radiotherapy alone in patients with Merkel cell carcinoma : the Westmead Hospital experience of 41 patients. Australas J Dermatol 56 : 19-24, 2015.
 
5) Iyer JG, et al : Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. Cancer Med 4 : 1161-1170, 2015.
PubMed
P.340 掲載の参考文献
1) 栗村理恵ほか : 化学療法が奏効したメルケル細胞癌の転移例. 臨床皮膚科 50 : 635-637, 1996.
 
2) 山田陽三, ほか : 多発肝転移を来した臀部メルケル細胞癌の1例. Skin Cancer 21 : 314-317, 2007.
 
3) 木本雅之, ほか : 下腿に生じたMerkel細胞癌. 皮膚病診療 26 : 1119-1122, 2004.
 
4) 畠山真弓, ほか : 3通りのレジメンによる抗癌剤治療を行ったメルケル細胞癌の1例. Skin Cancer 26 : 179-183, 2011.
 
5) 前川武雄ほか : CBDCA+VP-16による化学療法を施行したメルケル細胞癌の2例. 第32回日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, p172, 2016.
 
6) 前田麗子, ほか : Merkel細胞癌の2例. 皮膚科の臨床 51 : 1299-1302, 2009.
 
7) 田中真紀, ほか : 皮下型Merkel cell carcinomaの2例. 臨床皮膚科 59 : 1230-1232, 2005.
 
8) 今田微香, ほか : 脳転移後, 3年間生存したメルケル細胞癌の1例. Skin Cancer 18 : 184-188, 2003.
 
9) 榎本美生, ほか : メルケル細胞癌の2例. 皮膚の科学 4 : 558-564, 2005.
 
10) 柴山慶継, ほか : 化学療法が奏功したメルケル細胞癌の1例. Skin Cancer 26 : 174-178, 2011.
 
11) 萱島研一, ほか : メルケル細胞癌. 臨床皮膚科 47 : 34-38, 1993.
 
12) 土肥凌, ほか : ほか : 急速に進行したMerkel細胞癌の1例. 臨床皮膚科 64 : 247-250, 2010.
 
13) 安田佳世, ほか : Merkel cell carcinomaの1例. Skin Cancer 9 : 185-188, 1994.
 
14) 佐藤俊宏, ほか : 右大転子部皮下腫瘤として発症したメルケル細胞癌. Skin Cancer 18 : 17-21, 2003.
 
15) Sharma D, et al : Chemotherapy of metastatic Merkel cell carcinoma : case report and review of the literature. Am J Clin Oncol 14 : 166-169, 1991.
PubMed
16) Voog E, et al : Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85 : 2589-2595, 1999.
 
17) Tai PT, et al : Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin : case series and review of 204 cases. J Clin Oncol 18 : 2493-2499, 2000.
 
18) Iyer JG, et al : Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med 5 : 2294-2301, 2016.
PubMed
19) Poulsen MG, et al : Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys 64 : 114-119, 2006.
 
20) Eng TY, et al : Treatment of merkel cell carcinoma. Am J Clin Oncol 27 : 510-515, 2004.
PubMed
P.347 掲載の参考文献
1) Kelly K, et al : Safety profile of avelumab in patients with advanced solid tumors : A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer 124 : 2010-2017, 2018.
PubMed
2) Kaufman HL, et al : Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≧ 1 year of follow-up : JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 6 : 7, 2018.
 
3) Kaufman HL, et al : Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma : amulticentre, single-group, open-label, phase 2 trial. Lancet Oncol 17 : 1374-1385, 2016.
PubMed
4) Winkler JK, et al : Ipilimumab has efficacy in metastatic Merkel cell carcinoma : acase series of five patients. J Eur Acad Dermatol Venereol 31 : e389-e391, 2017.
 
5) Topalian SL, et al : Abstract CT074 : Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358) : Efficacy and safety in Merkel cell carcinoma (MCC). AACR Annual Meeting, 2017. (DOI : 10.1158/1538-7445.AM2017-CT074)
 
6) Gaiser MR, et al : PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. Expert Rev Clin Pharmacol 11 : 345-359, 2018.
PubMed
7) Patnaik A, et al : Phase I Study of Pembrolizumab (MK-3475 ; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res 21 : 4286-4293, 2015.
PubMed
8) Nghiem PT, et al : PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 374 : 2542-2552, 2016.
PubMed
9) Asgari MM, et al : Effect of host, tumor, diagnostic, and treatment variables on outcomes in a large cohort with Merkel cell carcinoma. JAMA Dermatol 150 : 716-723, 2014.
 
10) Walsh NM : Complete spontaneous regression of Merkel cell carcinoma (1986-2016) : a 30 year perspective. J Cutan Pathol 43 : 1150-1154, 2016.
PubMed
11) Paulson KG, et al : Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol 133 : 642-646, 2013.
 
12) Paulson KG, et al : Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res 70 : 8388-8397, 2010.
PubMed
13) Goh G, et al : Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 7 : 3403-3415, 2016.
PubMed
14) Knepper TC, et al : The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res 25 : 5961-5971, 2019.
PubMed
15) Nakamura M, et al : Increased programmed death ligand-1 expression in metastatic Merkel cell carcinoma associates with better prognosis. J Dermatol Sci 97 : 165-167, 2020.
PubMed
16) Nakamura M, et al : Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma. J Immunother Cancer 8 : e001679, 2020.
PubMed
17) Topalian SL, et al : Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. J Clin Oncol 38 : 2476-2487, 2020.
 
P.352 掲載の参考文献
1) Harms KL, et al : Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 23 : 3564-3571, 2016.
PubMed
2) Voog E, et al : Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85 : 2589-2595, 1999.
 
3) Nghiem P, et al : Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol 13 : 1263-1279, 2017.
PubMed
4) D'Angelo SP, et al : Avelumab in patients with previously treated metastatic Merkel cell carcinoma : long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer 8 : e000674, 2020.
 
5) Walker JW, et al : Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma : experience from a global expanded access program. J Immunother Cancer 8 : e000313, 2020.
 
6) Nghiem P, et al : Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. J Clin Oncol 37 : 693-702, 2019.
PubMed
7) Topalian SL, et al : Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. J Clin Oncol 38 : 2476-2487, 2020.
 
8) Akaike T, et al : High somatostatin receptor expression and efficacy of somatostatln analogues in patients with metastatic Merkel cell carcinoma, Br J Dermatol 184 : 319-327, 2021.
PubMed
9) West AC, Johnstone RW : New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124 : 30-39, 2014.
PubMed
10) Song L, et al : The HDAC inhibitor domatinostat promotes cell-cycle arrest, induces apoptosis, and increases immunogenicity of Merkel cell carcinoma cells. J Invest Dermatol 141 : 903-912. e4, 2021. [DoI : 10.1016/j.jid.2020.08.023]
 
11) Knepper TC, et al : The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res 25 : 5961-5971, 2019.
PubMed
12) Park DE, et al : Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response. Proc Natl Acad Sci U S A 116 : 1027-1032, 2019.
PubMed
13) Tarabadkar ES, et al : Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma : A Case Series of 5 Patients. Am J Case Rep 19 : 505-511, 2018.
 
14) Rabinowits G, et al : Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist 23 : 814-821, 2018.
PubMed
15) Kannan A, et al : Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth. Oncotarget 7 : 6576-6592, 2016.
PubMed

VI 血管肉腫

P.359 掲載の参考文献
1) Toro JR, et al : Incidence patterns of soft tissue sarcomas. regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001 : An analysis of 26,758 cases. Int J Cancer 119 : 2922-2930, 2006.
PubMed
2) National Cancer Intelligence Network (NCIN) Soft tissue sarcoma incidence and survival ; tumours diagnosed in England between 1985 and 2009. report No. Rl2/06. Dec 2012. [www.ncin.org.uk]
 
3) Lahat G, et al : Angiosarcoma : clinical and molecular insights. Ann Surg 251 : 1098-1106, 2010.
PubMed
4) Goldblum JR, et al : Enzinger and Weiss's Soft Tissue Tumors, 6th ed, Saunders/Elsevier, Philadelphia PA, 2014.
 
5) Rouhani P, et al : Cutaneous soft tissue sarcoma incidence patterns in the U. S. : an analysis of 12,114 cases. Cancer 113 : 616-627, 2008.
PubMed
6) Fujisawa Y, et al : Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan. J Dermatol Sci 92 : 230-236, 2018.
PubMed
7) Stewart FW, Treves N : Lymphangiosarcoma in postmastectomy lymphedema ; a report of six cases in elephantiasis chirurgica. Cancer 1 : 64-81, 1948.
PubMed
8) Weiss SW, Goldblum JR : Enzinger and Weiss's Soft Tissue Tumors, 4th ed, Vol 1, Mosby. St Louis, 2001.
 
9) Mankey CC, et al : Can lymphangiosarcoma be resurrected? A clinicopathological and immunohistochemical study of lymphatic differentiation in 49 angiosarcomas. Histopathology 56 : 364-371, 2010.
PubMed
10) Masuzawa M, et al : Establishment and characterization of a novel lymphangiosarcoma cell line (MOLAS) compared with the hemangiosarcoma cell line (ISO-HAS). Cancer Med 1 : 39-46, 2012.
 
11) Shustef E, et al : Cutaneous angiosarcoma : a current update. J Clin Pathol 70 : 917-925, 2017.
PubMed
12) Pawlik TM, et al : Cutaneous angiosarcoma of the scalp : a multidisciplinary approach. Cancer 98 : 1716-1726, 2003.
PubMed
13) Guadagnolo BA, et al : Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 33 : 661-667, 2011.
PubMed
14) Vogt T, et al : Brief S1 guidelines-Cutaneous angiosarcoma and Kaposi sarcoma. J Dtsch Dermatol Ges 11 (Suppl 3) : 2-9, 2-10, 2013.
 
15) Buschmann A, et al : Surgical treatment of angiosarcoma of the scalp : less is more. Ann Plast Surg 61 : 399-403, 2008.
PubMed
16) Fujisawa Y, et al : Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma : a multicentre, retrospective study. Br J Dermatol 171 : 1493-1500, 2014.
PubMed
17) Shin JY, et al : Predisposing factors for poor prognosis of angiosarcoma of the scalp and face : Systematic review and meta-analysis. Head Neck 39 : 380-386, 2017.
PubMed
18) Trofymenko O, Curiel-Lewandrowski C : Surgical treatment associated with improved survival in patients with cutaneous angiosarcoma. J Eur Acad Dermatol Venereol 32 : e29-e31, 2018.
PubMed
19) 水上晶子, ほか : 血管肉腫ガイドライン作成に向けて血管肉腫 日本皮膚外科学会アンケート調査結果を中心に. Skin Cancer 24 : 350-362, 2010.
 
20) 増澤幹男, ほか : 日本皮膚科学会ガイドライン 頭部血管肉腫診療ガイドライン. 日本皮膚科学会雑誌 125 : 1871-1888. 2015.
 
21) Hodgkinson DJ, et al : Cutaneous angiosarcoma of the head and neck. Cancer 44 : 1106-1113, 1979.
PubMed
22) Patel SH, et al : Angiosarcoma of the scalp and face : the Mayo Clinic experience. JAMA Otolaryngol Head Neck Surg 141 : 335-340, 2015.
 
23) Abraham JA, et al : Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 14 : 1953-1967, 2007.
PubMed
24) Espat NJ, et al : Confirmed angiosarcoma : prognostic factors and outcome in 50 prospectively followed patients. Sarcoma 4 : 173-177, 2000.
PubMed
25) Sinnamon AJ, et al : A prognostic model for resectable soft tissue and cutaneous angiosarcoma. J Surg Oncol 114 : 557-563, 2016.
PubMed
26) 山崎直也 : 血管肉腫治療ガイドライン作成に向けて 血管肉腫に対する国立がんセンターの治療戦略. Skin Cancer 24 : 385-391, 2010.
 
27) Fujisawa Y, et al : Cutaneous Angiosarcoma : The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor. Front Oncol 8 : 46, 2018.
PubMed
28) 藤澤康弘, ほか : 皮膚悪性腫瘍診療ガイドライン 第3版 皮膚血管肉腫診療ガイドライン 2021. 日本皮膚科学会雑誌 131 : 245-277, 2021.
 
29) Chen W, et al : Angiosarcoma with pulmonary metastasis presenting with spontaneous bilateral pneumothorax in an elderly man. J Formos Med Assoc 105 : 238-241, 2006.
 
30) Mark RJ, et al : Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 77 : 2400-2406, 1996.
 
31) Morgan MB, et al : Cutaneous angiosarcoma : a case series with prognostic correlation. J Am Acad Dermatol 50 : 867-874, 2004.
PubMed
32) Ogawa K, et al : Treatment and prognosis of angiosarcoma of the scalp and face : a retrospective analysis of 48 patients. Br J Radiol 85 : e1127-1133, 2012.
 
33) 増澤幹男 : 頭部脈管肉腫に対する局所rIL-2/LAK療法-実践, 反省, 夢. Skin Cancer 11 : 42-45, 1996.
 
34) 池田重雄, 石原和之 : 皮膚悪性腫瘍に対する遺伝子組換え型ヒトインターロイキン 2 (rIL-2 : TGP-3) の臨床第2相試験. Skin Cancer 4 : 367-387, 1989.
 
35) Rosenberg SA, Lotze MT : Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 4 : 681-709, 1986.
PubMed
36) 高久史麿 : S-6820 (遺伝子組換えヒトインターロイキン 2) の臨床第II相試験. Biotherapy 3 : 796-805, 1989.
 
37) 増澤幹男 : 治療のトピックスIL-2による悪性血管内皮細胞腫の治療. 臨床皮膚科 45 : 188-191, 1991.
 
38) 増澤幹男, ほか : 悪性血管内皮細胞腫に対するインターロイキン-2局注療法の検討. 日本皮膚科学会雑誌 99 : 1459-1466, 1989.
 
39) 鈴木裕介, ほか : rlL-2の局注・動注・切除術の組み合わせで完全に寛解した悪性血管内皮細胞腫の一例. 皮膚科紀要 87 : 47-52, 1992.
 
40) Elias A, et al : Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol 17 : 41-49, 1990.
PubMed
41) 黒岡定浩, ほか : MAID療法が著効した血管肉腫の1例. 日本皮膚科学会雑誌 121 : 691-697, 2011.
 
42) 山崎直也, ほか : 血管肉腫に対するMesna, Adriamycin, Ifosfamide, Dacarbazine (MAID) 療法. 日本皮膚科学会雑誌 115 : 2299-2301, 2005.
 
43) Swain SM, et al : Congestive heart failure in patients treated with doxorubicin : a retrospective analysis of three trials. Cancer 97 : 2869-2879, 2003.
PubMed
44) Von Hoff DD, et al : Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 : 710-717, 1979.
PubMed
45) Verweij J, et al : Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or rnetastatic soft tissue sarcomas in adults : a study of the European Organization for Research and Treatment of Cancer soft tissue and bone sarcoma group. J Clin Oncol 18 : 2081-2086, 2000.
PubMed
46) Fata F, et al : Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86 : 2034-2037, 1999.
PubMed
47) Penel N. et al : Phase II trial of weekly paclitaxel for unresectable angiosarcoma : the ANGIOTAX Study. J Clin Oncol 26 : 5269-5274, 2008.
PubMed
48) Chen JP, et al : Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers. Lung Cancer 60 : 92-97, 2008.
PubMed
49) Fujisawa Y, et al : The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane : a multicentre prospective observational study. Br J Dermatol 183 : 831-839, 2020.
PubMed
50) Goodman AM, et al : Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther 16 : 2598-2608, 2017.
PubMed
51) Potter JW, et al : Sarcoma-The standard-bearer in cancer discovery. Crit Rev Oncol Hematol 126 : 1-5, 2018.
PubMed
52) Boichard A, et al : Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade : insights from genomic sequencing. Genome Med 12 : 61, 2020.
PubMed
53) Painter CA, et al : The Angiosarcoma Project : enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med 26 : 181-187, 2020.
 
P.365 掲載の参考文献
1) Albores-Saavedra J, et al : Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007. Ann Diagn Pathol 15 : 93-97, 2011.
PubMed
2) Fujisawa Y, et al : Cutaneous Angiosarcoma : The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor. Front Oncol 8 : 46, 2018. [DOI : 10.3389/fonc.2018]
 
3) Dennis N, et al : Soft tissue Sarcoma Incidence and Survival Tumours Diagnosed in England Between 1985 and 2009. National Cancer Intelligence Network, 2012. [http://www.ncin.org.uk/view?rid=2062] (2021年6月閲覧)
 
4) 石原和之, ほか ; 日本皮膚悪性腫瘍学会予後統計調査委員会 : 皮膚悪性腫瘍の発生数に関する全国アンケート (1997～2001年). Skin Cancer 19 : 147-155, 2004.
 
5) Fujisawa Y, et al : Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan. J Dermatol Sci 92 : 230-236, 2018.
PubMed
6) Weiss SW, Goldblum JR : Enzinger and Weiss's Soft Tissue Tumors, 4th ed, Mosby, St Louis, 2001.
 
7) Lahat G, et al : Angiosarcoma : clinical and molecular insights. Ann Surg 251 : 1098-1106, 2010.
PubMed
8) Morgan EA, et al : Cutaneous radiation-associated angiosarcoma of the breast : poor prognosis in a rare secondary malignancy. Ann Surg Oncol 19 : 3801-3808, 2012.
 
9) 水上晶子, ほか : [血管肉腫ガイドライン作成に向けて] 血管肉腫 日本皮膚外科学会アンケート調査結果を中心に. Skin Cancer 24 : 350-362, 2010.
 
10) Sharma A, Schwart RA : Stewart-Treves syndrome : pathogenesis and management. J Am Acad Dermatol 67 : 1342-1348, 2012.
 
11) Yang WT, et al : Mammary angiosarcomas : imaging findings in 24 patients. Radiology 242 : 725-734, 2007,
PubMed
12) Deyrup AT, et al : Sporadic cutaneous angiosarcomas : a proposal for risk stratification based on 69 cases. Am J Surg Pathol 32 : 72-77, 2008.
PubMed
13) Hwang K, et al : Recommendations for therapeutic decisions of angiosarcoma of the scalp and face. J Craniofac Surg 26 : e253-256, 2015. [DOI : 10.1097/SCS.0000000000001495]
 
14) Bernstein JM, et al : Survival outcomes for cutaneous angiosarcoma of the scalp versus face. Head Neck 39 : 1205-1211, 2017.
PubMed
15) Shin JY, et al : Predisposing factors for poor prognosis of angiosarcoma of the scalp and face : Systematic review and meta-analysis. Head Neck 39 : 380-386, 2017.
PubMed
P.369 掲載の参考文献
1) Painter CA, et al : The Angiosarcoma Project : enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med 26 : 181-187, 2020.
 
2) Lee KC, et al : Characteristics and Prognosis of Primary Head and Neck Angiosarcomas : A Surveillance, Epidemiology, and End Results Program (SEER) Analysis of 1250 Cases. Head Neck Pathol 13 : 378-385, 2019.
PubMed
3) 水上晶子, ほか : 血管肉腫 : 日本皮膚外科学会アンケート調査結果を中心に. Skin Cancer 24 : 350-362, 2009.
 
4) Sharma A, Schwartz RA : Stewart-Treves syndrome : pathogenesis and management. J Am Acad Dermatol 67 : 1342-1348, 2012.
PubMed
5) Co M, et al : Cutaneous angiosarcoma secondary to lymphoedema or radiation therapy-A systematic review. Clin Oncol 31 : 225-231, 2019.
PubMed
6) 花城ふく子, ほか : 診断に苦慮した紫斑を呈さない頭部血管肉腫の1例. 西日本皮膚科 80 : 345-348, 2018.
 
7) Trinh NQ, et al : Unusual clinical presentation of cutaneous angiosarcoma masquerading as eczema : A case report and review of the literature. Case Rep Dermatol Med 2013 : 906426, 2013. [DOI : 10.1155/2013/906426]
 
8) Mentzel T, et al : Cutaneous angiosarcoma of the face : clinicopathologic and immunohistochemical study of a case resembling rosacea clinically. J Am Acad Dermatol 38 : 837-840, 1998.
PubMed
9) 石原和之, ほか : 血管肉腫の統計. Skin Cancer 16 : 281-288, 2001.
 
10) Rouhani P, et al : Cutaneous soft tissue sarcoma incidence patterns in the U. S. : an analysis of 12,114 cases. Cancer 113 : 616-627, 2008.
PubMed
11) 藤澤康弘, ほか ; 皮膚悪性腫瘍診療ガイドライン改訂委員会 : 皮膚悪性腫瘍ガイドライン 第3版 皮膚血管肉腫臨床ガイドライン 2021. 日本皮膚科学会雑誌 131 : 245-277, 2021.
 
12) Awazawa R, et al : High Prevalence of Distinct Human Herpesvirus 8 Contributes to the High Incidence of Non-acquired Immune Deficiency Syndrome-Associated Kaposi's Sarcoma in Isolated Japanese Islands. J Infect Dis 216 : 850-858, 2017.
 
P.373 掲載の参考文献
1) 増澤幹男, ほか ; 頭部血管肉腫診療ガイドライン作成委員会 : 日本皮膚科学会ガイドライン 頭部血管肉腫ガイドライン . 日皮会誌 125 : 1871-1888, 2015.
 
2) Donghi D, et al : Cutaneous angiosarcoma : own experience over 13 years. Clinical features, disease course and immunohistochemical profile. J Eur Acad Dermatol Venereol 24 : 1230-1234, 2010.
PubMed
3) Fraga-Guedes C, et al : Angiosarcoma and atypical vascular lesions of the breast : diagnostic and prognostic role of MYC gene amplification and protein expression. Breast Cancer Res Treat 151 : 131-140, 2015.
PubMed
4) Arbiser JL, et al : Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-l and VEGFR-2 in vivo. Am J Pathol 156 : 1469-1476, 2000.
 
5) Mandahl N, et al : Trisomy 5 and loss of the Y chromosome as the sole cytogenetic anomalies in a cavernous hemangioma/angiosarcoma. Genes Chromosomes Cancer 1 : 315-316, 1990.
 
6) Behjati S, et al : Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet 46 : 376-379, 2014.
PubMed
7) Errani C, et al : A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 50 : 644-653, 2011.
PubMed
8) Giacomini CP, et al : Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS Genet 9 : e1003464, 2013.
PubMed
9) Gru AA, et al : Angiosarcoma of the parotid gland with a t (12 ; 22) translocation creating a EWSR1-ATF1 fusion : adiagnostic dilemma. J Clin Pathol 66 : 452-454, 2013.
 
10) Shimozono N, et al : NUP160-SLC43A3 is a novel recurrent fusion oncogene in angiosarcoma. Cancer Res 75 : 4458-4465, 2015.
PubMed
11) 藤澤康弘 : 血管肉腫 : 最近の知見と治療方針. 日皮会誌 124 : 2956-2959, 2014.
 
12) Holden CA, et al : Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 59 : 1046-1057, 1987.
PubMed
P.377 掲載の参考文献
1) Guadagnolo BA, et al : Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 33 : 661-667, 2011.
PubMed
2) Vogt T, et al : Brief S1 guidelines--Cutaneous angiosarcoma and Kaposi sarcoma. J Dtsch Dermatol Ges 11 (Suppl 3) : 2-9, 2-10, 2013.
 
3) Sharma A, Schwartz RA : Stewart-Treves syndrome : pathogenesis and management. J Am Acad Dermatol 67 : 1342-1348, 2012.
PubMed
4) Nascimento AF, et al : Primary angiosarcoma of the breast : clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol 32 : 1896-1904, 2008.
 
5) Depla AL, et al : Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer : a systematic review. Eur J Cancer 50 : 1779-1788, 2014.
PubMed
6) Shin JY, et al : Predisposing factors for poor prognosis of angiosarcoma of the scalp and face : Systematic review and meta-analysis. Head Neck 39 : 380-386, 2017.
PubMed
7) Trofymenko O, Curiel-Lewandowski C : Surgical treatment associated with improved survival in patients with cutaneous angiosarcoma. J Eur Acad Dermatol Venereol 32 : e29-e31, 2018.
 
8) Fujisawa Y, et al : Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma : amulticentre, retrospective study. Br J Dermatol 171 : 1493-1500, 2014.
PubMed
9) 水上晶子, ほか : 血管肉腫ガイドライン作成に向けて 血管肉腫 日本皮膚外科学会アンケート調査結果を中心に. Skin Cancer 24 : 350-362, 2010.
 
10) 増澤幹男, ほか : 日本皮膚科学会ガイドライン 頭部血管肉腫診療ガイドライン . 日本皮膚科学会雑誌 125 : 1871-1888, 2015.
 
11) Buschmann A, et al : Surgical treatment of angiosarcoma of the scalp : less is more. Ann Plast Surg 61 : 399-403, 2008.
PubMed
12) Morgan MB, et al : Cutaneous angiosarcoma : a case series with prognostic correlation. J Am Acad Dermatol 50 : 867-874, 2004.
PubMed
13) 山崎直也 : 血管肉腫に対する国立がんセンターの治療戦略. Skin Cancer 24 : 385-391, 2009.
 
14) Lim SY, et al : Surgical treatment of angiosarcoma of the scalp with superficial parotidectomy. Ann Plast Surg 64 : 180-182, 2010.
PubMed
15) Co M, et al : Cutaneous Angiosarcoma Secondary to Lymphoedema or Radiation Therapy-A Systematic Review. Clin Oncol (R Coll Radiol) 31 : 225-231, 2019.
PubMed
16) Jallali N, et al : Surgical management of radiation-induced angiosarcoma after breast conservation therapy. Am J Surg 203 : 156-161, 2012.
PubMed
17) Lindford A, et al : Surgical management of radiation-associated cutaneous breast angiosarcoma. J Plast Reconstr Aesthet Surg 64 : 1036-1042, 2011.
PubMed
18) Li GZ, et al : Cutaneous Radiation-associated Breast Angiosarcoma : Radicality of Surgery Impacts Survival. Ann Surg 265 : 814-820, 2017.
PubMed
19) Ragavan S, et al : Axillary Lymph Node Dissection in Angiosarcomas of the Breast : An Asian Institutional Perspective. Sarcoma 2020 : 4890803, 2020.
PubMed
20) Constantinidou A, et al : Evaluation of the use and efficacy of (neo) adjuvant chemotherapy in angiosarcoma : a multicentre study. ESMO Open 5 : e000787, 2020.
PubMed
P.383 掲載の参考文献
1) 水上晶子, ほか : 血管肉腫 : 日本皮膚外科学会アンケート調査結果を中心に. Skin Cancer 24 : 350-362, 2009.
 
2) Penel N, et al : Phase II trial of weekly paclitaxel for unresectable angiosarcoma : the ANGIOTAX Study. J Clin Oncol 26 : 5269-5274, 2008.
PubMed
3) Ray-Coquard IL, et al : Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma : A Randomized Phase II Trial. J Clin Oncol 33 : 2797-2802, 2015.
PubMed
4) Nagano T, et al : Docetaxel : a therapeutic option in the treatment of cutaneous angiosarcoma : report of 9 patients. Cancer 110 : 648-651, 2007.
PubMed
5) D'Angelo SP, et al : Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. Oncology 89 : 205-214, 2015.
 
6) Italiano A, et al : Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 118 : 3330-3336, 2012.
PubMed
7) Penel N, et al : Metastatic angiosarcomas : doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol 23 : 517-523, 2012.
PubMed
8) Schlemmer M, et al : Paclitaxel in patients with advanced angiosarcomas of soft tissue : a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 44 : 2433-2436, 2008.
 
9) Fujisawa Y, et al : Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma : a multicentre, retrospective study. Br J Dermatol 171 : 1493-1500, 2014.
PubMed
10) Elias A, et al : Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7 : 1208-1216, 1989.
PubMed
11) Antman K, et al : An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11 : 1276-1285, 1993.
PubMed
12) 黒岡定浩, ほか : MAID療法が著効した血管肉腫の1例. 日本皮膚科学会雑誌 121 : 691-697, 2011.
 
13) 山崎直也, ほか : 血管肉腫に対するMesna, Adriamycin, Ifosfamide, Dacarbazine (MAID) 療法. 日本皮膚科学会雑誌 115 : 2299-2301, 2005.
 
14) 倉田裕介, ほか : MAID療法を試みた頭部血管肉腫の1例. 山口医学 64 : 199-203, 2015.
Medical*Online
15) Iwamoto K, et al : A case of cutaneous angiosarcoma successfully treated with eribulin. Eur J Dermatol 28 : 410-412, 2018.
PubMed
16) Wada N, et al : Case of angiosarcoma of the scalp successfully controlled by eribulin. J Dermatol 45 : 116-117, 2018.
PubMed
17) Fujisawa Y, et al : The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane : a multicentre prospective observational study. Br J Dermatol 183 : 831-839, 2020.
PubMed
18) Kollar A, et al : Pazopanib in advanced vascular sarcomas : an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis, Acta Oncol 56 : 88-92, 2017.
PubMed
19) Ogata D, et al : Pazopanib treatment slows progression and stabilizes disease in patients with taxaneresistant cutaneous angiosarcoma. Med Oncol 33 : 116, 2016. [DOI : 10.1007/s12032-016-0831-z]
 
20) Kitamura S, et al : Pazopanib does not bring remarkable improvement in patients with angiosarcoma. J Dermatol 44 : 64-67, 2017.
 
21) Fujiwara S, et al : Pazopanib as a potential chemotherapy for cutaneous angiosarcoma : A case series of 10 patients from a single institution. J Dermatol 47 : e273-e274, 2020.
PubMed
22) Ray-Coquard, et al : Sorafenib for patients with advanced angiosarcoma : A phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist 17 : 260-266, 2012.
PubMed
23) Maki RG, et al : Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27 : 3133-3140, 2009.
 
24) Agulnik M, et al : An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 24 : 257-263, 2013.
PubMed
25) 増澤幹男, ほか : 悪性血管内皮細胞腫に対するインターロイキン-2局注療法の検討. 日本皮膚科学会雑誌 99 : 1459-1466, 1989.
 
26) Honda Y, et al : Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology 6 : e1253657, 2017.
 
27) Shimizu A, et al : Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma. J Glob Oncol 3 : 360-369, 2017.
PubMed
28) Botti G, et al : Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma. J Cancer 8 : 3166-3172, 2017.
PubMed
29) Sindhu S, et al : Angiosarcoma treated successfully with anti-PD-1 therapy-a case report. J Immunother Cancer 5 : 58, 2017. [DOI : 10.1186/s40425-017-0263-0]
 
P.390 掲載の参考文献
1) Goldblum JR, et al : Enzinger and Weiss's Soft Tissue Tumors, 6th ed, Saunders/Elsevier, Philadelphia, 2014.
 
2) Manner J, et al : MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 176 : 34-39, 2010.
PubMed
3) Guo T, et al : Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer 50 : 25-33, 2011.
 
4) Penel N, et al : Angiosarcomas and taxanes. Curr Treat Options Oncol 8 : 428-434, 2007.
PubMed
5) Shin JY, et al : Predisposing factors for poor prognosis of angiosarcoma of the scalp and face : Systematic review and meta-analysis. Head Neck 39 : 380-386, 2017.
PubMed
6) Patel SH, et al : Angiosarcoma of the scalp and face : the Mayo Clinic experience. JAMA Otolaryngol Head Neck Surg 141 : 335-340, 2015.
 
7) Kohler HF, et al : Cutaneous angiosarcoma of the head and neck : report of 23 cases from a single institution. Otolaryngol Head Neck Surg 139 : 519-524, 2008.
PubMed
8) Buschmann A, et al : Surgical treatment of angiosarcoma of the scalp : less is more. Ann Plast Surg 61 : 399-403, 2008.
PubMed
9) Guadagnolo BA, et al : Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 33 : 661-667, 2011.
PubMed
10) Pawlik TM, et al : Cutaneous angiosarcoma of the scalp : a multidisciplinary approach. Cancer 98 : 1716-1726, 2003.
PubMed
11) Mark RJ, et al : Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 77 : 2400-2406, 1996.
 
12) Hwang K, et al : Recommendations for therapeutic decisions of angiosarcoma of the scalp and face. J Craniofac Surg 26 : e253-256, 2015.
PubMed
13) Oashi K, et al : Surgery with curative intent is associated with prolonged survival in patients with cutaneous angiosarcoma of the scalp and face-a retrospective study of 38 untreated cases in the Japanese population. Eur J Surg Oncol 44 : 823-829, 2018.
 
14) Hodgkinson DJ, et al : Cutaneous angiosarcoma of the head and neck. Cancer 44 : 1106-1113, 1979.
PubMed
15) Ogawa K, et al : Treatment and prognosis of angiosarcoma of the scalp and face : a retrospective analysis of 48 patients. Br J Radiol 85 : e1127-1133, 2012.
 
16) Hata M, et al : Radiation therapy for angiosarcoma of the scalp : treatment outcomes of total scalp irradiation with X-rays and electrons. Strahlenther Onkol 190 : 899-904, 2014.
PubMed
17) Ohguri T, et al : Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy. Int J Radiat Oncol Biol Phys 61 : 1446-1453, 2005.
PubMed
18) Suzuki G, et al : Definitive Radiation Therapy for Angiosarcoma of the Face and Scalp. In Vivo 30 : 921-926, 2016.
PubMed
19) Miki Y, et al : Single institutional experience of the treatment of angiosarcoma of the face and scalp. Br J Radiol 86 : 20130439, 2013.
PubMed
20) Fayette J, et al : Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site : a retrospective study of 161 cases. Ann Oncol 18 : 2030-2036, 2007.
 
21) Fujisawa Y, et al : Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma : amulticentre, retrospective study. Br J Dermatol 171 : 1493-1500, 2014.
PubMed
22) Ward JR, et al : Radiation therapy for angiosarcoma. Head Neck 25 : 873-878, 2003.
PubMed
23) Sasaki R, et al : Angiosarcoma treated with radiotherapy : impact of tumor type and size on outcome. Int J Radiat Oncol Biol Phys 52 : 1032-1040, 2002.
PubMed
24) Morrison WH, et al : Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer 76 : 319-327, 1995.
PubMed
25) Hirata T, et al : Efficacy of taxane regimens in patients with metastatic angiosarcoma. Eur J Dermatol 21 : 539-545, 2011.
PubMed
26) Italiano A, et al : Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 118 : 3330-3336, 2012.
PubMed
27) Milas L, et al : Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. Radiother Oncol 40 : 163-170, 1996.
PubMed
28) Mason K, et al : Enhancement of tumor radioresponse by docetaxel : Involvement of immune system. Int J Oncol 18 : 599-606, 2001.
PubMed
29) Depla AL, et al : Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer : asystematic review. Eur J Cancer 50 : 1779-1788, 2014.
 
30) Tomasini C, et al : Cutaneous angiosarcoma arising in an irradiated breast. Case report and review of the literature. Dermatology 209 : 208-214, 2004.
 
31) Yap J, et al : Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 52 : 1231-1237, 2002.
PubMed
32) Li GZ, et al : Cutaneous Radiation-associated Breast Angiosarcoma : Radicality of Surgery Impacts Survival. Ann Surg 265 : 814-820, 2017.
PubMed
33) Merfeld E, et al : Clinical Outcomes and Prognostic Features of Angiosarcoma : Significance of Prior Radiation Therapy. Clin Oncol (R Coll Radiol) 31 : 232-241, 2019.
PubMed
34) Fraga-Guedes C, et al : Primary and secondary angiosarcomas of the breast : a single institution experience. Breast Cancer Res Treat 132 : 1081-1088, 2012.
PubMed
35) Ghareeb ER, et al : Primary and Radiation-induced Breast Angiosarcoma : Clinicopathologic Predictors of Outcomes and the Impact of Adjuvant Radiation Therapy. Am J Clin Oncol 39 : 463-467, 2016.
PubMed
36) Abdou Y, et al : Primary and secondary breast angiosarcoma : single center report and a metaanalysis. Breast Cancer Res Treat 178 : 523-533, 2019.
 
37) Yin M, et al : Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma : a comparative study. BMC Cancer 17 : 295, 2017.
PubMed
38) Torres KE, et al : Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol 20 : 1267-1274, 2013.
PubMed
39) Vorburger SA, et al : Angiosarcoma of the breast. Cancer 104 : 2682-2688, 2005.
PubMed
40) 水上晶子, ほか : [血管肉腫ガイドライン作成に向けて] 血管肉腫 : 日本皮膚外科学会アンケート調査結果を中心に. Skin Cancer 24 : 350-362, 2009.
 
41) Smith TL, et al : Angiosarcoma after breast-conserving therapy : long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART). Acta Oncol 53 : 235-241, 2014.
PubMed
P.396 掲載の参考文献
1) Quek R, et al : 501O_PR Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia : A report from the Asian Sarcoma Consortium (ASC). Ann Oncol 27 (Suppl 9) : ix163, 2016. (DOI : 10.1093/annonc/mdw597)
 
2) Lydiatt WM, et al : Angiosarcoma of the head and neck. Am J Surg 168 : 451-454, 1994.
PubMed
3) Steward WP, et al : Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas : preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. J Cancer Res Clin Oncol 117 (Suppl 4) : S193-197, 1991.
 
4) Young RJ, et al : First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes : pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer 50 : 3178-3186, 2014.
PubMed
5) Italiano A, et al : Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 118 : 3330-3336, 2012.
PubMed
6) Penel N, et al : Phase II trial of weekly paclitaxel for unresectable angiosarcoma : the ANGIOTAX Study. J Clin Oncol 26 : 5269-5274, 2008.
PubMed
7) Fata F, et al : Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86 : 2034-2037, 1999.
PubMed
8) Nagano T, et al : Docetaxel : atherapeutic option in the treatment of cutaneous angiosarcoma : report of 9 patients. Cancer 110 : 648-651, 2007.
 
9) Stacchiotti S, et al : Gemcitabine in advanced angiosarcoma : a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol 23 : 501-508, 2012.
PubMed
10) Fujisawa Y, et al : The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane : a multicentre prospective observational study. Br J Dermatol 183 : 831-839, 2020.
PubMed
11) Ray-Coquard IL, et al : Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma : A Randomized Phase II Trial. J Clin Oncol 33 : 2797-2802, 2015.
PubMed
12) Schoffski P, et al : Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet 387 : 1629-1637, 2016.
 
13) Itakura E, et al : Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 97 : 74-81, 2008.
 
14) Arbiser JL, et al : Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am J Pathol 156 : 1469-1476, 2000.
PubMed
15) Hasenstein JR, et al : Efficacy of Tie2 receptor antagonism in angiosarcoma. Neoplasia 14 : 131-140, 2012.
PubMed
16) Agulnik M, et al : An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 24 : 257-263, 2013.
PubMed
17) Bui N, et al : A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma. Rare Tumors 10 : 2036361318771771, 2018.
 
18) Jones RL, et al : Results of the TAPPAS trial : An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS). Ann Oncol 30 (Suppl 5) : v683, 2019. (DOI : 10.1093/annonc/mdz283)
 
19) Ray-Coquard I, et al : Sorafenib for patients with advanced angiosarcoma : a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist 17 : 260-266, 2012.
PubMed
20) Maki RG, et al : Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27 : 3133-3140, 2009.
 
21) Kollar A, et al : Pazopanib in advanced vascular sarcomas : an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 56 : 88-92, 2017.
PubMed
22) Agulnik M, et al : Multicenter, open-label phase II study of daily oral regorafenib for chemotherapyrefractory, metastatic and locally advanced angiosarcoma. J Clin Oncol 38 (15 Suppl) : 11561, 2020.
 
23) Painter CA, et al : The Angiosarcoma Project : enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med 26 : 181-187, 2020.
 
24) Florou V, et al : Angiosarcoma patients treated with immune checkpoint inhibitors : a case series of seven patients from a single institution. J Immunother Cancer 7 : 213, 2019.
PubMed

VII 皮膚リンパ腫

P.406 掲載の参考文献
1) 大塚幹夫, ほか : 皮膚悪性腫瘍ガイドライン 第3版 皮膚リンパ腫診療ガイドライン . 日本皮膚科学会雑誌 130 : 1347-1423, 2020.
 
2) 戸倉新樹 : 菌状息肉症, セザリー症候群, 原発性皮膚CD30陽性T細胞増殖性疾患. WHO分類第4版による白血病・リンパ系腫瘍の病態学 (押味和夫監, 木崎昌弘, 田丸淳一編), p347-362, 中外医学社, 2009.
 
3) 戸倉新樹 : 偽リンパ腫. 日皮会誌 119 : 1059-1064, 2009.
 
4) Sawada Y, et al : Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 117 : 3961-3967, 2011.
PubMed
5) Vonderheid EC, et al : Update on erythrodermic cutaneous T-cell lymphoma : report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46 : 95-106, 2002.
PubMed
6) 龍野一樹 : フローサイトメトリによる診断皮膚リンパ腫アトラス 第3版 (岩月啓氏, ほか編), p31-34, 文光堂, 2017.
 
7) Sugaya M, et al : Phase II study of i. v. interferon-gamma in Japanese patients with mycosis fungoides. J Dermatol 41 : 50-56, 2014.
 
8) Hamada T, et al : Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma : The results of a phase 2 study (B-1201). J Dermatol 46 : 557-563, 2019.
PubMed
9) Qu K, et al : Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. Cancer Cell 32 : 27-41. e4, 2017.
 
10) Kim YH, et al : Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC) : an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19 : 1192-1204, 2018.
 
11) Masuda Y, et al : Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms. J Eur Acad Dermatol Venereol 32 : 1456-1460, 2018.
PubMed
12) Prince HM, et al : Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA) : an international, open-label, randomised, phase 3, multicentre trial. Lancet 390 : 555-566, 2017.
 
13) Ohmachi K, et al : E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma : A phase I study. Cancer Sci 109 : 794-802, 2018.
PubMed
P.412 掲載の参考文献
1) Willemze R, et al : The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 133 : 1703-1714, 2019.
PubMed
2) 藤井一恭, ほか : 皮膚リンパ腫 全国症例数調査の結果 (2019年版). [http://www.skincancer.jp/report-skincancer_lymphoma_2019.pdf] (2021年6月閲覧)
 
3) Olsen E, et al : Revisions to the staging and classification of mycosis fungoides and Sezary syndrome : a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 : 1713-1722, 2007.
 
4) Pimpinelli N, et al : Defining early mycosis fungoides. J Am Acad Dermatol 53 : 1053-1063, 2005.
PubMed
5) Kim YH, et al : Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome : clinical prognostic factors and risk for disease progression. Arch Dermatol 139 : 857-866, 2003.
PubMed
6) Agar NS, et al : Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome : validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 : 4730-4739, 2010.
PubMed
7) Olsen EA, et al : Clinical end points and response criteria in mycosis fungoides and Sezary syndrome : a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29 : 2598-2607, 2011.
 
8) Scarisbrick JJ, et al : Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome : Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33 : 3766-3773, 2015.
 
9) Kim YH, et al : TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome : a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 : 479-484, 2007.
PubMed
10) 造血器腫瘍診療ガイドライン (2018年版補訂版), 日本血液学会, 2020. [http://www.jshem.or.jp/guihemali/table.html] (2021年6月閲覧)
 
11) Cetinozman F, et al : Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol 36 : 109-116, 2012.
PubMed
12) Woo DK, et al : Prognostic factors in primary cutaneous anaplastic large cell lymphoma : characterization of clinical subset with worse outcome. Arch Dermatol 145 : 667-674, 2009.
PubMed
13) Willemze R, et al : Primary cutaneous CD30+ T-cell lymphoproliferative disorders. In WHO Classification of Skin Tumours (ed by Elder DE, et al), p236-239, IARC, Lyon, 2018.
 
14) van Maldegem F, et al : The majority of cutaneous marginal zone B-cell lymphomas expresses classswitched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood 112 : 3355-3361, 2008.
 
15) Willemze R, et al : EORTC classification for primary cutaneous lymphomas : a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90 : 354-371, 1997,
 
16) Willemze R, et al : WHO-EORTC classification for cutaneous lymphomas. Blood 105 : 3768-3785, 2005.
PubMed
17) Merrill DE, et al : Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous γδ T-Cell Lymphomas. Am J Surg Pathol 41 : 204-215, 2017.
 
P.417 掲載の参考文献
1) 大塚幹夫, ほか : 皮膚リンパ腫診断に必要な知識. 皮膚悪性腫瘍ガイドライン 第3版 皮膚リンパ腫診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 1356-1357, 2020
 
2) ゲノム研究用・診療用病理組織検体取扱い規程 (日本病理学会編), p130-132, 羊土社, 2019.
 
3) Chan JK, et al : Nonnasal lymphoma expressing the natural killer cell marker CD56 : a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 89 : 4501-4513, 1997.
PubMed
4) Harrington AM, et al : Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. Am J Clin Pathol 132 : 60-66, 2009.
PubMed
5) Murphy M, et al : Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates : experience with an antibody reactive with paraffin-embedded tissue. Am J Dermatopathol 24 : 6-16, 2002.
PubMed
6) Seliem RM, et al : Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol 14 : 18-23, 2006.
 
7) Brousset P, et al : Comparison of in situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohistochemical correlation with anti-latent membrane protein antibody. Lab Invest 67 : 457-464, 1992.
PubMed
8) Remer M, et al : Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Immunotherapy 6 : 1187-1206, 2014.
PubMed
P.425 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed (ed by Swerdlow SH, et al), IARC Press, 2017.
 
2) 一迫玲 : フローサイトメトリーによる悪性リンパ腫の診断. 血液・腫瘍科 59 : 642-651, 2009.
 
P.432 掲載の参考文献
1) van Dongen JJM, et al : Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations : report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17 : 2257-2317, 2003.
 
P.436 掲載の参考文献
1) 科学的根拠に基づく皮膚悪性腫瘍診療ガイドライン II [第1版] 皮膚リンパ腫 (日本皮膚科学会, 日本皮膚悪性腫瘍学会編), 金原出版, 2010.
 
2) 菅谷誠ほか : 日本皮膚科学会ガイドライン 皮膚リンパ腫診療ガイドライン 2011年改訂版. 日本皮膚科学会雑誌 122 : 1513-1531, 2012.
 
3) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed (ed by Swerdlow SH, et al), IARC Press, Lyon, 2017.
 
4) WHO Classification of Skin Tumours, 4th ed (ed by Elder DE, et al), IARC Press, Lyon, 2018.
 
5) 大塚幹夫, ほか : 皮膚悪性腫瘍ガイドライン 第3版 皮膚リンパ腫診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 1347-1423, 2020.
 
6) Ohtsuka M, et al : Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. J Dermatol 48 : e49-e71, 2021.
PubMed
7) Gilson D, et al : British Association of Dermatologists and U. K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol 180 : 496-526, 2019.
 
8) Trautinger F, et al : European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome-Update 2017. Eur J Cancer 77 : 57-74, 2017.
PubMed
9) Willemze R, et al : Primary cutaneous lymphomas : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29 (Suppl 4) : iv30-iv40, 2018.
 
10) NCCN clinical practice in oncology (NCCN guidelines), Primary cutaneous lymphoma, version 1, 2021-October 12, NCCN. Org, 2020.
 
P.443 掲載の参考文献
1) Olsen E, et al : Revisions to the staging and classification of mycosis fungoides and Sezary syndrome : a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 : 1713-1722, 2007.
 
2) Olsen EA, et al : Clinical end points and response criteria in mycosis fungoides and Sezary syndrome : aconsensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29 : 2598-2607, 2011.
 
3) 大塚幹夫, ほか : 皮膚悪性腫瘍ガイドライン 第3版 皮膚リンパ腫診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 1347-1423, 2020.
 
4) Kim YH, et al : TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome : a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 : 479-484, 2007.
PubMed
5) Agar NS, et al : Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome : validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 : 4730-4739, 2010.
PubMed
6) Talpur R, et al : Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res 18 : 5051-5060, 2012.
PubMed
7) Quaglino P, et al : Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides : a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 118 : 5830-5839, 2012.
PubMed
8) Scarisbrick JJ, et al : Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome : Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33 : 3766-3773, 2015.
 
9) Willemze R, et al : WHO-EORTC classification for cutaneous lymphomas. Blood 105 : 3768-3785, 2005.
PubMed
10) Woo DK, et al : Prognostic factors in primary cutaneous anaplastic large cell lymphoma : characterization of clinical subset with worse outcome. Arch Dermatol 145 : 667-674, 2009.
PubMed
11) Benner MF, Willemze R : Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol 145 : 1399-1404, 2009.
PubMed
12) Hapgood G, et al : Outcome of primary cutaneous anaplastic large cell lymphoma : a 20-year British Columbia Cancer Agency experience. Br J Haematol 176 : 234-240, 2017.
PubMed
13) Willemze R, et al : Subcutaneous panniculitis-like T-cell lymphoma : definition, classification, and prognostic factors : an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 111 : 838-845, 2008.
 
14) Senff NJ, et al : Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas : Comparison with previous classifications and identification of prognostic markers. J Clin Oncol 25 : 1581-1587, 2007.
 
P.448 掲載の参考文献
1) Sugaya M, et al : CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol 42 : 613-615, 2015.
PubMed
2) Shono Y, et al : Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sezary Syndrome. Acta Derm Venereol 99 : 809-812, 2019.
PubMed
3) Miyagaki T, et al : IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 17 : 7529-7538, 2011.
 
4) Ikeda S, et al : Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma. Oncotarget 7 : 13563-13574, 2016.
PubMed
5) Suga H, et al : The role of IL-32 in cutaneous T-cell lymphoma. J Invest Dermatol 134 : 1428-1435. 2014.
PubMed
6) Kamijo H, et al : Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma. Blood 132 : 1922-1935, 2018.
PubMed
7) Kamijo H, et al : Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47. Leukemia 34 : 845-856, 2020.
PubMed
8) Sugaya M, et al : Association of the numbers of CD163 (+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci 68 : 45-51, 2012.
PubMed
9) Wu X, et al : A Small Molecule CCR2 Antagonist Depletes Tumor Macrophages and Synergizes with Anti-PD-1 in a Murine Model of Cutaneous T-Cell Lymphoma (CTCL). J Invest Dermatol 140 : 1390-1400. e4, 2020.
 
10) Miyagaki T, et al : Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributesto a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma. J Invest Dermatol 132 : 1280-1289, 2012.
 
11) Aronovich A, et al : Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12/CXCR4. J Invest Dermatol 141 : 619-627. e2, 2021.
 
12) Litvinov IV, et al : Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. Oncoimmunology 6 : e1306618, 2017.
PubMed
13) Wang L, et al : Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 47 : 1426-1434, 2015.
 
14) Buus TB, et al : Single-cell heterogeneity in Sezary syndrome. Blood Adv 2 : 2115-2126, 2018.
PubMed
15) Borcherding N, et al : Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression. Clin Cancer Res 25 : 2996-3005, 2019.
PubMed
P.453 掲載の参考文献
1) Willemze R, et al : WHO-EORTC classification for cutaneous lymphomas. Blood 105 : 3768-3785, 2005.
PubMed
2) Fujii K et al : Cutaneous lymphoma in Japan, 2012-2017 : A nationwide study. J Dermatol Sci 97 : 187-193, 2020.
PubMed
3) Zackheim HS, et al : Prognosis in cutaneous T-cell lymphoma by skin stage : long-term survival in 489 patients. J Am Acad Dermatol 40 : 418-425, 1999.
PubMed
4) Kim YH, et al : Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome : clinical prognostic factors and risk for disease progression. Arch Dermatol 139 : 857-866, 2003.
PubMed
5) Scarisbrick JJ, et al : Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome : where are we now? Br J Dermatol 170 : 1226-1236, 2014.
PubMed
6) Kim YH, et al : Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132 : 1309-1313, 1996.
PubMed
7) Toro JR, et al : Prognostic factors and evaluation of mycosis fungoides and Sezary syndrome. J Am Acad Dermatol 37 : 58-67, 1997.
PubMed
8) Kim YH, et al : Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 135 : 26-32, 1999.
 
9) Agar NS, et al : Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome : validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 : 4730-4739, 2010.
PubMed
10) Talpur R, et al : Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res 18 : 5051-5060, 2012.
PubMed
11) Scarisbrick JJ, et al : Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome : Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33 : 3766-3773, 2015.
 
12) Axelrod PI, et al : Infections complicating mycosis fungoides and Sezary syndrome. JAMA 267 : 1354-1358, 1992.
PubMed
13) Blaizot R, et al : Infectious events and associated risk factors in mycosis fungoides/Sezary syndrome : a retrospective cohort study. Br J Dermatol 179 : 1322-1328, 2018.
PubMed
14) Krejsgaard T, et al : Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood 124 : 761-770, 2014.
PubMed
15) Jackow CM, et al : Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vβ gene expansion. Blood 89 : 32-40, 1997.
 
16) Lindahl LM, et al : Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood 134 : 1072-1083, 2019.
PubMed
17) Posner LE, et al : Septicemic complications of the cutaneous T-cell lymphomas. Am J Med 71 : 210-216, 1981.
PubMed
P.459 掲載の参考文献
1) Mehrany K, et al : Cutaneous T-cell lymphoma and atopy : is there an association? Br J Dermatol 149 : 1013-1017, 2003.
PubMed
2) Nikolaou V, et al : Psoriasis in patients with mycosis fungoides : aclinicopathological study of 25 patients. J Eur Acad Dermatol Venereol 31 : 1848-1852, 2017.
 
3) Scarisbrick JJ, et al : The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 181 : 350-357, 2019.
PubMed
4) Fujii K, et al : Cutaneous lymphoma in Japan, 2012-2017 : Anationwide study. J Dermatol Sci 97 : 187-193, 2020.
 
5) Pimpinelli N, et al : Defining early mycosis fungoides. J Am Acad Dermatol 53 : 1053-1063, 2005.
PubMed
6) Massone C, et al : Histopathologic features of early (patch) lesions of mycosis fungoides : a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 29 : 550-560, 2005.
 
7) Wood GS : Analysis of clonality in cutaneous T cell lymphoma and associated diseases. Ann N Y Acad Sci 941 : 26-30, 2001.
PubMed
8) Sufficool KE, et al : T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides. J Am Acad Dermatol 73 : 228-236. e2, 2015.
 
9) Miyagaki T, Sugaya M : Erythrodermic cutaneous T-cell lymphoma : how to differentiate this rare disease from atopic dermatitis. J Dermatol Sci 64 : 1-6, 2011.
PubMed
10) Vandergriff T, et al : Defining early mycosis fungoides : validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas. J Cutan Pathol 42 : 318-328, 2015.
PubMed
11) Alsayyah A : Is it mycosis fungoides? A comprehensive guide to reaching the diagnosis and avoiding common pitfalls. Ann Diagn Pathol 47 : 151546, 2020.
PubMed
12) Suga H, et al : Skin barrier dysfunction and iow antimicrobial peptide expression in cutaneous T-cell lymphoma. Clin Cancer Res 20 : 4339-4348, 2014.
 
13) Vowels BR, et al : Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 103 : 669-673, 1994.
PubMed
14) Beynon T, et al : 'We had to change to single beds because I itch in the night' : a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma. Br J Dermatol 173 : 83-92, 2015.
PubMed
15) Yuki A, et al : CADM1 is a diagnostic marker in early-stage mycosis fungoides : Multicenter study of 58 cases. J Am Acad Dermatol 79 : 1039-1046, 2018.
 
16) Sasaki H, et al : Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood 105 : 1204-1213, 2005.
PubMed
17) Yamaguchi M, et al : The expression of cell adhesion molecule 1 and its splicing variants in Sezary cells and cell lines from cutaneous T-cell lymphoma. J Dermatol 46 : 967-977, 2019.
PubMed
18) Rovner R, et al : Influence of clinical and pathologic features on the pathologist's diagnosis of mycosis fungoides : a pilot study. J Cutan Pathol 42 : 471-479, 2015.
PubMed
P.462 掲載の参考文献
1) Nieto-Rementeria N, et al : Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol 160 : 519-526, 2009.
PubMed
2) Zhang C, et al : Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells : relevance to mechanism of therapeutic action. Clin Cancer Res 8 : 1234-1240, 2002.
PubMed
3) Budgin JB, et al : Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 141 : 315-321, 2005.
PubMed
4) Scarisbrick JJ, et al : U. K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 168 : 192-200, 2013.
 
5) Duvic M, et al : Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137 : 581-593, 2001.
PubMed
6) Duvic M, et al : Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma : multinational phase II-III trial results. J Clin Oncol 19 : 2456-2471, 2001.
 
7) Prince HM, et al : Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA) : an international, open-label, randomised, phase 3, multicentre trial. Lancet 390 : 555-566, 2017.
 
8) Vakeva L, et al : Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol 92 : 258-263, 2012.
PubMed
9) Hamada T, et al : Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas. J Dermatol 44 : 135-142, 2017.
PubMed
10) Hamada T, et al : Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma : The results of a phase 2 study (B-1201). J Dermatol 46 : 557-563, 2019.
PubMed
11) Duvic M, et al : Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. Clin Cancer Res 23 : 3552-3556, 2017.
PubMed
12) Illidge T, et al : Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. Br J Cancer 109 : 2566-2573, 2013.
PubMed
13) Kannangara AP, et al : Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. J Dermatolog Treat 20 : 169-176, 2009.
PubMed
14) Morita A, et al : Efficacy and safety of bexarotene combined with photo (chemo) therapy for cutaneous T-cell lymphoma. J Dermatol 47 : 443-451, 2020.
PubMed
P.466 掲載の参考文献
1) 大塚幹夫, ほか ; 公益社団法人日本皮膚科学会, 一般社団法人日本皮膚悪性腫瘍学会, 皮膚悪性腫瘍診療ガイドライン改訂委員会皮膚リンパ腫診療ガイドライングループ : 皮膚悪性腫瘍ガイドライン 第3版 皮膚リンパ腫診療ガイドライン 2020. 日皮会誌 130 : 1347-1423, 2020.
 
2) Miller CHT, et al : Clinical use of interferon-y. Ann N Y Acad Sci 1182 : 69-79, 2009.
 
3) Hino R, et al : Treatment with IFN-gamma increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides. J Dermatol Sci 38 : 189-195, 2005.
PubMed
4) Spaccarelli N, Rook AH : The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol Clin 33 : 731-745, 2015.
PubMed
5) Kaplan EH, et al : Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82 : 208-212, 1990.
PubMed
6) 石原和之, ほか : 皮膚悪性腫瘍におけるSUN4800後期臨床第II相試験. 西日皮膚 51 : 766-775, 1989.
 
7) 石原和之 : 菌状息肉症に対するOH-6000後期臨床第II相試験. Skin Cancer 8 : 352-367, 1993.
 
8) Sugaya M, et al : Phase II study of i. v. interferon-gamma in Japanese patients with mycosis fungoides. J Dermatol 41 : 50-56, 2014.
 
9) Shimauchi T, et al : Alterations of serum Th1 and Th2 chemokines by combination therapy of interferon-gamma and narrowband UVB in patients with mycosis fungoides. J Dermatol Sci 50 : 217-225, 2008.
PubMed
P.472 掲載の参考文献
1) Ushijima T : Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5 : 223-231, 2005.
PubMed
2) Nebbioso A, et al : Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11 : 77-84, 2005.
PubMed
3) Zhao Y, et al : Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 102 : 16090-16095, 2005.
PubMed
4) Vrana JA, et al : Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18 : 7016-7025, 1999.
PubMed
5) Qiu L, et al : Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11 : 2069-2083, 2000.
PubMed
6) Qian DZ, et al : Targeting tumor angiogenesis with histone deacetylase inhibitors : the hydroxamic acid derivative LBH589. Clin Cancer Res 12 : 634-642, 2006.
PubMed
7) Qian DZ, et al : Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 67 : 1182-1193, 2007.
PubMed
8) Kim IA, et al : Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells : class differences and the potential influence of p53. Clin Cancer Res 12 : 940-949, 2006.
PubMed
9) Qian DZ, et al : The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64 : 6626-6634, 2004.
 
10) Wang XF, et al : Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 11 : 3535-3542, 2005.
PubMed
11) Kato Y, et al : Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 6 : 70-81, 2007.
PubMed
12) Armeanu S, et al : Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65 : 6321-6329, 2005.
PubMed
13) Kato Y, et al : Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 13 : 4538-4546, 2007.
 
14) Kato Y : Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation. J Dermatol Sci 81 : 17-25, 2016.
 
15) Reddy P, et al : Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graftversus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 101 : 3921-3926, 2004.
 
16) Fischer A, et al : Recovery of learning and memory is associated with chromatin remodelling. Nature 447 : 178-182, 2007.
PubMed
17) Vojinovic J, et al : Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 63 : 1452-1458, 2011.
PubMed
18) Roseboom T, et al : The Dutch famine and its long-term consequences for adult health. Early Hum Dev 82 : 485-491, 2006.
PubMed
19) Barker DJ : The origins of the developmental origins theory. J Intern Med 261 : 412-417, 2007.
PubMed
P.478 掲載の参考文献
1) Kaye FJ, et al : A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 : 1784-1790, 1989.
PubMed
2) Hughes CF, et al : Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome : a comparative study of systemic therapy. Blood 125 : 71-81, 2015.
PubMed
3) Zackheim HS, et al : Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma : results in twenty-nine patients. J Am Acad Dermatol 34 : 626-631, 1996.
PubMed
4) Zackheim HS, et al : Low-dose methotrexate to treat mycosis fungoides : a retrospective study in 69 patients. J Am Acad Dermatol 49 : 873-878, 2003.
PubMed
5) Foss F, et al : Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides : a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk 12 : 238-243, 2012.
PubMed
6) Marchi E, et al : Gemcitabine as frontline treatment for cutaneous T-cell lymphoma : phase II study of 32 patients. Cancer 104 : 2437-2441, 2005.
PubMed
7) Zinzani PL, et al : Gemcitabine treatment in pretreated cutaneous T-cell lymphoma : experience in 44 patients. J Clin Oncol 18 : 2603-2606, 2000.
PubMed
8) Zinzani PL, et al : Gemcitabine as single agent in pretreated T-cell lymphoma patients : evaluation of the long-term outcome. Ann Oncol 21 : 860-863, 2010.
 
9) Duvic M, et al : Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 7 : 51-58, 2006.
PubMed
10) Molina A, et al : Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 23 : 6163-6171, 2005.
PubMed
11) Duarte RF, et al : Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome : a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28 : 4492-4499, 2010.
 
12) Duarte RF, et al : Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome : a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol 32 : 3347-3348, 2014.
PubMed
13) Domingo-Domenech E, et al : Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sezary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant, 2021. (DOI : 10.1038/s41409-020-01197-3)
 
14) Lechowicz MJ, et al : Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant 49 : 1360-1365, 2014.
PubMed
15) Hosing C, et al : Allogeneic stem-cell transplantation in patients with cutaneous lymphoma : updated results from a single institution. Ann Oncol 26 : 2490-2495, 2015.
PubMed
16) Mori T, et al : Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sezary syndrome. Hematol Oncol 38 : 266-271, 2020.
PubMed
17) Iqbal M, et al : Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma : Results of a Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 26 : 76-82, 2020.
PubMed
P.484 掲載の参考文献
1) Kakinuma T, et al : Thymus and activation-regulated chemokine (TARC/CCLI7) in mycosis fungoides : serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 48 : 23-30, 2003.
 
2) Kim YH, et al : Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC) : an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19 : 1192-1204, 2018.
 
3) Fuji S, et al : Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol 34 : 3426-3433, 2016.
PubMed
4) Lundin J, et al : Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101 : 4267-4272, 2003.
PubMed
5) de Masson A, et al : Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol 170 : 720-724, 2014.
PubMed
6) Prince HM, et al : Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA) : an international, open-label, randomised, phase 3, multicentre trial. Lancet 390 : 555-566, 2017.
 
7) Prince HM, et al : Phase III placebo-controlled triai of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28 : 1870-1877, 2010.
 
8) Horwitz SM, et al : Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 : 4115-4122, 2012.
PubMed
9) Maruyama D, et al : Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci 108 : 2061-2068, 2017.
PubMed
10) Dummer R, et al : Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome). Ann Oncol 25 : 1807-1812, 2014.
PubMed
11) Maruyama D, et al : Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. Ann Hematol 98 : 131-142, 2019.
PubMed
12) Duvic M, et al : Panobinostat activity in both bexarotene-exposed and-naive patients with refractory cutaneous T-cell lymphoma : results of a phase II trial. Eur J Cancer 49 : 386-394, 2013.
PubMed
13) Foss F, et al : A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 168 : 811-819, 2015.
 
14) Querfeld C, et al : Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood 123 : 1159-1166, 2014.
PubMed
15) Zinzani PL, et al : Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 25 : 4293-4297, 2007.
PubMed
P.488 掲載の参考文献
1) Ohtsuka M, et al : Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. J Dermatol 48 : e49-e71, 2021.
PubMed
2) Querfeld C, et al : Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141 : 305-311, 2005.
 
3) Wackernagel A, et al : Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides. Br J Dermatol 154 : 519-523, 2006.
PubMed
4) Herrmann JJ, et al : Treatment of mycosis fungoides with photochemotherapy (PUVA) : long-term follow-up. J Am Acad Dermatol 33 : 234-242, 1995.
PubMed
5) Pavlotsky E et al : Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides. J Am Acad Dermatol 71 : 536-541, 2014.
 
6) Anderson RR, Parrish JA : The optics of human skin. J Invest Dermatol 77 : 13-19, 1981.
PubMed
7) Aufiero BM, et al : Narrow-band UVB induces apoptosis in human keratinocytes. J Photochem Photobiol B 82 : 132-139, 2006.
PubMed
8) Sigmundsdottir H, et al : Narrowband-UVB irradiation decreases the production of pro-inflammatory cytokines by stimulated T cells. Arch Dermatol Res 297 : 39-42, 2005.
PubMed
9) Pavlotsky F, et al : UVB in the management of early stage mycosis fungoides. J Eur Acad Dermatol Venereol 20 : 565-572, 2006.
PubMed
10) Olsen EA, et al : Guidelines for phototherapy of mycosis fungoides and Sezary syndrome : A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 74 : 27-58, 2016.
PubMed
11) Pattamadilok B, Poompustar T : Aretrospective, descriptive study of patients with Mycosis fungoides treated by phototherapy (oral PUVA, NB-UVB) with a twice-weekly regimen at the Institute of Dermatology, Bangkok, Thailand, with an experiential timeline of 13 years. Photodermatol Photoimmunol Photomed 37 : 49-55, 2021.
 
12) Ponte P, et al : Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatol Venereol 24 : 716-721, 2010.
PubMed
13) Diederen PV, et al : Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides : a retrospective study. J Am Acad Dermatol 48 : 215-219, 2003.
PubMed
14) Jang MS, et al : Folliculotropic Mycosis Fungoides in 20 Korean Cases : Clinical and Histopathologic Features and Response to Ultraviolet A-1 and/or Photodynamic Therapy. Ann Dermatol 30 : 192-201, 2018.
 
15) Raone B, et al : Cutaneous carcinogenic risk evaluation in 375 patients treated with narrowband-UVB phototherapy : A 15-year experience from our Institute. Photodermatol Photoimmunol Photomed 34 : 302-306, 2018.
PubMed
P.495 掲載の参考文献
1) Specht L, et al ; International Lymphoma Radiation Oncology Group : Modern radiation therapy for primary cutaneous lymphomas : field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 92 : 32-39, 2015.
PubMed
2) Cotter GW, et al : Palliative radiation treatment of cutaneous mycosis fungoides--a dose response. Int J Radiat Oncol Biol Phys 9 : 1477-1480, 1983.
PubMed
3) Jones GW, et al : Total skin electron radiation in the management of mycosis fungoides : Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 47 : 364-370, 2002.
 
4) Micaily B, et al : Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 42 : 361-364, 1998.
PubMed
5) Wilson LD, et al : Local superficial radiotherapy in the management of minimal stage IA cutaneous T cell lymphoma (Mycosis Fungoides). Int J Radiat Oncol Biol Phys 40 : 109-115, 1998.
PubMed
6) Micaily B, et al : Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 42 : 361-364, 1998.
PubMed
7) NCCN Guidelines Versoin 1.2021 Primary Cutaneous Lymphomas.
PubMed
8) Neelis KJ, et al : Low-dose palliative radiotherapy for cutaneous B-and T-cell lymphomas. Int J Radiat Oncol Biol Phys 74 : 154-158, 2009.
 
9) Thomas TO, et al : Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 : 747-753, 2013.
PubMed
10) Trump JG, et al : High energy electrons for the treatment of extensive superficial malignant lesions. Am J Roentgenol Radium Ther Nucl Med 69 : 623-629, 1953.
PubMed
11) Jones GW, et al : Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9 : 1057-1076, 1995.
PubMed
12) Fuks Z, et al : The role of total skin irradiation with electrons in the management of mycosis fungoides. Bull Cancer 64 : 291-304, 1977.
PubMed
13) Harrison C, et al : Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 81 : e651-657, 2011.
PubMed
14) Kamstrup MR, et al : A prospective, open-label study of low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 71 : 1204-1207, 2008.
PubMed
15) Kamstrup MR, et al : Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma : an open-label prospective phase II study. Br J Dermatol 166 : 399-404, 2012.
PubMed
16) Hoppe RT, et al : Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides : results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 72 : 286-292, 2015.
PubMed
17) Kamstrup MR, et al : Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma : an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys 92 : 138-143, 2015.
PubMed
18) Morris S, et al : The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. Int J Radiat Oncol Biol Phys 99 : 627-633, 2017.
PubMed
19) Klein RS, et al : Improvement in peripheral blood disease burden in patients with Sezary syndrome and leukemic mycosis fungoides after total skin electron beam therapy. J Am Acad Dermatol 68 : 972-977, 2013.
PubMed
20) Wilson LD, et al : Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol 35 : 69-73, 1996.
PubMed
21) Hoppe RT : Mycosis fungoides : radiation therapy. Dermatol Ther 16 : 347-354, 2003.
PubMed
22) Hoppe RT, et al : Mycosis fungoides and the Sezary syndrome : pathology, staging, and treatment. Curr Probl Cancer 14 : 293-371, 1990.
PubMed
23) Kitaguchi M, et al : Helical skin radiation therapy including total skin radiation therapy using tomotherapy for primary cutaneous lymphoma with bone marrow suppression as a related adverse event. Pract Radiat Oncol, 2021. (DOI : 10.1016/j.prro.2020.11.007)
 
P.501 掲載の参考文献
1) Scarisbrick JJ, et al : Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome : Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33 : 3766-3773, 2015.
 
2) Kaye FJ, et al : A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 : 1784-1790, 1989.
PubMed
3) Quaglino P, et al : Treatment of early-stage mycosis fungoides : results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol 184 : 722-730, 2021.
PubMed
4) Ohtsuka M, et al : Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. J Dermatol 48 : e49-e71, 2021.
PubMed
5) Molin L, et al : Combination chemotherapy in the tumour stage of mycosis fungoides with cyclophosphamide, vincristine, vp-16, adriamycin and prednisolone (cop, chop, cavop) : a report from the Scandinavian mycosis fungoides study group. Acta Derm Venereol 60 : 542-544, 1980.
 
6) Quaglino P, et al : Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome : a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol 28 : 2517-2525, 2017.
 
7) Hughes CF, et al : Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome : a comparative study of systemic therapy. Blood 125 : 71-81, 2015.
PubMed
8) Kim YH, et al : Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC) : an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19 : 1192-1204, 2018.
 
9) Prince HM, et al : Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA) : an international, open-label, randomised, phase 3, multicentre trial. Lancet 390 : 555-566, 2017.
 
10) Wu PA, et al : A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biol Blood Marrow Transplant 15 : 982-990, 2009.
PubMed
11) Lechowicz MJ, et al : Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant 49 : 1360-1365, 2014.
PubMed
12) Duarte RF, et al : Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome : a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28 : 4492-4499, 2010.
 
13) Mori T, et al : Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sezary syndrome. Hematol Oncol 38 : 266-271, 2020.
PubMed
14) Fuji S, et al : Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol 34 : 3426-3433, 2016.
PubMed
15) Duvic M, et al : Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. Clin Cancer Res 23 : 3552-3556, 2017.
PubMed
P.506 掲載の参考文献
1) Willemze R, et al : WHO-EORTC classification for cutaneous lymphomas. Blood 105 : 3768-3785, 2005.
PubMed
2) van Santen S, et al : Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. JAMA Dermatol 152 : 992-1000, 2016.
PubMed
3) Hodak E, et al : Juvenile mycosis fungoides : cutaneous T-cell lymphoma with frequent follicular involvement. J Am Acad Dermatol 70 : 993-1001, 2014.
PubMed
4) van Doorn R, et al : Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis : a clinicopathologic and follow-up study of 51 patients. Arch Dermatol 138 : 191-198, 2002.
PubMed
5) Wieser I, et al : Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. Arch Dermatol Res 309 : 453-459, 2017.
PubMed
6) Agar NS, et al : Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome : validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 : 4730-4739, 2010.
PubMed
7) Scarisbrick JJ, et al : Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome : Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33 : 3766-3773, 2015.
 
8) Haghighi B, et al : Pagetoid reticulosis (Woringer-Kolopp disease) : an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol 13 : 502-510, 2000.
PubMed
9) Convit J, et al : Progressive, atrophying, chronic granulomatous dermohypodermitis. Autoimmune disease? Arch Dermatol 107 : 271-274, 1973.
PubMed
10) LeBoit PE, et al : Granulomatous slack skin : clonal rearrangement of the T-cell receptor β gene is evidence for the lymphoproliferative nature of a cutaneous elastolytic disorder. J Invest Dermatol 89 : 183-186, 1987.
 
11) Kempf W, et al : Granulomatous mycosis fungoides and granulomatous slack skin : a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol 144 : 1609-1617, 2008.
PubMed
12) Li JY, et al : A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides. J Am Acad Dermatol 69 : 366-374, 2013.
PubMed
13) Shah A, Safaya A : Granulomatous slack skin disease : a review, in comparison with mycosis fungoides. J Eur Acad Dermatol Venereol 26 : 1472-1478, 2012.
PubMed
P.512 掲載の参考文献
1) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed (ed by Swerdlow SH, et al), IARC Press, Lyon, 2017.
 
2) Hamada T, Iwatsuki K : Cutaneous lymphoma in Japan : a nationwide study of 1733 patients. J Dermatol 41 : 3-10, 2014.
PubMed
3) Willemze R, et al : The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 133 : 1703-1714, 2019.
PubMed
4) Scarisbrick JJ, et al : Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome : Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol 33 : 3766-3773, 2015.
 
5) Huang KP, et al : Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome : evidence from population-based and clinical cohorts. Arch Dermatol 143 : 45-50, 2007.
PubMed
6) Thompson AK, et al : Sezary syndrome without erythroderma : A review of 16 cases at Mayo Clinic. J Am Acad Dermatol 76 : 683-688, 2017.
 
7) Kamijo H, et al : Sezary syndrome without erythroderma : A case report and review of published work. J Dermatol 46 : 61-64, 2019.
 
8) Campbell JJ, et al : Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets : a biologic rationale for their distinct clinical behaviors. Blood 116 : 767-771, 2010.
PubMed
9) van Doorn R, et al : Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 113 : 127-136, 2009.
PubMed
10) Wolk K, et al : Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas : role of Th2-mediated biased Th17 function. Clin Cancer Res 20 : 5507-5516, 2014.
PubMed
11) Jackow CM, et al : Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood 89 : 32-40, 1997.
PubMed
12) Guenova E, et al : TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 19 : 3755-3763, 2013.
 
13) Querfeld C, et al : Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6 : 900-909, 2018.
PubMed
14) Ohmatsu H, et al : Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. Acta Derm Venereol 92 : 282-283, 2012.
PubMed
15) Yamada A, et al : Recovery from Sezary syndrome following Mycobacterium avium spondylitis. Br J Dermatol 157 : 1270-1271, 2007.
PubMed
P.516 掲載の参考文献
1) 大塚幹夫, ほか : 日本皮膚科学会ガイドライン 皮膚悪性腫瘍ガイドライン 第3版 皮膚リンパ腫診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 1347-1423, 2020.
 
2) Mehta-Shah N, et al : NCCN Guidelines Insights : Primary Cutaneous Lymphomas, Version 2. 2020. J Natl Compr Canc Netw 18 : 522-536, 2020.
PubMed
3) Willemze R, et al : Primary cutaneous lymphomas : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29 (Suppl 4) : iv30-iv40, 2018.
 
4) Hughes CE et al : Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome : a comparative study of systemic therapy. Blood 125 : 71-81, 2015.
 
5) Photiou L, et al : Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sezary Syndrome. Curr Oncol Rep 20 : 32, 2018.
PubMed
6) Straus DJ, et al : Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 109 : 1799-1803, 2007.
PubMed
7) Foss F, et al : A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106 : 454-457, 2005.
PubMed
8) Akpek G, et al : Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 86 : 1368-1376, 1999.
PubMed
9) Scarisbrick JJ, et al : A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 144 : 1010-1015, 2001.
PubMed
10) Johnson LDS, et al : Targeting CD47 in Sezary syndrome with SIRPαFc. Blood Adv 3 : 1145-1153, 2019.
 
11) Roelens M, et al : Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sezary syndrome with the KIR3DL2 marker. Br J Dermatol 182 : 1415-1422, 2020.
PubMed
12) Bagot M, et al : IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma : an international, first-in-human, open-label, phase 1 trial. Lancet Oncol 20 : 1160-1170, 2019.
PubMed
13) Cetinozman F, et al : Differential expression of programmed death-1 (PD-1) in Sezary syndrome and mycosis fungoides. Arch Dermatol 148 : 1379-1385, 2012.
 
14) Khodadoust MS, et al : Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sezary Syndrome : A Multicenter Phase II Study. J Clin Oncol 38 : 20-28, 2020.
PubMed
P.522 掲載の参考文献
1) Dobos G, et al : Epidemiology of Cutaneous T-Cell Lymphomas : A Systematic Review and Meta-Analysis of 16,953 Patients. Cancers 12 : 2921, 2020.
 
2) Fujii K, et al : Cutaneous lymphoma in Japan, 2012-2017 : Anationwide study. J Dermatol Sci 97 : 187-193, 2020.
 
3) Onaindia A, et al : Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features. Histopathology 66 : 846-855, 2015.
PubMed
4) Wada DA, et al : Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma : a multicenter study of 204 skin biopsies. Mod Pathol 24 : 596-605, 2011.
PubMed
5) Velusamy T, et al : A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 124 : 3768-3771, 2014.
PubMed
6) Wang X, et al : Expression of p63 protein in anaplastic large cell lymphoma : implications for genetic subtyping. Hum Pathol 64 : 19-27, 2017.
 
7) Sun J, et al : SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile. J Invest Dermatol 138 : 1795-1804, 2018.
PubMed
8) Magro CM, Dyrsen ME : Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B-and T-cell lymphoid infiltrates. J Cutan Pathol 35 : 1040-1049, 2008.
 
9) Kempf W, et al : EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders : lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118 : 4024-4035, 2011.
PubMed
10) Melchers RC, et al : Recommendations for the Optimal Radiation Dose in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma : A Report of the Dutch Cutaneous Lymphoma Group. Int J Radiat Oncol Biol Phys 99 : 1279-1285, 2017.
PubMed
11) Bekkenk MW, et al : Primary and secondary cutaneous CD30+ lymphoproliferative disorders : a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95 : 3653-3661, 2000.
 
12) Prince HM, et al : Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA) : an international, open-label, randomised, phase 3, multicentre trial. Lancet 390 : 555-566, 2017.
 
13) Woo DK, et al : Prognostic factors in primary cutaneous anaplastic large cell lymphoma : characterization of clinical subset with worse outcome. Arch Dermatol 145 : 667-674, 2009.
PubMed
14) Benner MF, Willemze R : Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol 145 : 1399-1404, 2009.
PubMed
15) Hapgood G, et al : Outcome of primary cutaneous anaplastic large cell lymphoma : a 20-year British Columbia Cancer Agency experience. Br J Haematol 176 : 234-240, 2017.
PubMed
P.526 掲載の参考文献
1) Willemze R, et al : The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 133 : 1703-1714, 2019.
PubMed
2) Verallo VM, et al : Mucha-Habermann's disease simulating lymphoma cutis. Report of two cases. Arch Dermatol 94 : 295-299, 1966.
 
3) Macaulay WL : Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign-histologically malignant. Arch Dermatol 97 : 23-30, 1968.
PubMed
4) Swerdlow SH, et al (ed) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed, IARC Press, Lyon, 2017.
 
5) Kempf W : Cutaneous CD30-Positive Lymphoproliferative Disorders. Surg Pathol Clin 7 : 203-228, 2014.
PubMed
6) de Souza A, et al : In search of prognostic indicators for lymphomatoid papulosis : a retrospective study of 123 patients. J Am Acad Dermatol 66 : 928-937, 2012.
PubMed
7) Wieser I, et al : Lymphomatoid papulosis : Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol 74 : 59-67, 2016.
 
8) Kempf W : CD30+ lymphoproliferative disorders : histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 33 (Suppl 1) : 58-70, 2006.
PubMed
9) Kempf W, et al : EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders : lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118 : 4024-4035, 2011.
PubMed
P.532 掲載の参考文献
1) Willemze R, et al : WHO-EORTC classification for cutaneous lymphomas. Blood 105 : 3768-3785, 2005.
PubMed
2) Hamada T, Iwatsuki K : Cutaneous lymphoma in Japan : a nationwide study of 1733 patients. J Dermatol 41 : 3-10, 2014.
PubMed
3) Ohtsuka M, et al : Clinical characteristics, differential diagnosis, and treatment outcome of subcutaneous panniculitis-like T-cell lymphoma : a literature review of published Japanese cases. Eur J Dermatol 27 : 34-41, 2017.
PubMed
4) Willemze R, et al : Subcutaneous panniculitis-like T-cell lymphoma : definition, classification, and prognostic factors : an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 111 : 838-845, 2008.
 
5) Bosisio F, et al : Lobular panniculitic infiltrates with overlapping histopathologic features of lupus panniculitis (lupus profundus) and subcutaneous T-cell lymphoma : a conceptual and practical dilemma. Am J Surg Pathol 39 : 206-211, 2015.
PubMed
6) Jaffe ES, et al : Subcutaneous panniculitis-like T-cell lymphoma. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed (ed by Swerdlow SH, et al), p383-385, IARC Press, Lyon, 2017.
 
7) Willemze R, et al : Primary cutaneous lymphomas : ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29 (Suppl 4) : iv30-iv40, 2018.
 
8) Gilson D, et al : British Association of Dermatologists and U. K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol 180 : 496-526, 2019.
 
9) 大塚幹夫, ほか : 皮膚悪性腫瘍ガイドライン 第3版 皮膚リンパ腫診療ガイドライン 2020. 日皮会誌 130 : 1347-1423, 2020.
 
10) Garcia-Herrera A, et al : Primary cutaneous small/medium CD4+ T-cell lymphomas : a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol 26 : 3364-3371, 2008.
PubMed
11) Cetinozman F, et al : Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol 36 : 109-116, 2012.
PubMed
12) Gauland P, et al : Primary cutaneous peripheral T-cell lymphomas, rare subtypes. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed (ed by Swerdlow SH, et al), p397-402, IARC Press, Lyon, 2017.
 
13) Rodriguez Pinilla SM, et al : Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol 33 : 81-90, 2009.
PubMed
14) Berti E, et al : Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 155 : 483-492, 1999.
PubMed
15) Toro JR, et al : Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 101 : 3407-3412, 2003.
PubMed
16) Rodriguez-Pinilla SM, et al : TCR-γ expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol 37 : 375-384, 2013.
 
17) Massone C, et al : The prognosis of early mycosis fungoides is not influenced by phenotype and T cell clonality. Br J Dermatol 159 : 881-886, 2008.
 
18) Guitart J, et al : Cutaneous γδ T-cell lymphomas : a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol 36 : 1656-1665, 2012.
 
19) Merrill ED, et al : Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous γδ T-Cell Lymphomas. Am J Surg Pathol 41 : 204-215, 2017.
 
20) Petrella T, et al : Indolent CD8-positive lymphoid proliferation of the ear : adistinct primary cutaneous T-cell lymphoma? Am J Surg Pathol 31 : 1887-1892, 2007.
 
21) Greenblatt D, et al : Indolent CD8 (+) lymphoid proliferation of acral sites : a clinicopathologic study of six patients with some atypical features. J Cutan Pathol 40 : 248-258, 2013.
 
22) Kluk J, et al : Indolent CD8-positive lymphoid proliferation of acral sites : three further cases of a rare entity and an update on a unique patient. J Cutan Pathol 43 : 125-136, 2016.
 
23) Bekkenk MW, et al : Peripheral T-cell lymphomas unspecified presenting in the skin : analysis of prognostic factors in a group of 82 patients. Blood 102 : 2213-2219, 2003.
 
24) Tolkachjov SN, et al : Cutaneous peripheral T-cell lymphoma, not otherwise specified : A single-center prognostic analysis. J Am Acad Dermatol 75 : 992-999, 2016.
 
P.539 掲載の参考文献
1) Willemze R, et al : The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 133 : 1703-1714, 2019.
PubMed
2) Chan JKC, Ko YH : Extranodal NK/T-cell lymphoma, nasal type. In : WHO Classification of Skin Tumours, 4th ed (ed by Elder DE, et al), p246-247, IARC, Lyon, 2018.
 
3) Quintanila-Martinez L, et al : Cutaneous manifestations of chronic active EBV infection. In : WHO Classification of Skin Tumours, 4th ed (ed by Elder DE, et al), p244-246, IARC, Lyon, 2018.
 
4) Luo Y, et al : Signaling pathways of EBV-induced oncogenesis. Cancer Cell Int 21 : 93, 2021. [DOI : 10.1186/s12935-021-01793-3]
 
5) Xue W, Zhang M : Updating targets for natural killer/T-cell lymphoma immunotherapy. Cancer Biol Med 18 : 52-62, 2021. [DOI : 10.20892/j.issn.2095-3941.2020.0400]
 
6) Takata K, et al : Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma : a cellular lineage and clinicopathologic study of 60 patients from Asia. Am J Surg Pathol 39 : 1-12, 2015.
PubMed
7) Iwatsuki K, et al : The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 140 : 715-721, 1999.
PubMed
8) Cohen JI, et al : Epstein-Barr virus NK and T cell lymphoproliferative disease : report of a 2018 international meeting. Leuk Lymphoma 61 : 808-819, 2020.
 
9) Okuno Y, et al : Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol 4 : 404-413, 2019.
PubMed
10) Hirai Y, et al : Hydroa vacciniforme is associated with increased numbers of Epstein-Barr virus-infected γδ T cells. J Invest Dermatol 132 : 1401-1408, 2012.
 
11) Miyake T, et al : Survival rates and prognostic factors of Epstein-Barr virus-associated hydroa vacciniforme and hypersensitivity to mosquito bites, Br J Dermatol 172 : 56-63, 2015.
PubMed
12) Iwatsuki K, et al : Hydroa vacciniforme : adistinctive form of Epstein-Barr virus-associated T-cell lymphoproliferative disorders. Eur J Dermatol 29 : 21-28, 2019.
 
13) Miyake T, et al : The aim of the measurement of Epstein-Barr virus DNA in hydroa vacciniforme and hypersensitivity to mosquito bites. J Med Virol 92 : 3689-3696, 2020. [https://doi.org/10.1002/jmv.25811]
 
14) Yamamoto T, et al : A novel, noninvasive diagnostic probe for hydroa vacciniforme and related disorders : detection of latency-associated Epstein-Barr virus transcripts in the crusts. J Microbiol Methods 68 : 403-407, 2007.
 
P.545 掲載の参考文献
1) Swerdlow SH, et al (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th Ed, IARC Press, Lyon, 2017.
 
2) Haverkos BM, et al : Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT) : An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. Curr Hematol Malig Rep 11 : 514-527, 2016.
 
3) Hamada T, Iwatsuki K : Cutaneous lymphoma in Japan : anationwide study of 1733 patients. J Dermatol 41 : 3-10, 2014.
 
4) Fujikura K, et al : Intravascular NK/T-cell lymphoma : clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis. J Clin Pathol 72 : 642-646, 2019.
PubMed
5) Su YJ, et al : Extranodal NK/T-cell lymphoma, nasal type : Clinical features, outcome, and prognostic factors in 101 cases. Eur J Haematol 101 : 379-388, 2018.
PubMed
6) Yamaguchi M, et al : Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood 131 : 2528-2540, 2018.
PubMed
7) Sanchez-Romero C, et al : Extranodal NK/T cell lymphoma, nasal type : An updated overview. Crit Rev Oncol Hematol 159 : 103237, 2021.
PubMed
8) Suzuki R, et al : Prognostic factors for mature natural killer (NK) cell neoplasms : aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 21 : 1032-1040, 2010.
PubMed
9) Bekkenk MW, et al : CD56+ hematological neoplasms presenting in the skin : a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 15 : 1097-1108, 2004.
PubMed
10) Takata K, et al : Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma : a cellular lineage and clinicopathologic study of 60 patients from Asia. Am J Surg Pathol 39 : 1-12, 2015.
PubMed
P.551 掲載の参考文献
1) Fujii K, et al : Cutaneous lymphoma in Japan, 2012-2017 : A nationwide study. J Dermatol Sci 97 : 187-193, 2020.
PubMed
2) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed (ed by Swerdlow SH, et al), IARC Press, Lyon, 2017.
 
3) WHO Classification of Skin Tumours, 4th ed (ed by Elder DE, et al), IARC Press, Lyon, 2018.
 
4) Willemze R, et al : The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 133 : 1703-1714, 2019.
PubMed
5) Pham-Ledard A, et al : Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol 27 : 402-411, 2014.
 
6) Schrader AMR et al : High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B. Cell Lymphoma, Leg Type. Am J Surg Pathol 42 : 1488-1494, 2018.
PubMed
7) 大塚幹夫, ほか : 皮膚悪性腫瘍ガイドライン 第3版 皮膚リンパ腫診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 1347-1423, 2020.
 
P.556 掲載の参考文献
1) Gessain A, Cassar O : Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol 3 : 388, 2012.
PubMed
2) 藤澤順一 : HTLV-1のウイルス学. HTLV-1と疾患 (渡邉俊樹, ほか編), p152-165, 文光堂, 2007.
 
3) Feuer G, Green PL : Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene 24 : 5996-6004, 2005.
PubMed
4) 森直樹, 山本直樹 : ヒトレトロウイルス研究の現状. HTLV-1と疾患 (渡邉俊樹, ほか編), p124, 文光堂, 2007.
 
5) Green PL, Chen IS : Regulation of human T cell leukemia virus expression. FASEB J 4 : 169-175, 1990.
PubMed
6) Zhang LL, et al : Human T-cell lymphotropic virus type 1 and its oncogenesis. Acta Pharmacol Sin 38 : 1093-1103, 2017.
PubMed
7) Younis I, Green PL : The human T-cell leukemia virus Rex protein. Front Biosci 10 : 431-445, 2005.
PubMed
8) Matsuoka M, Jeang KT : Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7 : 270-280, 2007.
PubMed
9) Ratner L : Molecular biology of human T cell leukemia virus. Semin Diagn Pathol 37 : 104-109, 2020.
PubMed
10) Yasunaga JI : Strategies of Human T-Cell Leukemia Virus Type 1 for Persistent Infection : Implications for Leukemogenesis of Adult T-Cell Leukemia-Lymphoma. Front Microbiol 11 : 979, 2020.
PubMed
11) Gaudray G, et al : The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 76 : 12813-12822, 2002.
PubMed
12) Matsuoka M, Mesnard JM : HTLV-1 bZIP factor : the key viral gene for pathogenesis. Retrovirology 17 : 2, 2020.
PubMed
13) Ureta-Vidal A, et al : Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I : implication of high antiviral antibody titer and high proviral load in carrier mothers. Int J Cancer 82 : 832-836, 1999.
PubMed
14) Suzuki S, et al : Prevalence of human T-cell leukemia virus type 1 carrier in Japanese pregnant women in 2013. J Clin Med Res 7 : 499-500, 2015.
PubMed
15) Roucoux DF, et al : A prospective study of sexual transmission of human T lymphotropic virus (HTLV) -I and HTLV-II. J Infect Dis 191 : 1490-1497, 2005.
PubMed
P.562 掲載の参考文献
1) Van Dooren S, et al : Dating the origin of the African human T-cell lymphotropic virus type-1 (HTLV-1) subtypes. Mol Biol Evol 18 : 661-671, 2001.
PubMed
2) Sonoda S, et al : Ethnoepidemiology of HTLV-1 related diseases : ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Sci 102 : 295-301, 2011.
PubMed
3) Matsuoka M, Jeang KT : Human T-cell leukemia virus type I at age 25 : a progress report. Cancer Res 65 : 4467-4470, 2005.
PubMed
4) Watanabe T : Current status of HTLV-1 infection. Int J Hematol 94 : 430-434, 2011.
PubMed
5) Hermine O, et al : A Review of New Findings in Adult T-cell Leukemia lymphoma : A Focus on Current and Emerging Treatment Strategies. Adv Ther 35 : 135-152, 2018.
PubMed
6) Rodriguez-Zuniga MJM, et al : Adult T-Cell Leukemia/Lymphoma. Review of the Literature. Actas Dermosifiliogr 109 : 399-407, 2018.
PubMed
7) Nosaka K, et al : Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011 : A nationwide survey. Cancer Sci 108 : 2478-2486, 2017.
PubMed
8) 内丸薫 : I. HTLV-1関連疾患の疫学. 日本内科学会雑誌 106 : 1370-1375, 2017.
 
9) 豊田康祐, ほか : ヒトT細胞白血病ウイルス1型の戦略と病原性. ウイルス 69 : 37-46, 2019.
 
10) 山野嘉久 : HTLV-1関連脊髄症 (HAM). ウイルス 69 : 29-36, 2019.
 
11) Iwanaga M, et al : Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers : a nationwide prospective study in Japan. Blood 116 : 1211-1219, 2010.
PubMed
12) 天野正宏 : HTLV-1と皮膚疾患. 癌と化学療法 40 : 466-469, 2013.
Medical*Online
13) Bangham CRM, Osama M : Cellular immune response to HTLV-1. Oncogene 24 : 6035-6046, 2005.
 
14) Tattermusch S, et al : Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog 8 : e1002480, 2012.
PubMed
15) Farre L, et al : Early sequential development of infective dermatitis, human T cell lymphotropic virus type 1-associated myelopathy, and adult T cell leukemia/lymphoma. Clin Infect Dis 46 : 440-442, 2008.
PubMed
P.567 掲載の参考文献
1) Sawada Y, et al : Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 117 : 3961-3967, 2011.
PubMed
2) Dewan MZ, et al : Critical role for TSLC1 expression in the growth and organ infiltration of adult T-cell leukemia cells in vivo. J Virol 82 : 11958-11963, 2008.
PubMed
3) Takasaki Y, et al : Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 115 : 4337-4343, 2010.
PubMed
4) Shimoyama M : Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma A report from the Lymphoma Study Group (1984-87). Br J Haematol 79 : 428-437, 1991.
 
5) Cook LB, et al : Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol 37 : 677-687, 2019.
PubMed
6) Tsukasaki K, et al : Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma : a proposal from an international consensus meeting. J Clin Oncol 27 : 453-459, 2009.
PubMed
7) Iwanaga M, et al : Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers : a nationwide prospective study in Japan. Blood 116 : 1211-1219, 2010.
PubMed
8) Corcoran RB, Chabner BA : Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med 379 : 1754-1765, 2018.
PubMed
9) Pise-Masison CA, et al : Gene expression profiling of ATL patients : compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood 113 : 4016-4026, 2009.
PubMed
10) Nakahata S, et al : Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma. Leukemia 26 : 1238-1246, 2012.
PubMed
11) Sasaki H, et al : Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood 105 : 1204-1213, 2005.
PubMed
12) Masuda M, et al : CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells. J Biol Chem 285 : 15511-15522, 2010.
 
13) Nakahata S, et al : Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. Haematologica 106 : 532-542, 2021.
PubMed
14) Katsuya H, et al : Prognostic index for chronic-and smoldering-type adult T-cell leukemialymphoma. Blood 130 : 39-47, 2017.
 
15) Nishioka C, et al : Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci 96 : 810-815, 2005.
PubMed
16) Tanaka Y, et al : Association of high levels of plasma OX40 with acute adult T-cell leukemia. Int J Hematol 109 : 319-327, 2019.
PubMed
P.573 掲載の参考文献
1) Tsukasaki K, et al : Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma : a proposal from an international consensus meeting. J Clin Oncol 27 : 453-459, 2009.
PubMed
2) Tsukasaki K, et al : Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma. J Dermatol 41 : 26-28, 2014.
PubMed
3) 菅谷誠, ほか : 日本皮膚科学会ガイドライン 皮膚リンパ腫診療ガイドライン 2011年改訂版. 日本皮膚科学会雑誌 122 : 1513-1531, 2012.
 
4) Bittencourt AL, et al : Adult T-cell leukemia/lymphoma in Bahia, Brazil : analysis of prognostic factors in a group of 70 patients. Am J Clin Pathol 128 : 875-882, 2007.
 
5) Sawada Y, et al : Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 117 : 3961-3967, 2011.
PubMed
6) Cook LB, et al : Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol 37 : 677-687, 2019.
PubMed
7) 大塚幹夫, ほか : 皮膚悪性腫瘍ガイドライン 第3版 皮膚リンパ腫診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 1347-1423, 2020.
 
8) Katsuya H, et al : Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood 130 : 39-47, 2017.
PubMed
9) Yonekura K, et al : Therapeutic Efficacy of Etretinate on Cutaneous-type Adult T-cell Leukemia-Lymphoma. Acta Derm Venereol 99 : 774-776, 2019.
PubMed
P.579 掲載の参考文献
1) Tsukasaki K, et al : VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25 : 5458-5464, 2007.
 
2) Ishida T, et al : Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma : a multicenter phase II study. J Clin Oncol 30 : 837-842, 2012.
PubMed
3) Ishida T, et al : Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma : a randomized phase II study. Br J Haematol 169 : 672-682, 2015.
PubMed
4) 大塚幹夫, ほか : 皮膚悪性腫瘍ガイドライン 第3版 皮膚リンパ腫診療ガイドライン 2020. 日本皮膚科学会雑誌 130 : 1347-1423, 2020.
 
5) Ishii T, et al : Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 16 : 1520-1531, 2010.
PubMed
6) Kawano N, et al : Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012). Intern Med 54 : 1489-1498, 2015.
 
7) Yonekura K, et al : Mogamulizumab for adult T-cell leukemia-lymphoma : a multicenter prospective observational study. Blood Adv 4 : 5133-5145, 2020.
PubMed
8) Yonekura K, et al : Cutaneous Adverse Reaction to Mogamulizumab May Indicate Favourable Prognosis in Adult T-cell Leukaemia-lymphoma. Acta Derm Venereol 96 : 1000-1002, 2016.
PubMed
9) Tokunaga M, et al : Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma. Br J Haematol 181 : 539-542, 2018.
PubMed
10) Ishida T, et al : Mogamulizumab for relapsed adult T-cell leukemia-lymphoma : Updated follow-up analysis of phase I and II studies. Cancer Sci 108 : 2022-2029, 2017.
PubMed
11) Ishida T, et al : Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 104 : 647-650, 2013.
PubMed
12) Inoue Y, et al : Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transplant 51 : 725-727, 2016.
PubMed
13) Kawano N, et al : The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. J Clin Exp Hematop 56 : 135-144, 2017.
PubMed
14) Sakamoto Y, et al : CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood 132 : 758-761, 2018.
PubMed
15) Ishida T, et al : Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma : ATLL-002. J Clin Oncol 34 : 4086-4093, 2016.
PubMed

書評

最近チェックした商品履歴

Loading...